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ABSTRACT 
 
Nephropathia epidemica (NE), a mild type of hemorrhagic fever of renal syndrome 
(HFRS), is caused by Puumala hantavirus (PUUV). A sudden onset of high fever, 
headache, nausea and back and abdominal pain are the most typical symptoms. 
Renal involvement comprises oliguria followed by polyuria together with 
proteinuria and hematuria. Renal histopathology reveals acute tubulointerstitial 
nephritis. A complete recovery is the usual outcome.  
The long-term prognosis of NE has previously been assessed in a retrospective 
study of 46 patients with previous NE (Mäkelä et al. 2000). Three to seven years 
after serologically confirmed PUUV infection, patients evinced a higher glomerular 
filtration rate (GFR), more proteinuria and higher ambulatory blood pressure (ABP) 
than healthy, seronegative controls (Mäkelä et al. 2000). This cohort of NE patients 
and controls were re-examined a median of 10 years after acute NE. Thirty-six 
patients and 29 controls took part. There were no longer significant differences in 
GFR and ABP or in the amount of proteinuria between patients and controls. There 
was nevertheless a slight predominance of hypertensive subjects in the patient 
group.  
In the present series, the renal outcome and blood pressure (BP) of patients with 
previous NE were further studied in a prospectively collected group of 37 patients. 
Six years after acute NE, the patients had higher GFR, more proteinuria and higher 
ABP compared with 38 seronegative controls. The clinical severity of the acute 
phase of NE did not influence the long-term findings.  
Serum hormonal levels were studied in 54 patients during acute NE, after 3 
months, and after 1 and 5 years. All levels were analyzed retrospectively. During 
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acute NE, 56 % of the patients evinced hormonal abnormalities. Chronic, overt 
hormonal deficits were detected in 17 % of the patients after a median follow-up of 
5 years: 5 had hypopituitarism and 5 had primary hypothyroidism. Furthermore, in 5 
males chronic subclinical testicular failure was diagnosed. The acute-phase central 
hormonal deficiencies correlated with the severity of the acute renal failure and 
inflammatory markers. In contrast, the severity of acute NE was not associated with 
the development of chronic hormonal deficiencies. 
The clinical courses of seven patients with nephrotic-range proteinuria 
concomitant with hematuria emerging 1 to 12 weeks after acute NE have been 
described. In five cases a renal biopsy specimen showed membranoproliferative 
glomerulonephritis (MPGN), while membranous glomerulonephritis (MGN) and 
mesangial glomerulonephritis (MesGN) were detected each in one. All patients 
achieved remission in a median of 0.6 years, indicating a good prognosis.  
In conclusion, the present series confirms the favorable long-term outcome of 
acute NE. However, the possibility remains that NE may predispose patients to 
hypertension. Hormonal alterations are common during and after acute NE. 
Furthermore, as a rare phenomenon, the convalescent phase of acute NE may be 
complicated by glomerulonephritis. 
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TIIVISTELMÄ 
 
Myyräkuume on munuaisoireinen verenvuotokuume, jonka aiheuttaa hantavirusten 
ryhmään kuuluva Puumala-virus. Tavanomaisia oireita ovat äkillinen korkea kuume, 
päänsärky, pahoinvointi sekä selkä- ja vatsakivut. Munuaisvaurioon liittyvät 
ohimenevä oliguria ja sitä seuraava polyuria, ja virtsanäytteessä nähdään protein- ja 
hematuriaa. Munuaisvaurion vaikeusaste vaihtelee, ja vain pieni osa potilaista 
tarvitsee dialyysihoitoa. Munuaisen histopatologisessa tutkimuksessa todetaan 
äkillinen tubulointerstitiaalinen nefriitti. Myyräkuumeen ennustetta on pidetty 
hyvänä. 
Taudin pitkäaikaisennustetta on aiemmin tutkittu retrospektiivisesti kerätyssä 46 
potilaan aineistossa. Tutkimuksessa havaittiin, että 3-7 vuotta akuutin vaiheen 
jälkeen myyräkuumeen sairastaneilla oli korkeampi glomerulusten suodatusnopeus 
(GFR) 51CrEDTA-menetelmällä mitattuna, enemmän proteinuriaa sekä korkeampi 
systolinen verenpaine vuorokausimittauksessa kuin terveillä verrokeilla. 
Tässä väitöskirjatyössä kutsuttiin em. retrospektiivisesti kerätyn aineiston potilaat 
ja verrokit uudestaan tutkimuksiin, kun potilaiden myyräkuumeen sairastamisesta 
oli kulunut keskimäärin 10 vuotta. Havaittiin, että 36 potilaan ja 29 verrokin välillä 
ei ollut enää eroa GFR:ssa, proteinurian määrässä tai verenpaineen 
vuorokausimittauksen tuloksissa. Kuitenkin näytti siltä, että potilasryhmässä oli 
enemmän kohonnutta verenpainetta sairastavia kuin verrokkiryhmässä, kun otettiin 
huomioon verenpaineen vuorokausirekisteröinnin lisäksi verenpainelääkkeiden 
käyttö sekä vuorokausirekisteröintiin osallistumattomien potilaiden vastaanotolla 
mitattu verenpaine. 
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Munuaisten toimintaa ja verenpainetta tutkittiin myös 37 prospektiivisesti 
kerätyn potilaan aineistossa 6 vuotta akuutin taudin jälkeen, ja tuloksia verrattiin 38 
seronegatiiviseen verrokkiin. Potilailla todettiin retrospektiivistä tutkimusta 
vastaavasti korkeampi GFR ja verenpaine sekä enemmän proteinuriaa kuin 
verrokeilla. Myyräkuumeen akuutin vaiheen taudin vaikeusaste ei vaikuttanut 
pitkäaikaislöydöksiin. 
Viidenkymmenenneljän myyräkuumepotilaan aineistossa tutkittiin aivolisäke-, 
sukupuoli- ja kilpirauhashormonien seerumipitoisuuksia taudin akuutissa vaiheessa, 
3 kuukauden, sekä 1 ja 5 vuoden kuluttua tautiin sairastumisesta. 
Hormonipitoisuudet analysoitiin jälkikäteen. Myyräkuumeen akuutissa vaiheessa 56 
%:lla potilaista todettiin poikkeavuuksia seerumin hormonipitoisuuksissa. Kroonisia 
poikkeavuuksia todettiin puolestaan 17 %:lla potilaista 5 vuoden seurannan jälkeen: 
5 potilaalla aivolisäkkeen vajaatoiminta ja 5 potilaalla primaarinen kilpirauhasen 
vajaatoiminta. Subkliininen kivesten vajaatoiminta diagnosoitiin lisäksi 5 
miespotilaalla. Myyräkuumeen akuutin vaiheen sentraaliset hormonipuutokset 
korreloivat akuutin munuaisten vajaatoiminnan vaikeusasteen sekä tulehdusta 
kuvaavien muuttujien kanssa. Sen sijaan krooniset hormonipoikkeavuudet eivät 
näyttäneet olevan yhteydessä myyräkuumeen vaikeusasteeseen. 
Väitöskirjassa kuvataan myös 7 potilasta, joilla todettiin nefroottinen oireyhtymä 
ja hematuria 1-12 viikkoa myyräkuumeen akuutin vaiheen jälkeen. Viidellä oli 
munuaisbiopsiassa löydöksenä membranoproliferatiivinen, yhdellä membranoosi ja 
yhdellä mesangiaalinen glomerulonefriitti. Kaikki potilaat saavuttivat remission 
keskimäärin 0.6 vuoden aikana viitaten hyvään ennusteeseen. 
Väitöskirja vahvistaa aiempaa käsitystä myyräkuumeen hyvästä 
pitkäaikaisennusteesta. Myyräkuume saattaa kuitenkin altistaa joitakin potilaita 
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verenpaineen kohoamiselle. Seerumin hormonipitoisuuksien poikkeavuudet ovat 
tavallisia taudin akuutissa vaiheessa, ja osalla potilaista havaitaan 
hormonimuutoksia vuosien kuluttua sairastumisesta. Myyräkuumeen mahdollisia 
pitkäaikaishaittoja ei voida ennustaa taudin akuutin vaiheen vaikeusasteen 
perusteella. Myyräkuumeen toipumisvaiheeseen voi myös harvinaisissa tapauksissa 
liittyä glomerulonefriitti, jonka ennuste vaikuttaa suotuisalta. 
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1. INTRODUCTION 
Nephropathia epidemica (NE) is a zoonosis belonging to the group of hemorrhagic 
fever with renal syndrome (HFRS). HFRS drew significant attention in the 1950s, 
when United Nations soldiers from the Korean War suffered from an acute illness 
later known to be caused by Hantaan virus (HTNV) (Smadel 1953, Lee et al. 1978). 
In 1980 NE was reported to be caused by Puumala virus (PUUV) carried by bank 
voles (Myodes glareolus) (Brummer-Korvenkontio et al. 1980). Several other 
hantaviruses causing human disease have since been found. In the Americas, a 
severe hantavirus infection with high mortality was described in the 1990s (Nichol 
et al. 1993), and subsequently named hantavirus cardiopulmonary syndrome 
(HCPS). 
The clinical picture of acute NE is characterized by a sudden onset of fever with 
headache, nausea and back and abdominal pain together with acute renal failure and 
thrombocytopenia accompanied by hemorrhagic manifestations (Lähdevirta 1971, 
Settergren et al. 1989, Mustonen et al. 1994a, Braun et al. 2010). Renal 
histopathology reveals acute tubulointerstitial nephritis (AIN) (Mustonen et al. 
1994b). The clinical course varies from subclinical to fatal, although mortality is 
rare (Vapalahti et al. 2003).  
The long-term prognosis of NE is considered to be favorable. However, previous 
studies have suggested changes in renal function or proteinuria up to 6 years 
(Lähdevirta 1971, Lähdevirta et al. 1978, Settergren et al. 1989, Settergren et al. 
1990, Elisaf et al. 1993, Mäkelä et al. 2000, Ala-Houhala et al. 2002), and elevated 
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blood pressure (BP) up to 5 years after acute NE (Mäkelä et al. 2000). Furthermore, 
NE may be complicated by pituitary hormonal disturbances (Saltevo and Forslund 
1992, Settergren et al. 1992, Hautala et al. 2002, Sane and Färkkilä 2002, Pekic et 
al. 2005) or consequent glomerulonephritis (GN) (Grcevska et al. 1990, Mustonen et 
al. 2001).  
Between the years 1990 and 2006 a total of 34 000 hantavirus infections were 
confirmed in Europe, and 70 % of them were reported from Finland as being caused 
by PUUV (Heyman and Vaheri 2008). The number of hantavirus infections 
diagnosed in Europe has recently been on the increase (Heyman and Vaheri 2008). 
Wide awareness of the disease and better diagnostics are obvious explanations for 
this. However, climate change may contribute to the problem in that in Northern 
Europe milder winters and thinner snow cover have probably led to the higher 
incidences of NE during the last few years (Pettersson et al. 2008a, Evander and 
Ahlm 2009). Further, in Western Europe the increased incidences may be explained 
by higher summer temperatures, offering more nourishment for bank voles (Tersago 
et al. 2009). 
The present study was undertaken to examine the long-term outcome of NE in 
respect of renal function, proteinuria and BP. Hormonal changes during and after 
acute disease were also assessed. Further, the study describes seven patients with 
glomerulonephritis shortly after acute NE. 
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2. REVIEW OF THE 
LITERATURE 
2.1 Hantaviruses and hantavirus infections 
2.1.1 History  
In Finland in 1926 Theodor Waldemar Tallqvist recognized a clinical syndrome 
resembling acute NE in the southern part of the country (Forsius 1995). NE itself, 
however, was first described in 1934 independently by two Swedish physicians 
(Myhrman 1934, Zetterholm 1934), the first case being observed in 1933 in north-
central Sweden. The clinical picture of the “new” disease was an acute onset of 
fever with chills, malaise, vomiting, headache, and back and abdominal pain. Renal 
syndrome was characterized by heavy proteinuria with oliguria and azotemia. The 
disease had a good prognosis. Subsequently the investigators Stuhlfauth from 
Germany and Hortling from Finland described a similar epidemic disease occurring 
among German and Finnish soldiers in northern Finland during World War II, this 
being also reported by Fredrik Saltzman in 1945 (Forsius 1995). The histopathology 
of the renal manifestation of acute NE was first described in Finland by Kuhlbäck 
and co-workers (1964). The term “Nephropathia epidemica” was suggested by 
Myhrman in 1945, although he himself also named the condition Myhrman’s 
disease (Forsius 1995). In Finland, “myyräkuume” was proposed as the Finnish 
name for this disease in 1980s (Lähdevirta and Savola 1985).   
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As far back as the first millennium (Lee 1982a) and the Middle Ages (Bridson 
2001), however, there are descriptions of HFRS-like diseases. Furthermore, it has 
also been suggested that hantavirus disease may have appeared during the American 
civil war in the 1860s and during World War I in 1915 and 1916, as well as in 
Vladivostok regional hospital in 1913–1914 (Heyman et al. 2009). However, it was 
not until the Korean War in 1951–1954 that HFRS became better known to Western 
medicine. More than 3000 United Nations soldiers near the small Hantaan River 
suffered from an acute febrile disease with nephritis, mortality rising to 7 % 
(Smadel 1953, Johnson 2001). It was this epidemic which gave impulse to more 
extensive research into this disease.  
In the past HFRS went under many names, until a working group on HFRS in the 
World Health Organization (WHO) meeting in Tokyo in 1982 recommended the 
current term (Lee 1982a). In the Soviet Union the condition had been named 
hemorrhagic nephroso-nephritis or HFRS, in China Songo fever, in Scandinavia NE 
and in Eastern Europe epidemic nephritis (Lee 1982a). The term epidemic 
hemorrhagic fever was also used in Japan, Eastern Europe and China (Lee 1982a). 
2.1.2 Virology 
As far back as 1953 Gajdusek suggested a relationship of NE to Korean 
hemorrhagic fever, and the possible viral etiology of these diseases was first 
proposed first in 1960s (Gajdusek 1962). However, it was not until 1976 that Lee 
and co-workers identified the causative agent of Korean hemorrhagic fever, 
currently named Hantaan virus (Lee et al. 1978). It was isolated near the Hantaan 
River in the lungs of striped field mice (Apodemus agrarius). A few years later the 
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causative agent of NE was found in the lungs of bank voles in Puumala, Finland, 
and named Puumala hantavirus (Brummer-Korvenkontio et al. 1980).  
Up to now, over 40 different hantavirus species belonging to the family 
Bunyaviridae have been found almost all over the world (Heyman et al. 2009), and 
20 of them have so far been described as being pathogenic to humans (Table 1) 
(Jonsson et al. 2010).  The genus Hantavirus can be divided into two groups: Old 
World and New World hantaviruses. Pathogenic Old World hantaviruses comprise 
Asian and European viruses and New World hantaviruses North and South America 
viruses. The main natural reservoirs of these organisms are muroid rodents (Table 
1): the Old World rats and mice (family Muridae, subfamily Murinae), the New 
World rats and mice (family Cricetidae, subfamily Sigmodontinae) and the voles 
and lemmings (family Cricetidae, subfamily Arvicolinae). The most widely 
distributed rodent source of hantaviruses in Europe is the bank vole, the carrier of 
PUUV (Jonsson et al. 2010). This creature is found throughout Europe, with the 
exception of the Mediterranean region and northern parts of Finland, Sweden and 
Norway (Vapalahti et al. 2003).  
It seems that hantaviruses have coevolved with their rodent hosts for millions of 
years (Plyusnin et al. 1996). Such a conception is supported by molecular evidence 
showing a high degree of similarity between the phylogenetic structure of the host 
rodent and that of the viruses (Plyusnin and Morzunov 2001). However, it is 
possible that hantavirus has multiple rodent hosts and multiple viruses have a single 
host species (Nemirov et al. 2002, Scharninghausen et al. 2004, Weidmann et al. 
2005). The distribution of discrete hantavirus species appears to correlate with the 
geographic extension of their hosts, and the hantavirus genotypes of the same 
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geographic area are phylogenetically related (Plyusnin and Morzunov 2001, 
Plyusnin 2002). 
Table 1. Human pathogenic hantaviruses with recognized clinical disease and their 
geographic distribution.
1
 
Group and 
subfamily 
Virus Rodent host Disease Area 
Old World     
 Murinae Hantaan  Apodemus agrarius HFRS Asia 
 Dobrava  Apodemus flavicollis HFRS Europe 
 Seoul  Rattus norvegicus HFRS Worldwide 
 Saaremaa  Apodemus agrarius HFRS Europe 
 Amur  Apodemus peninsulae HFRS Asia 
 Arvicolinae Puumala  Myodes glareolus HFRS/NE Europe 
     
New World     
 Sigmodontinae Sin Nombre  Peromyscus maniculatus HCPS North America 
 New York  Peromyscus leucopus HCPS North America 
 Monongahela Peromyscus leucopus HCPS North America 
 Black Creek 
Canal  
Sigmodon hispidus HCPS North America 
 Bayou  Oryzomys palustris HCPS North America 
 Choclo  Oligoryzomys fulvescens HCPS South America 
 Andes  Oligoryzomys 
longicaudatus 
HCPS South America 
 Bermejo  Oligoryzomys chocoensis HCPS South America 
 Lechiguanas  Oligoryzomys flavescens HCPS South America 
 Maciel  Bolomys obscurus HCPS South America 
 Oran  Oligoryzomus 
longicaudatus 
HCPS South America 
 Laguna Negra Calomys laucha HCPS South America 
 Araraquara  Bolomys lasiurus HCPS South America 
 Juquitiba  Oligoryzomus nigripes HCPS South America 
 
1Table adopted and modified from the article by Jonsson et al. 2010. Only hantaviruses known to induce a 
recognized clinical disease in humans are included.  
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Hantaviruses are enveloped ribonucleic acid (RNA) viruses with diameter 
varying from 70 to 120 nm (Figure 1) (Vaheri et al. 2011). They are composed of a 
spherical lipid envelope, four viral proteins and three single-stranded, negative-
sensed RNA segments designated S (small), M (medium) and L (large) which code 
for the nucleocapsid protein (NP), the surface envelope glycoproteins Gn and Gc, 
and the RNA-dependent RNA polymerase, respectively (Figure 1). NP is the most 
abundant of these viral proteins, and also has an important role in the life cycle of 
the virus (Jonsson et al. 2010).  
 
Figure 1. Hantavirus structure, genes and gene products. Hantaviruses have a tri-
segmented (L, M, S) negative-stranded RNA genome. The termini of the 
segments are conserved and complementary to each other. Hantaviruses 
carried by Cricetidae (but not Muridae) rodents have in the S segment an 
additional open reading frame (ORF).                                                                                          
Reproduced with permission from Oxford University Press (Vaheri et al. 2011: 
Hantaviruses. In “Oxford Textbook of Zoonoses ─ Biology, Clinical Practice 
and Public Health Control” 2nd edition. Oxford University Press. Oxford U.K.) 
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2.1.3 Ecology  
Rodent carriers of hantaviruses are chronically and asymptomatically infected. They 
shed the virus into the environment in their urine, saliva and feces perhaps 
throughout their lifetime, shedding, however, probably being greatest during the 
first 2–8 weeks after infection (Lee et al. 1981, Yanagihara et al. 1985, Hutchinson 
et al. 1998, Hardestam et al. 2008). Recent data indicate that hantaviruses are 
particularly stable, and remain infectious for up to ten days at room temperature, in 
winter possibly longer (Kallio et al. 2006, Hardestam et al. 2007). 
Humans do not belong to the natural host range of hantaviruses, and infection is 
suggested to occur via inhalation of virus-containing, aerosolized rodent excretions 
(Gajdusek 1982). In contrast, the Andes virus has been found to be transmittable 
from person to person (Padula et al. 1998), and also the transmission of PUUV via 
blood products has recently been suspected (Sinisalo et al. 2010). Nevertheless, 
living in close contact with infected rodents, work in professions such as forestry 
and farming, and outdoor activities in general are risk factors for HFRS (Ahlm et al. 
1994a, Zöller et al. 1995, Vapalahti et al. 1999, Olsson et al. 2003). Typically, the 
risk of infection is increased in activities such as cleaning out barns or summer 
cottages, and inhaling contaminated dry dust in a poorly ventilated space (Zeitz et 
al. 1995, Crowcroft et al. 1999, Van Loock et al. 1999). Interestingly, recent data 
also show that cigarette smoking increases the risk of NE (Vapalahti et al. 2010). 
This supports the previous conception that hantavirus transmission occurs by 
inhalation, the condition of the respiratory tract possibly contributing to the 
infection. 
In Northern Europe, bank voles undergo a 3–4 year cycle of population 
irruptions. These cycles are linked to the inter-annual variation in the incidence of 
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HFRS, and have been explained by variations in predator populations and 
availability of food (Crespin et al. 2002, Hörnfeldt 2004). During the peak phases of 
the bank vole population cycle, vole densities are high from the late summer of the 
peak year to late winter 1.5 years later (Vapalahti et al. 2003). The majority of NE 
cases occur from November to February, with a minor peak in PUUV infections 
also seen in August (Vapalahti et al. 2003, Heyman et al. 2009). The possible 
explanation for NE cases appearing during the late autumn and early winter is that 
the rodents are moving into human dwellings to avoid the cold winter (Niklasson 
and LeDuc 1987). Summer cases are probably a consequence of urban dwellers 
being infected during their summer vacations (Heyman et al. 2009). However, in 
continental Europe, the high epidemic years are predicted by the climate and tree 
seed production, conspicuous bank vole abundance and the highest numbers of NE 
cases occuring during the summer (Tersago et al. 2009).  
2.1.4 Epidemiology  
Worldwide, approximately 200 000 cases of HFRS are hospitalized annually 
(Muranyi et al. 2005). Globally most HFRS cases occur in the Far East, but the 
incidences of hantavirus infections are influenced in part by the use of diagnostic 
tests. In Europe, PUUV is the most common cause of HFRS. There is an increasing 
trend in the incidence of NE, with an average annual figure of 31/100 000 (Makary 
et al. 2010). In Finland 3200 cases of NE were recognized in 2008, but the incidence 
during recent years has usually ranged from 1000 to 3000 cases per year (National 
Institute of Health and Welfare, Finland 2010). In Sweden there are around 100–300 
HFRS cases per year and in Norway around 50 cases (Vapalahti et al. 2003). In 
2007, however, there were over 2000 PUUV infections in Sweden (Heyman et al. 
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2009). Climate change has probably contributed to the rise. In Northern Europe mild 
winters cause lack of snow cover and force rodents to seek shelter from the cold and 
predators in houses and other buildings (Pettersson et al. 2008a, Evander and Ahlm 
2009). In continental Europe, a combination of high summer temperatures and low 
precipitation, and high tree seed production has led to increases in bank vole 
populations, and also an increased incidence of NE cases (Tersago et al. 2009). 
The average PUUV seroprevalence in Finland is 5 % (in eastern Finland 11 %), 
suggesting that many infections remain subclinical and undiagnosed (Brummer-
Korvenkontio et al. 1999). Furthermore, antibodies to PUUV are present in 5.4 % of 
the healthy population in northern Sweden (Ahlm et al. 1994a), 5.1 % in Estonia and 
3.4 % in Saaremaa (Golovljova et al. 2002). Recent registry data on 22681 NE cases 
from Finland showed that 62 % of cases were males, and the highest incidences 
were observed in the age groups 34-49 years and 50-64 years (Makary et al. 2010). 
The reasons why children are less likely to suffer from HFRS, and why their 
infections seem to be milder than in adults remain obscure (Mustonen et al. 1994c, 
Huttunen et al. 2011).  
In the Balkans PUUV is also probably the most frequent cause of HFRS 
(Lundkvist et al. 1997, Hukic et al. 2010). However, Dobrava virus (DOBV), 
isolated from the yellow-necked mouse (Apodemus flavicollis) in Slovenia in 1988 
(Avsic-Zupanc et al. 1992), is the main cause of severe HFRS in the area 
(Antoniadis et al. 1996, Lundkvist et al. 1997, Avsic-Zupanc et al. 1999, Markotic et 
al. 2002). An epidemic of more than 2000 cases of DOBV infection was reported 
from 1995 to 1996 in Yugoslavia (Skataric et al. 1998) (cited in Bi et al. 2008), and 
the hantavirus antibody seroprevalences have been reported to be 5 % in Bosnia, 4 
% in Greece, 1.7 % in Slovenia and 1-6 % in Croatia (Heyman et al. 2009). 
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Saaremaa virus (SAAV), antigenically closely related to DOBV, was detected in 
field mice (Apodemus agrarius) in Estonia in the 1990s (Plyusnin et al. 1997a, 
Nemirov et al. 1999, Avsic-Zupanc et al. 2000). However, compared to DOBV, 
SAAV probably causes a milder type of HFRS (Golovljova et al. 2007). 
Furthermore, the European common vole (Microtus Arvalis) is a carrier of Tula 
virus, which appears to be apathogenic to human, but has also been linked to a 
clinical infection (Plyusnin et al. 1994, Vapalahti et al. 1996a, Schultze et al. 2002).  
In Russia there are a number of hyperendemic areas with high incidences of 
HFRS (58/100 000), although the figure is lower in the European part (5/100 000) 
(Vapalahti et al. 2003). Most cases are probably caused by PUUV (Vapalahti et al. 
2003). China has been the most markedly endemic country for HFRS, with 40000–
60000 cases reported annually during the last few years (Bi et al. 2008). Besides 
HTNV, in Asia Seoul virus, transmitted by urban rat (Rattus norvegicus), was 
shown to cause HFRS in Seoul in 1980s (Table 1) (Lee et al. 1982b). Furthermore, 
Amur virus has been isolated from the Korean field mouse (Apodemus peninsulae) 
(Yashina et al. 2001) causing HFRS in the area of Asia, and Thailand virus has been 
isolated from the bandicoot rat (Bandicota indica) (Pattamadilok et al. 2006, 
Nakamura et al. 2008).  
The first pathogenic hantavirus in the New World was discovered in 1993 in the 
southwestern part of the United States, causing hantavirus pulmonary syndrome, 
currently named hantavirus cardiopulmonary syndrome (HCPS). It was detected in 
deer mice (Peromyscus maniculatus), and named Sin Nombre virus (SNV) (Nichol 
et al. 1993). Other hantaviruses causing human disease in North America are listed 
in Table 1. From 1993 to March 2007 465 HCPS cases were reported from the 
United States (Jonsson et al. 2010). The first cases of HCPS in South America were 
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recognized in Brazil in 1993, caused by Juquitiba virus (Vasconcelos et al. 1997), 
and several other pathogenic hantaviruses have since been detected (Table 1). 
Interestingly, as far back as in 1982 Prospect Hill virus, apathogenic to humans, had 
been isolated from a meadow vole (Microtus Pennsylvanicus) in the United States 
(Yanagihara et al. 1984). 
2.2 Clinical features of hantavirus infections 
2.2.1 Clinical, laboratory and radiological findings in nephropathia 
epidemica 
The incubation period of acute PUUV infection has been estimated to vary from 1 to 
8 weeks (Settergren et al. 1989). Usually, the condition is characterized by a sudden 
onset of fever and headache, nausea, backache and abdominal pains. The most 
typical symptoms and laboratory findings in acute NE are described in detail in 4 
studies involving from 37 to 126 hospitalized patients and shown in Table 2 
(symptoms) and Table 3 (laboratory findings) (Lähdevirta 1971, Settergren et al. 
1989, Mustonen et al. 1994a, Braun et al. 2010). Typical renal findings are the phase 
of oliguria or anuria followed by polyuria (Table 2). Proteinuria, hematuria and 
increased serum creatinine levels are common (Table 3).  
Although NE belongs to the group of hemorrhagic fevers, serious hemorrhagic 
complications are rare. Epistaxis is found in up to 28 % of patients (Settergren et al. 
1989). Hemoptysis and diffuse bleedings from mucosal membranes have also been 
described (Settergren et al. 1988, Forslund et al. 1992). Hematemesis and melena 
are seen in a minority of the NE cases (Table 2), but hemorrhagic gastropathy is 
probably more usual (Nuutinen et al. 1992).  
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Table 2. Clinical symptoms and findings in patients with PUUV infection.                    
References: a=Lähdevirta 1971, b=Settergren et al. 1989, c=Mustonen et al. 1994a, d=Braun et al. 
2010. 
Symptom or finding Percentages of symptoms or findings (%) References 
General symptoms   
Fever 98-100 a,b,c,d 
Edema 9-59 a,b,c 
Lymphadenopathy  2-15 a,b,c 
Petechial rash 1-12 a,b,c 
Pain   
Backache 33-82 a,b,c,d 
Abdominal pains 30-67 a,b,c,d 
Myalgia 27-69 b,c,d 
Arthralgia 1-15 b,c 
Neurologic   
Headache 34-90 a,b,c,d 
Dizziness 9-34 a,b,c 
Meningism 1-5 a,c 
Nephrologic   
Tenderness in kidney area 48-84 a,c 
Oliguria/anuria 34-70 a,b,c,d 
Polyuria 45-100 a,b,c,d 
Visible hematuria 1-7 a,b,c 
Dysuria <1-12 b,c,d 
Ophthalmologic   
Visual disturbance 31-36 b,c 
Sensitivity to light  7-10 b,c 
Conjunctival bleeding 6-9 a,c 
Gastroenterologic   
Nausea 58-84 a,b,c 
Vomiting 51-70 a,b,c 
Diarrhea 7-20 a,b,c,d 
Constipation 8-34 a,b,c 
Melena/hematemesis 1-2/1 b,c 
Respiratory   
Red throat/tonsil exudates 19-67 a,c 
Cough 14-32 b,c 
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Table 3.  Laboratory findings in patients with acute PUUV infection. 
 Percentages of abnormal findings (%) 
Finding Lähdevirta
1 
(n=16-76) 
Settergren
2 
(n=74) 
Mustonen
3 
(n=126) 
 
Braun
4 
(n=75) 
Leukocytosis 57 NA 50 36 
Thrombocytopenia 57 NA 75 69
 
Elevated plasma CRP NA 96 NA 100 
Decreased serum 
albumin 
88 NA 50 NA 
Elevated serum 
creatinine 
85 96 NA 96 
Proteinuria 100 100 94 82 
Microscopic hematuria 74 85 58 65 
References: 
1
Lähdevirta 1971, 
2
Settergren et al. 1989, 
3
Mustonen et al. 1994a, 
4
Braun et al. 2010. 
Abbreviations: CRP=C-reactive protein, NA=not available. 
 
Thrombocytopenia is common (Table 3), and anemia is seen in 50 % of cases 
(Mustonen et al. 1994a). Recently, thrombocytopenia was found to be associated 
with a decrease in natural anticoagulants, shortened thrombin time and enhanced 
fibrinolysis (Laine et al. 2010) as well as activation of the thrombocytes (Laine et al. 
2011).  Disseminated intravascular coagulation was also diagnosed in 26 % of NE 
patients (Laine et al. 2010). The possible mechanisms underlying anemia are 
infection as such and acute renal failure, perhaps also aggravated by a bleeding 
tendency. However, high blood haemoglobin values may also be observed in the 
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early phase of NE, suggested to be a sign of hemoconcentration caused by increased 
capillary permeability (Kanerva et al. 1998a). Another possible mechanism involved 
in hemoconcentration is dehydration due to fever and vomiting (Lähdevirta 1971). 
Leukocytosis in NE is usually mild (Lähdevirta 1971, Mustonen et al. 1994a, 
Braun et al. 2010), and shifts to the left in differential counts of leukocytes 
(Lähdevirta 1971) and the presence of atypical lymphocytes can be detected as well 
(Settergren et al. 1989, Braun et al. 2010). A case with pronounced monocytosis has 
been described as well (Ala-Houhala et al. 2000). Increased levels of plasma C-
reactive protein (CRP) are found in almost all cases (Table 3). It has recently been 
shown, however, that high plasma CRP does not reflect the severity of the disease, 
but might even have a protective effect on renal function during acute NE (Outinen 
et al. 2010). 
Further, elevated levels of the liver enzymes are usual (Lähdevirta 1971, 
Settergren et al. 1989), although in a recent study from Germany they remained 
essentially unaffected (Braun et al. 2010). Transient electrolyte abnormalities such 
as hypocalcemia, hyponatremia, hyperphosphatemia, hypokalemia and 
hyperkalemia are often recorded (Mustonen et al. 1994a), and they are mainly 
related to acute renal failure. Decreased serum albumin levels have also been 
reported in most cases (Table 3), mainly associated with acute infection and often 
heavy proteinuria.   
Ocular symptoms and visual disturbances are commonly encountered during 
acute NE (Table 2), and the incidence of transient myopia has been found to be 8 % 
(Kontkanen et al. 1994). In a recent Finnish study, a total of 70 % of NE patients 
complained of ocular symptoms, and myopic refractation change was found in 74 % 
of cases (Hautala et al. 2010). Diminution of visual acuity affected 87 % and 
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decreased intraocular pressure 88 % of patients (Hautala et al. 2010). Since these 
visual disturbances were only partially explained by the myopic shift, there may also 
be extraocular mechanisms in the etiology of ocular symptoms. Further, 
conjunctival bleedings (Lähdevirta 1971, Mustonen et al. 1994a) and chemosis 
(Hautala et al. 2010) have been described during acute NE.  
Abnormal electrocardiogram (ECG) findings were observed in one third of 70 
PUUV-infected patients in a study from Croatia (Puljiz et al. 2005). In a Finnish 
study of 70 NE patients, 57 % presented with ECG changes (Mäkelä et al. 2009). 
Transient T-wave inversions have proved to be the most common findings (Mäkelä 
et al. 2009), and sinus tachycardia and bradycardia, and conduction defects have 
also been detected (Puljiz et al. 2005). In a study by Mäkelä and co-workers (2009), 
16 % of patients showed abnormalities in echocardiography (ECHO). Impaired 
contraction of the left ventricle was the most common finding, and one patient also 
had pericardial fluid. The abnormal ECHO findings could suggest myocarditis, 
although plasma troponin I levels were normal in all patients (Mäkelä et al. 2009). 
These results could also indicate myocardial dysfunction caused by fluid retention, 
abnormal plasma electrolyte levels, fever and cytokine release during acute 
infection. Nevertheless, during the follow-up both ECG and ECHO abnormalities 
reverted to normal in all patients, which would indicate their benign nature. 
However, acute clinical perimyocarditis may complicate acute NE (Lähdevirta 
1971, Mustonen et al. 1994a), and has also been reported in fatal cases (Valtonen et 
al. 1995).  
Abnormal findings in chest radiography are reported in 16-35 % of PUUV-
infected patients (Lähdevirta 1971, Mustonen et al. 1994a, Kanerva et al. 1996, 
Paakkala et al. 2004). The most usual findings are pleural effusions, atelectasis and 
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interstitial infiltrates (Lähdevirta 1971, Mustonen et al. 1994a, Kanerva et al. 1996, 
Paakkala et al. 2004). Frank pulmonary edema is rare (Kanerva et al. 1996), but in a 
few NE cases the clinical picture of the disease has been reported to be similar to 
HCPS with acute non-cardiogenic pulmonary edema (Clement et al. 1994, Launay 
et al. 2003, Seitsonen et al. 2006, Rasmuson et al. 2011a). 
Data on the clinical picture of NE in children are limited. However, the 
symptoms and clinical findings largely resemble those in adults, although the 
disease is usually milder in children than in adults (Mustonen et al. 1994c, Huttunen 
et al. 2011). Nausea, vomiting and abdominal pain have been reported more often in 
children than in adults (Ahlm et al. 1994b, Mustonen et al. 1994c). A recent 
systematic literature review likewise confirmed the clinical impression that NE is 
milder in children (Huttunen et al. 2011). Severe complications and deaths have 
been reported only in adult patients.  
2.2.2 Renal disease in nephropathia epidemica 
Back pain and tenderness of the kidneys are common symptoms in acute NE (Table 
2). Polyuria following the oliguric phase is reported in 45-100 % of patients, and 
may result in daily urine volumes up to 10 litres (Lähdevirta 1971, Settergren et al. 
1989, Mustonen et al. 1994a, Mäkelä et al. 2004, Braun et al. 2010). However, 
polyuria may also been seen without preceding oliguria indicating tubular 
dysfunction (Lähdevirta 1971). 
Proteinuria is the most common urinary sediment abnormality in patients with 
acute NE, detected in up to 100 % of cases (Lähdevirta 1971, Settergren et al. 1989, 
Mustonen et al. 1994a, Braun et al. 2010). It appears on the third to fifth day from 
the onset of fever, and peaks on average on day eight (Kanerva et al. 1998a). 
 33 
Nephrotic range proteinuria (> 3.5 g/day) is observed in 25-34 % of patients 
(Mustonen et al. 1994a, Mäkelä et al. 2004). Proteinuria in acute HFRS is non-
selective (Cosgriff 1991). Besides albumin, low-molecular-weight proteins such as 
β2-microglobulin, α1-microglobulin and immunoglobulin G (IgG) are detected in 
the urine during the acute phase of NE, contributing the proteinuria and reflecting 
tubular dysfunction (Settergren et al. 1990, Cosgriff 1991, Ala-Houhala et al. 2002, 
Mäkelä et al. 2004). Increased glomerular permeability is associated with both the 
size- and charge-selectivity properties of the glomerular filter in acute NE patients 
(Ala-Houhala et al. 2002). The pathogenesis of proteinuria in acute NE is not 
known. Immunological mechanisms may be important, as suggested by a positive 
correlation between increased urinary excretion of interleukin 6 (IL-6) and 
proteinuria (Mäkelä et al. 2004). However, proteinuria rapidly disappears during the 
polyuric phase of acute NE. 
Microscopic hematuria is detected in 58-85 % of cases with acute NE 
(Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, Braun et al. 2010), 
but macroscopic hematuria is rare (Table 2). Other urinary sediment findings 
reported are leukocyturia, granular and hyaline casts, and glucosuria (Lähdevirta 
1971, Settergren et al. 1989, Mustonen et al. 1994a, Braun et al. 2010).  
Transient impairment of renal function affects most hospitalized NE patients 
(Lähdevirta 1971, Settergren et al. 1989, Mustonen et al. 1994a, Braun et al. 2010). 
In the study by Settergren and co-workers (1989), 35 % of patients had serum 
creatinine levels over 500 μmol/l, the median value being 386 μmol/l. In one Finnish 
study the mean serum creatinine value was 439 μmol/l (Mustonen et al. 1994a). 
Measurement of the glomerular filtration rate (GFR) by 
51
Cr-EDTA or inulin 
clearance yields markedly reduced results during the acute phase of NE (Settergren 
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et al. 1990, Ala-Houhala et al. 2002). Ala-Houhala and co-workers (2002) have also 
shown that the effective renal plasma flow (ERPF) is significantly reduced and the 
filtration fraction (FF) markedly increased. Hypovolemia may contribute to these 
functional changes. However, acute renal failure may also affect patients without 
hypotension, which would point to intrarenal mechanisms of kidney injury (Cosgriff 
1991). The need for dialysis treatment is reported in 0-6 % of hospitalized NE cases 
(Settergren et al. 1989, Mustonen et al. 1994a, Mäkelä et al. 2004, Braun et al. 2010, 
Hukic et al. 2010), distinctly fewer compared with 16 % (Hukic et al. 2010) or even 
47 % in patients with DOBV infections (Avsic-Zupanc et al. 1999). 
Renal biopsies performed during the acute phase of NE reveal acute 
tubulointerstitial nephritis with minor glomerular changes (Collan et al. 1991, 
Mustonen et al. 1994b). The most characteristics lesions are interstitial edema and 
diffuse or focal inflammatory cell infiltrations consisting mainly of lymphocytes, 
monocytes, macrophages, plasma cells and eosinophilic granulocytes (Collan et al. 
1991, Mustonen et al. 1994b, Temonen et al. 1996).  Further, congestion or 
hemorrhages of the vessels in the outer medulla or corticomedullary junction have 
been detected (Collan et al. 1991, Mustonen et al. 1994b). Especially the interstitial 
hemorrhages should alert the pathologist to the possibility of NE (Mustonen et al. 
1994b). Tubular lumen dilatation and epithelial flattening as well as tubular casts are 
also common findings (Collan et al. 1991, Mustonen et al. 1994b). Mustonen and 
co-workers (1994b) found slight glomerular mesangial alterations, mainly 
hypersellularity or sclerosis, in 25 % of cases. Interestingly, the amount of 
proteinuria had no relation to the severity of histological findings in renal biopsy, 
but the highest serum creatinine level showed a slight correlation with tubular and 
interstitial findings (Mustonen et al. 1994b). Compared with the amount of 
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albuminuria seen during acute NE, the glomerular changes are surprisingly mild. In 
fatal cases of PUUV (Forslund et al. 1992, Valtonen et al. 1995) and DOBV 
infections (Avsic-Zupanc et al. 1999), hemorrhages and occasionally necrosis of the 
kidneys have been reported. 
Immunofluorescence (IF) studies show no specific deposits in renal biopsies 
performed during acute NE (van Ypersele de Strihou and Mery 1989, Mustonen et 
al. 1994b). Van Ypersele de Strihou and Mery (1989) reported mainly negative IF 
findings, but on a third of the biopsies complement (C) component 3 could be 
detected in the arterial walls. In one of the aforementioned Finnish studies, 
glomerular IF was negative in 43 % of biopsies (Mustonen et al. 1994b). Mainly 
mild mesangial and granular IgM, IgG, IgA, C3 or C1q were found. In one case a 
diagnosis of IgA nephropathy (IgAN) could be reached. Tubular and arteriolar C3 
was detected in a minority of the cases. Collan and co-workers (1978a, 1978b) 
studied 20 renal biopsy specimens from clinically diagnosed NE patients using 
electron microscopy. They found collections of light flocculent material under the 
endothelial cells and various deposits in the mesangium as well as splitting and 
thickening of the cortical and medullary tubular basement membranes.  
In the acute phase of NE, renal ultrasound study reveals an abnormal resistive 
index of renal parenchyma in half of the patients, and this is positively associated 
with the degree of clinical renal failure (Paakkala et al. 2002). Increased cortical 
echoicity and swelling as well as disturbances in corticomedullary border 
differentiation and perirenal fluid collections may also be seen, and altogether 47 % 
of NE patients may yield abnormal findings in renal ultrasound (Paakkala et al. 
2004). In HFRS patients, low signal intensity has been shown especially in the outer 
renal medulla by magnetic resonance imaging (MRI) probably representing 
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medullary hemorrhage (Kim et al. 1990). More recently, Paakkala and co-workers 
(2005) showed that renal parenchymal volume, renal length and parenchymal 
thickness are increased in MRI during acute NE, and these changes show a mild 
association with disease severity. Paakkala and co-workers (2006) have also 
performed magnetic resonance renography in acute NE patients and detected an 
abnormal uptake slope of the contrast enhancement curve. This finding likewise 
showed a mild positive correlation with the clinical severity of the renal 
insufficiency and fluid volume overload.  
2.2.3 Central nervous system symptoms and findings in nephropathia 
epidemica 
Central nervous system (CNS) symptoms are usual during acute NE (Lähdevirta 
1971, Settergren et al. 1989, Mustonen et al. 1994a, Alexeyev and Morozov 1995, 
Ahlm et al. 1998, Braun et al. 2010, Hautala et al. 2010). The most common CNS 
symptom is headache, which affects up to 97 % of patients (Alexeyev and Morozov 
1995). Other typical manifestations include insomnia in 83 % and vertigo in 79 % of 
patients (Ahlm et al. 1998), somnolence in 63 % and restlessness in 25 % 
(Lähdevirta 1971), and anxiety in 18 % (Settergren et al. 1989). Nausea and 
vomiting also characterize acute NE (Table 2), and may reflect the involvement of 
the CNS (Ahlm et al. 1998).  
Intracerebral hemorrhages predominantly in the region of the pituitary gland 
concomitant with necrosis have been diagnosed radiologically or found in autopsy 
studies in some cases with NE (Valtonen et al. 1995, Hautala et al. 2002, Hautala et 
al. 2010). In brain MRI, unspecific pituitary abnormalities such as uneven 
distribution of the contrast media and suspected edema have also been described 
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(Hautala et al. 2010). Furthermore, there are few reports of panhypopituitarism 
diagnosed during the acute phase of HFRS (Park and Pyo 1996, Hautala et al. 2002, 
Hautala et al. 2010), in one case only temporary (Hautala et al. 2010). Interestingly, 
PUUV antigen has been detected in the hypophysis in an autopsy of an NE patient 
(Hautala et al. 2002).  
One recent prospective study of 58 NE patients showed that altogether 87 % of 
patients experienced symptoms consistent with CNS involvement (Hautala et al. 
2010). Severe manifestations are, however, rarely reported. In a review of 811 NE 
cases, the incidence of severe neurological symptoms such as meningism, cerebral 
hemorrhage or seizures was only 1 % (Alexeyev and Morozov 1995). As rare 
phenomena, again, encephalitis (Launes and Hautanen 1988, Mustonen et al. 1994a, 
Bergmann et al. 2002, Hautala et al. 2002, Hautala et al. 2010), acute disseminated 
encephalomyelitis (Toivanen et al. 2002, Krause et al. 2003), meningism or seizures 
(Alexeyev and Morozov 1995), Guillain-Barre syndrome (Forslund et al. 1992, 
Esselink et al. 1994), and urinary bladder paralysis (Alexeyev and Morozov 1995) 
have been reported to complicate acute NE. 
In NE patients with CNS symptoms, analysis of cerebrospinal fluid specimens 
has revealed pleocytosis (Hautala et al. 2002, Hautala et al. 2010) or increased 
protein levels (Lähdevirta 1971, Settergren et al. 1988, Settergren et al. 1989, 
Forslund et al. 1992, Ahlm et al. 1998, Hautala et al. 2002, Hautala et al. 2010). 
Recently, PUUV RNA was also successfully detected in the cerebrospinal fluid of 
an NE patient evincing neurological symptoms (Mähönen et al. 2007, Hautala et al. 
2010). In one Swedish study, brain MRI showed minor, unspecific white matter 
lesions in about half of the patients investigated (Ahlm et al. 1998). In patients with 
encephalitis or acute disseminated encephalomyelitis, brain MRI has also revealed 
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abnormal signal intensity (Bergmann et al. 2002, Toivanen et al. 2002, Krause et al. 
2003). Furthermore, in one aforementioned Swedish study of 20 NE patients, 
electroencephalography (EEG) showed severe changes in one patient with seizures 
(Ahlm et al. 1998), while in a more recent study by Hautala and co-workers (2010), 
the EEGs of 33 NE patients were within normal limits. 
2.2.4 Clinical picture of nephropathia epidemica compared with other 
hemorrhagic fever of renal syndromes 
DOBV as well as HTNV infections usually cause similar, but more severe clinical 
courses of HFRS than PUUV infection (Lee and van der Groen 1989, Avsic-Zupanc 
et al. 1999). The five phases of HFRS (febrile, hypotensive, oliguric, diuretic and 
convalescent) described in HTNV-induced HFRS (Lee and van der Groen 1989) are 
not always clinically evident in acute NE. Mild and moderate cases constitute about 
90 % of all NE cases (Lähdevirta 1971). In the Balkans, the clinical picture of 
DOBV infection appears to be more severe than that of PUUV infection (Avsic-
Zupanc et al. 1999, Markotic et al. 2002, Hukic et al. 2010, Tulumovic et al. 2010). 
For example, severe hemorrhagic complications and shock have been described in 
DOBV but not in PUUV infections (Avsic-Zupanc et al. 1999). The reasons for the 
different clinical courses of hantavirus infections are unknown, but possibly the 
virulence of the individual virus, the infective dose or host factors contribute to the 
severity of the disease (Kanerva et al. 1998a). 
Mortality rates in PUUV infection range from 0.08 % in Scandinavia (Makary et 
al. 2010) to 0.4 % in Russia (Vapalahti et al. 2003). Only sporadic fatal cases have 
been described in Scandinavia (Linderholm et al. 1991, Forslund et al. 1992, 
Valtonen et al. 1995, Hautala et al. 2002). Lethality in PUUV infections has proved 
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attributable to shock and hemorrhages in several organs. In contrast, the mortality 
rate in DOBV infections has been reported to be 16 % (Avsic-Zupanc et al. 1999), 
while in HTNV infections it varies from 5 to 15 % (Lee 1996) (cited in Schmaljohn 
and Hjelle 1997).  
2.2.5 Hantavirus cardiopulmonary syndrome 
HCPS is a severe form of hantavirus infection typically characterized by severe 
pulmonary involvement. It comprises four clinical phases: prodrome, pulmonary 
edema and shock, diuresis and convalescence (Simpson et al. 2010). Cough is 
present in 60 % of HCPS patients on presentation, but dyspnea is not common until 
the phase of respiratory failure (Simpson et al. 2010). Ten percent of patients may 
suffer from severe abdominal tenderness during the prodromal phase. 
Thrombocytopenia develops in all patients, while petechiae are rare (Simpson et al. 
2010). The renal involvement in HCPS is not as marked as in HFRS, although 
proteinuria is detected in 40 % and hematuria in 57 % of HCPS cases on admission 
(Duchin et al. 1994). Serum creatinine values higher than 177 μmol/l have been 
detected in 20 % of HCPS patients (Peters et al. 1999). In case series from South 
America, the incidence of elevated serum creatinine values varied from 48 % to 54 
%, whereas severe renal failure and the need for dialysis treatment were uncommon 
(Castillo et al. 2001, Riquelme et al. 2003). Interestingly, the clinical picture of 
acute NE may in rare cases also resemble that of HCPS with noncardiogenic 
pulmonary edema (Clement et al. 1994, Launay et al. 2003, Seitsonen et al. 2006, 
Rasmuson et al. 2011a). These findings suggest the possibility of over-lapping in the 
clinical pictures of HFRS and HCPS. 
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Hypotension developing in the shock phase requires rapid, aggressive 
resuscitation (Simpson et al. 2010). Rapidly progressive pulmonary edema and 
hemorrhage may lead to respiratory distress syndrome requiring mechanical 
ventilation (Hallin et al. 1996, Dietl et al. 2008). Myocardial dysfunction is usual in 
the shock phase (Hallin et al. 1996), and recently Saggioro and co-workers (2007) 
showed typical myocarditis with hantaviral particles within endothelial and 
macrophage-type cells in an autopsy study. The authors thus proposed the name 
hantavirus cardiopulmonary syndrome instead of hantavirus pulmonary syndrome.  
Mortality in HCPS is very high. In data on 465 reported HCPS cases in the 
United States, the percentage of cases resulting in death was 35 % (Jonsson et al. 
2010). In case series mortality rates have been even higher, ranging from 59 % 
(Nolte et al. 1995) to 76 % (Duchin et al. 1994), and are highest during the first 24 
hours of shock phase. A detailed description of clinicopathological findings in 44 
fatal HCPS cases revealed multiorgan involvement with vascular congestion, but the 
main pathological findings were substantial pleural effusions and interstitial 
pneumonitis with congestion, edema and mononuclear cell infiltration (Zaki et al. 
1995). The alveoli contained abundant edema fluid and fibrin together with 
inflammatory cells as well as focal hyaline membranes. In the kidneys, no 
significant glomerular or tubulointerstitial changes were detected, although SNV 
antigens were found in the medulla and glomeruli. 
2.2.6 Diagnosis, treatment and prevention 
Acute hantavirus infection is currently diagnosed by an IgM enzyme immunoassay 
(EIA) test based on recombinant full-length hantavirus nucleocapsid protein (Vaheri 
et al. 2008). Rapid immunochromatographic IgM tests are also available for several 
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hantaviruses (Hujakka et al. 2001, Hujakka et al. 2003), and IgG EIAs can be used 
to confirm previous hantavirus infection. Hantaviral RNA can also be found in 
peripheral blood mononuclear cells, serum samples, urine, saliva or cerebrospinal 
fluid, but polymerase chain reaction (PCR) methods are not in routine use (Plyusnin 
et al. 1997b, Plyusnin et al. 1999, Evander et al. 2007, Mähönen et al. 2007, 
Pettersson et al. 2008b). 
Currently, no specific therapy for HFRS or HCPS is available. Of prime 
importantance is careful monitoring and supportive treatment of fluid balance, 
diuresis and respiration as well as pain relief (Vapalahti et al. 2003). Recently, Dietl 
and co-workers (2008) showed that in HCPS extracorporeal membrane oxygenation 
may reduce the complication rate and improve overall survival. HFRS patients may 
need hemodialysis sessions. In a prospective, randomized, double-blind study of 
antiviral agent ribavirin therapy in HFRS patients in China a sevenfold reduction in 
mortality was achieved compared with placebo (Huggins et al. 1991). Likewise, the 
risk of severe renal failure diminished almost fourfold, this probably contributing to 
the reduction in mortality. However, the total numbers of deaths in that study were 
small. A recent study of HNTV patients in Korea also suggested a decrease in renal 
complications in HFRS patients treated with ribavirin (Rusnak et al. 2009).  In 
contrast, one randomized study treating HCPS patients with ribavirin showed no 
benefit of the treatment (Mertz et al. 2004). Ribavirin has not so far been studied in 
Europe in the context of PUUV or DOBV infections. Two case reports have been 
published on the possible benefit of corticosteroids in PUUV infection. One 
involved treatment of marked and prolonged thrombocytopenia (Dunst et al. 1998), 
the other severe NE resembling HCPS (Seitsonen et al. 2006). Nevertheless, the role 
of corticosteroids in acute NE remains unclear. 
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Vaccines for HFRS have shown promise in clinical studies in Asia, but for 
European HFRS or HCPS there are for the present no available vaccines 
(Schmaljohn 2009). The only effective means of preventing hantavirus infection is 
avoidance of contact with rodents and rodent-occupied environments. It has been 
estimated that most HCPS cases (Armstrong et al. 1995) and Northern European 
HFRS cases (Olsson et al. 2003) occur in peridomestic areas. Holes in human 
dwellings should be blocked to prevent the entry of rodents (Vapalahti et al. 2010).  
Unoccupied buildings should also be allowed to air out properly before entering and 
starting cleaning, and dead or captured rodents or their excreta should be removed 
wearing rubber gloves and mask. Contaminated surfaces should be made wet, and 
handled with disinfectant. Poisoning may be better than trapping for rodent control, 
since poisoned rodents usually leave human dwellings before dying, whereas 
trapped rodents need to be removed (Vapalahti et al. 2010). Persons in occupations 
handling rodents or having repeated contacts with them should be educated to 
protect themselves from infection.   
2.3 Pathophysiology of hantavirus infections 
2.3.1 Endothelial cell 
It has not yet been determined how hantaviruses disseminate in the human body 
after inhalation, but immature dendritic cells may have an important role in that they 
may serve as vehicles for the virions to infect other immune cells, and they also 
express β3 integrins (Schönrich et al. 2008). Beta integrins are receptors for 
hantaviruses, allowing entry to the host cell, and β3 integrins are receptors for 
pathogenic and β1 integrins for apathogenic hantaviruses (Gavrilovskaya et al. 
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1998, Gavrilovskaya et al. 1999, Larson et al. 2005). Recently, a cell surface protein 
of the complement regulatory system, named decay-accelerating factor 
(DAF)/CD55, was also suggested to be important factor in hantavirus infection 
(Krautkrämer and Zeier 2008). Hantaviruses replicate in the cytoplasm, and the 
glycoproteins are targeted to the Golgi apparatus, where most hantaviruses bud 
(Spiropoulou 2001).  
Hantaviruses have been shown to infect endothelial, epithelial, macrophage, 
follicular dendritic and lymphocyte cells (Zaki et al. 1995, Mackow and 
Gavrilovskaya 2001, Raftery et al. 2002, Markotic et al. 2007). However, both 
clinical and pathological findings demonstrate that pathogenic hantaviruses 
specifically target the endothelial cells, and hantaviral antigens have been found 
especially in the kidneys and the lungs of infected patients (Yanagihara and 
Silverman 1990, Nolte et al. 1995, Zaki et al. 1995, Kanerva et al. 1998a, Maes et 
al. 2004).  
Increased capillary permeability and vascular leakage are the characteristic 
phenomena in hantavirus infection (Cosgriff 1991). However, the exact mechanisms 
involved in the pathogenesis of HFRS and HCPS are poorly understood. Beta3 
integrins regulate vascular integrity, endothelial cell permeability and platelet 
aggregation (Mackow and Gavrilovskaya 2009), and hantaviruses may inhibit these 
regular β3 integrin functions, probably interfering with the endothelial permeability 
function. The role of β3 integrins in patients with hantavirus infection has not 
however been evaluated (Mackow and Gavrilovskaya 2009). There are no data 
regarding direct viral cytotoxicity in vivo, and hantavirus infection alone does not 
affect the permeability of endothelial cells in vitro (Yanagihara and Silverman 1990, 
Pensiero et al. 1992, Temonen et al. 1993, Nolte et al. 1995, Zaki et al. 1995). 
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Prolonged response to cytokines (Niikura et al. 2004) and complement activation 
(Sane et al. 2011) may contribute to the increased vascular leakage. Recently, it was 
also suggested that pathogenic hantaviruses causing HFRS and HCPS sensitize 
human endothelial cells to the permeabilizing effects of vascular endothelial growth 
factor (Gavrilovskaya et al. 2008). Altogether, it is assumed that antiviral processes 
in the host cells and immune mechanisms are the main factors underlying the 
development of vascular dysfunction (Cosgriff 1991, Maes et al. 2004).  
2.3.2 Animal models 
The use of rodent-based models is limited in hantavirus infections, as these viruses 
causes an asymptomatic and persistent infection in their natural hosts. However, the 
nonhuman primate Cynomolgus macaque (Macaca fascicularis) can be 
experimentally infected with wild-type PUUV directly from Myodes glareolus, and 
develops symptoms and signs resembling human NE (Klingström et al. 2002). 
PUUV infection in the macaque resulted in lethargy, anorexia, proteinuria and 
hematuria, in addition to cytokine responses of interleukin 6 (IL-6), IL-10 and tumor 
necrosis factor alpha (TNF-α), as well as CRP, creatinine and nitric oxide (NO) 
responses. The increased titres of TNF-α seemed to correlate with a severe course of 
infection. The clinical picture of the disease also differed between the macaques as 
in humans. Recently, viral RNA and NP were observed in the kidneys, spleen and 
liver tissues of macaques with PUUV infection (Sironen et al. 2008). Inflammatory 
cell infiltrations in the kidneys contained mainly CD8-type T-cells, and they co-
localized with the markers of viral replication in the kidneys at the sites of tissue 
damage. 
 45 
2.3.3 Immune mechanisms 
2.3.3.1 Cellular and humoral immunology  and immunocomplexes 
Cytotoxic T lymphocytes (CTLs) are assumed to have an important role in the 
pathogenesis of hantavirus infections (Maes et al. 2004). Increased amounts of 
CD8
+ 
cells have been observed at the onset of HFRS (Huang et al. 1994, Markotic et 
al. 1999) and HCPS (Ennis et al. 1997, Kilpatrick et al. 2004), and have also been 
found in the lungs of patients dying from HCPS (Zaki et al. 1995).
 
 Higher numbers 
of CD8
+
 T cells have also been shown in bronchoalveolar lavage fluid (Linderholm 
et al. 1993) and in endobronchial mucosal biopsies (Rasmuson et al. 2011b) in 
patients with acute NE compared with healthy individuals. In patients with severe 
HCPS compared with those with moderate disease, the frequencies of SNV-specific 
CD8
+
 T cells in blood specimens have been particularly high (Kilpatrick et al. 
2004). Huang and co-workers (1994) also showed reduced ratios of T helper cells 
(CD4
+
) and CD8
+
 cells. In a recent study of HFRS patients, the peripheral subset of 
CD4
+
 cells appeared in reduced numbers compared with healthy individuals, and the 
frequency of the cells correlated positively with platelet count, and negatively with 
blood urea nitrogen, serum creatinine and serum aspartate aminotransferase (Zhu et 
al. 2009). In addition, a significant decrease in blood natural killer cells and an 
increase in these cells in bronchoalveolar lavage fluid have been found during the 
acute phase of NE, suggesting that natural killer cells migrate into infected tissue 
(Linderholm et al. 1993). In patients with NE, CD8
+
 memory cells have been shown 
to be rare during the acute phase, but gradually emerge in the convalescent phase 
(Tuuminen et al. 2007). It has also been shown that the virus-specific memory T 
cells persist for years after acute HTNV infection (Van Epps et al. 1999), Andes 
 46 
hantavirus infection (Manigold et al. 2010), and PUUV infection (Van Epps et al. 
2002).  
In recent years, indirect evidence has accumulated supporting the role of CTLs in 
the dysfunction of endothelial cells and increased capillary permeability in 
hantavirus infection (Terajima et al. 2007). Hayasaka and co-workers (2007) have 
shown that specific CTLs increase the permeability of an immortalized human 
leukocyte antigen (HLA)-matched human endothelial cell monolayer infected with 
SNV. In addition, a recent study of PUUV infection has suggested activation of 
CD8
+
 T cells and epithelial cell apoptosis (Klingström et al. 2006).  
Interestingly, one very recent study has shown the high activity of indoleamine 
2,3-dioxygenase (IDO) to be associated with higher maximum serum creatinine 
levels in acute NE patients (Outinen et al. 2011). IDO is an enzyme of amino acid 
metabolism expressed in immune cells such as macrophages and dendritic cells, and 
its increased activity probably leads to the inhibition of T-cell responses and 
proliferation (Outinen et al. 2011). 
The nucleocapsid protein of hantavirus is the major target of the early antibody 
response in HFRS and HCPS, whereas neutralizing antibodies for Gn and Gc 
glycoproteins appear later (Lundkvist et al. 1993a, Groen et al. 1994, Vapalahti et 
al. 1995, Bostik et al. 2000, Maes et al. 2004). There is also evidence from animal 
models indicating that NP induces efficient protective immunity (Lundkvist et al. 
1996, Maes et al. 2008).  An IgM response is seen during the acute phase of PUUV 
infection, and IgG antibodies also appear during acute disease, but an increase in 
IgG-antibody titres is seen later (Lundkvist et al. 1993a, Groen et al. 1994). 
Furthermore, increased titres of total and virus-specific IgE have been detected 
during the acute phase of PUUV infection (Alexeyev et al. 1994), and elevated 
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levels of specific IgA during the acute phase of HFRS (Groen et al. 1994, de 
Carvalho Nicacio et al. 2000) and HCPS (Bostik et al. 2000). Relatively high titres 
of neutralizing antibodies have been detected many years after PUUV infection 
(Lundkvist et al. 1993b) and HCPS (Ye et al. 2004, Valdivieso et al. 2006). In 
addition, in HCPS patients the clinical course of the disease is more benign if the 
titres of neutralizing antibodies are high in the acute phase (Bharadwaj et al. 2000). 
Activation of both the classical and alternative pathways of complement has been 
reported in acute NE, and shown to be associated with the severity of the disease 
(Paakkala et al. 2000, Sane et al. 2011). Immune complexes have also been 
demonstrated in serum, urine, glomeruli, tubules, skin and red blood cells as well as 
in platelets in HFRS patients (Jokinen et al. 1978, Penttinen et al. 1981, Chen and 
Yang 1990, Cosgriff 1991).  
2.3.3.2 Plasma and urinary cytokines and nitric oxide 
Several chemokines and cytokines are secreted in response to hantavirus infection 
(Muranyi et al. 2005). A study from Sweden showed in acute NE plasma TNF-α, 
IL-6 and IL-10 concentrations to be increased (Linderholm et al. 1996a). The 
maximum levels of plasma TNF-α concentration were seen 3 to 5 days after the 
onset of the infection. In a Finnish study, the serum concentrations of soluble IL-2 
receptor (sIL-2R), IL-6 and IL-8 were higher in patients with acute NE compared 
with healthy controls (Takala et al. 2000). Further, Stoltz and co-workers (2007) 
reported significantly decreased interferon lambda (IFN-λ) serum levels in NE 
patients in the acute phase compared to those in the convalescent phase, whereas the 
serum levels of IFN-α and IFN-β did not differ between acute and convalescent 
phases. Interestingly, in one recent study the plasma levels of IL-9, fibroblast 
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growth factor 2, and granulocyte-macrophage colony-stimulating factor were shown 
to be higher in female patients compared with males during the acute phase of NE 
(Klingström et al. 2008). In the same study, the plasma levels of IL-8 and IFN-γ-
induced protein 10 were lower in females than males. The authors concluded that 
the results may in part explain the higher rate of diagnosed NE in males than in 
females. However, the differences in plasma levels of cytokines no longer prevailed 
in the convalescent phase of the disease, implying that especially the acute cytokine 
responses are different between males and females (Klingström et al. 2008).  
In the context of HTNV infection, Krakauer and co-workers (1994) detected 
elevated plasma levels of IFN-γ and IFN-α in 110 patients from the Korean War. 
Furthermore, in the same material IL-1β was more often detected in patients than in 
controls, while the percentage of detectable TNF-α did not differ between the groups 
(Krakauer et al. 1995). In HCPS, there are only limited data regarding the serum 
levels of different cytokines. Borges and co-workers (2008) showed higher serum 
IL-6 and TNF-α levels in HCPS patients than in healthy controls, but the levels of 
anti-inflammatory cytokine transforming growth factor-β were significantly 
decreased in patients compared with the control group.  
Limited data have so far been published on the correlation of the clinical severity 
of human hantavirus infection with the serum levels of cytokines. A Finnish study 
of 19 patients with acute NE showed that serum levels of sIL-2R, IL-6 and IL-8 did 
not correlate with serum creatinine levels (Takala et al. 2000). However, sIL-2R 
correlated inversely with mean arterial pressure and minimum platelet count, and 
IL-6 also correlated inversely with minimum platelet count. In a Swedish study of 
15 NE patients, maximum levels of TNF-α and IL-6 correlated positively with the 
maximum levels of serum creatinine, and TNF-α also correlated inversely with 
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mean blood pressure (Linderholm et al. 1996a). Further, in a Belgian study, the 
highest serum levels of creatinine were detected in NE patients with lowest TNF-α 
production ex vivo (Maes et al. 2006). Another recent Finnish study showed that NE 
patients with high plasma IL-6 levels had higher maximum blood leukocyte counts 
and urinary protein excretion as well as lower minimum platelet count, hematocrit 
and urinary output compared to patients with low plasma IL-6 levels (Outinen et al. 
2010). Hospitalization was also longer in cases with high IL-6 levels. Furthermore, 
in HCPS, very high serum IL-6 levels are associated with hypotension and fatal 
outcome (Borges et al. 2008).  
Recently, high frequencies of HTNV-specific IFN-γ-producing T cells were 
detected during the acute phase of infection, and reported to be higher in patients 
with maximum serum creatinine ≤ 707 µmol/l compared with those with more 
severe renal failure (maximum serum creatinine > 707 µmol/l) (Wang M et al. 
2009). Moreover, the decrease in serum creatinine level was frequently 
accompanied by an increase in the magnitude of IFN-γ-producing T cells.  
There are limited data on the urinary excretion of different cytokines in 
hantavirus infection. In a study by Mäkelä and co-workers (2004), plasma IL-6 
concentrations and urinary IL-6 excretion were markedly increased in acute NE 
patients. There was no correlation between plasma and urinary IL-6 levels, probably 
reflecting the local production of IL-6 in the kidney during acute disease. 
Furthermore, increased urinary excretion of IL-6 correlated with urinary albumin, 
IgG and protein excretions, but not with serum creatinine levels (Mäkelä et al. 
2004).  
Increased production of NO induced by cytokines has been detected in acute 
PUUV infection (Groeneveld et al. 1995, Linderholm et al. 1996b) as well as in 
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HCPS (Davis et al. 2002), and may have a role in the pathogenesis of hantavirus 
infection. However, Borges and co-workers (2008) found no difference in serum 
levels of NO between HCPS patients and controls, although the levels were higher 
in fatal HCPS cases compared with survivors. In PUUV infection serum NO levels 
showed a positive correlation with the severity of the disease and serum creatinine 
(Groeneveld et al. 1995), and with the degree of hypotension (Linderholm et al. 
1996b). Serum NO levels also showed an inverse correlation with blood 
thrombocyte levels (Groeneveld et al. 1995).  
 
2.3.3.3 Immunohistochemical studies 
Immunohistochemical studies of tissue biopsies of patients with hantavirus infection 
also suggest a role of T lymphocyte activation and cytokines in the pathogenesis of 
the disease. In kidney biopsies from patients with NE, accumulations of mainly 
CD8
+
 T cells have been demonstrated in the peritubular areas (Temonen et al. 
1996). Also locally secreted cytokines, including TNF-α, TGF-β and platelet-
derived growth factor, have been seen in the peritubular areas of the distal nephron 
together with enhanced expression of adhesion molecules, including intercellular 
adhesion molecule-1, vascular cell adhesion molecule, and platelet endothelial cell 
adhesion molecule (Temonen et al. 1996).  
Autopsy studies of HCPS patients have shown that lung tissues contain abundant 
large immunoblasts consisting of CD4
+
 and CD8
+
 T cells (Nolte et al. 1995, Zaki et 
al. 1995). Mori and co-workers (1999) found high numbers of cells producing 
monocyte-derived (IL-1α, IL-1β, IL-6 and TNF-α) as well as lymphocyte-derived 
cytokines (IL-2, IFN-γ, IL-4 and TNF-β) in the spleen and lungs of HCPS patients. 
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The number of cytokine-producing cells was only moderately increased in the lungs 
of patients dying of non-HCPS acute respiratory distress syndrome (ARDS), and 
very few or no cytokine-producing cells were detected in the lungs of patients who 
died of causes other than ARDS. Recently, an autopsy study of heart biopsies from 
HCPS patients showed large macrophages and cardiomyocytes expressing TNF-α 
protein (Saggioro et al. 2007).  
 
2.3.4 Host genetic factors 
There are some data suggesting that the clinical course of HFRS and HCPS is to 
some extent influenced by host-related immunological factors. In a Finnish study of 
NE patients, most severe disease was seen in patients who had HLA B8 and 
DRB1*0301 alleles (Mustonen et al. 1996). All patients suffering from shock had 
these alleles, and also severe renal failure requiring dialysis treatment was 
associated with the same alleles. In contrast, only 8 % of 74 NE patients had the 
HLA B27 allele, and their disease showed a benign clinical course (Mustonen et al. 
1998). Kanerva and co-workers (1998b) studied the allelic polymorphism at position 
–308 of the TNF-α gene promoter region in NE patients and healthy controls, and 
found that the rarer TNF2 allele, associated with a high TNF-α producer phenotype, 
was more frequently present in NE patients than in controls. In another Finnish 
study of NE patients, the clinical course was also more severe in TNF2 allele 
carriers compared with non-carriers (Mäkelä et al. 2001). However, Mäkelä and co-
workers (2002) subsequently showed that the association of the TNF2 allele with 
severe NE may be due to strong linkage disequilibrium with HLA-B8-DR3. Maes 
and co-workers (2006) studied the TNF-α gene promoter polymorphism at position 
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–238 in 36 NE patients, and found patients with the GA-238 genotype (low TNF-α 
producers) to have a more severe clinical disease course. Further, Paakkala and co-
workers (2008) found the presence of HLA alleles B8, DR3 and TNF2 allele to be 
associated with the severity of abnormal chest radiography findings in NE patients, 
and especially with the presence of pleural effusion. In a study of NE patients with 
CNS symptoms, a significant negative correlation between cerebrospinal fluid 
inflammation and HLA-DR15(2)-DQ6 haplotype was found, indicating a possible 
role of genetic factors in central nervous system involvement (Hautala et al. 2010).  
Data on genetic susceptibility to other hantavirus infections are limited. In a 
recent study of HCPS patients from Brazil, TNF2 allele was more frequently present 
in HCPS patients compared to individuals with positive serology for HCPS without 
a history of clinical disease (Borges et al. 2010). However, there was no difference 
in the frequency of the TNF2 allele between infected patients and uninfected blood 
donors, suggesting that this allele does not select individuals who can be infected by 
hantavirus. Genetic susceptibility to HTNV infection has also been studied, and a 
significantly higher occurrence of HLA-DRB1*09 and HLA-B*46-DRB1*09 was 
revealed in Chinese patients compared to controls (Wang ML et al. 2009).   
2.4 Long-term prognosis 
2.4.1 Renal outcome 
The renal outcome of acute hantavirus infection has been considered favorable, 
although many previous studies have been uncontrolled, with small numbers of 
patients, or seroepidemiological studies or case reports. The first reports of long-
term renal outcome date from the 1960s and 1970s, and thus lack the serological 
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confirmation of hantavirus infection. Lähdevirta (1971) found no proteinuria in 20 
NE patients 1-6 years after acute disease, but renal concentration capacity was 
decreased in 8 patients and endogenous creatinine clearance in 5. Furthermore, 4 out 
of the 20 patients had creatinine clearance equally or above 130 ml/min/1.73m
2
,
 
indicating glomerular hyperfiltration. Later Lähdevirta and co-workers (1978) 
reported 5 out of 9 NE patients with slightly depressed tubular function 4-5 years 
after acute disease, but serum creatinine values and endogenous creatinine clearance 
were normal in all 9 patients. Earlier Rubini and co-workers (1960) had published a 
series of 9 HFRS patients of whom 4 developed impaired tubular function over 2 
years after the acute phase. 
In a prospective study of serologically verified NE cases from Sweden, 3 out of 
66 patients had persisting proteinuria (Settergren et al. 1989) and 3 had GFR < 80 
ml/min 6 months after acute disease (Settergren et al. 1990). Furthermore, after 8 
months of acute disease 3 patients had decreased urine osmolarity (Settergren et al. 
1990). However, 2 of the patients with decreased GFR had underlying chronic 
diseases and one had suffered from severe NE (Settergren et al. 1990). Also 3 
patients with tubular dysfunction had chronic diseases which may have contributed 
to the results (Settergren et al. 1990). A study from Greece, similarly, reported 3 
patients with renal tubular acidosis type I (complete in 1 and incomplete in 2 
patients) and 2 patients with reduced urine concentrating capacity 1-5 years after 
acute HFRS (Elisaf et al. 1993). Further, in a Finnish study of 8 NE patients, the 
urinary excretions and fractional clearances of albumin, IgG and IgG4 remained 
slightly increased 1 year after acute disease, and ERPF was also significantly lower 
and FF higher than in healthy controls (Ala-Houhala et al. 2002). Increased urinary 
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excretion of α1-microglobulin was likewise detected in NE patients 3 months after 
the acute phase.  
Ledina and co-workers (2003) have reported decreased creatinine clearance 
values in 4 out of 30 (13 %) HFRS patients examined 3-6 years after acute disease. 
In contrast, increased creatinine clearance was recorded in 10 out of 30 (33 %) 
patients. Six out of 23 (26 %) patients also had increased urinary excretion of β2-
microglobulin, and proteinuria was detected in 11 out of the 23 (48 %) patients. In a 
register study of patients undergoing quantitative urine protein tests, the prevalence 
of chronic renal disease was higher in 15 hantavirus seropositive patients compared 
with 73 seronegative controls (80 % vs. 44 %) (Glass et al. 1990). Glass and co-
workers (1993) have also shown that patients with proteinuria or end-stage renal 
disease are more commonly seropositive for hantavirus infection than the reference 
group. Furthermore, as a rare phenomenon, a case report from France has described 
a 15-year old boy with chronic renal failure 30 months after acute NE (Novo et al. 
1999), and a report from the United States described two patients with chronic renal 
failure over 13 months after acute HFRS (Glass et al. 1994). 
In a controlled study of the long-term prognosis of NE, Mäkelä and co-workers 
(2000) retrospectively collected 46 NE patients and compared them with 38 
seronegative healthy controls 5 years after the acute phase. Higher GFR and FF 
were noted in patients than in controls, but there was no difference between ERPF 
values. Increased glomerular filtration (GFR above 130 ml/min/1.73 m
2
) was 
detected in 13 out of 44 patients (30 %) and in 4 out of 38 controls (11 %). Patients 
also had higher urinary protein excretion than controls, although the amount of 
proteinuria could be classified as mild. However, this study added to the evidence of 
tubular dysfunction several years after acute HFRS, as 9 patients had increased 
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overnight urinary excretion of α1-microglobulin compared with only one of the 
controls showing signs of tubular dysfunction. 
Although renal complications during the acute phase of HCPS are not so 
commonly reported, patients may nonetheless have renal sequelae. In a recent study 
by Pergam and co-workers (2009), half of their 30 HCPS patients had proteinuria 
and in 25 % of the patients creatinine clearance was below 90 ml/min/1.73 m
2 
from 
4 to 96 months after acute disease.  
2.4.2 Blood pressure 
The first published observations of a possible relationship between hantavirus 
infection and elevated BP are from HTNV infection in the Korean War. Rubini and 
co-workers (1960) described 2 out of 13 patients evincing hypertensive vascular 
disease more than 2 years after acute infection. In a study by Lähdevirta (1971) 7 
out of 20 patients had systolic BP over 139 mmHg and 14 had diastolic BP over 89 
mmHg 1-6 years after the acute phase. Lähdevirta and co-workers (1978) also 
reported 1 out of 9 patients as hypertensive 4 years after NE. In a short report by 
Kleinknecht and Rollin (1994), 2 previously normotensive men needed 
antihypertensive therapy 2-6 months after acute HFRS. Further, in a retrospective 
study from Croatia, elevated BP was detected in 9 out of 30 (30 %) patients 3-6 
years after HFRS (Ledina et al. 2003). 
Seroepidemiological studies from Baltimore have also suggested an association 
of hantavirus infection with hypertensive renal disease. Hypertensive renal disease 
was diagnosed in 70 % of 15 seropositive patients compared with 9 % of 73 
seronegative patients (Glass et al. 1990). Furthermore, 6.5 % of patients with end-
stage renal disease due to hypertension were found to be seropositive for hantavirus 
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infection (Glass et al. 1993). In a Swedish study comparing 110 PUUV seropositive 
patients with 682 seronegative patients, hypertension correlated with seropositivity 
only in 60-year-old individuals, but not in younger patient groups (Niklasson et al. 
1994). In contrast with these results, a seroepidemiological study conducted by 
Ahlm and co-workers (1994a) found no association of hypertension with NE in 83 
seropositive patients compared with seronegative controls. In a study by Mäkelä and 
co-workers (2000), the BP of NE patients were evaluated by ambulatory BP (ABP) 
measurement. NE patients were found to have higher systolic BP 5 years after acute 
disease compared with healthy controls. Nine out of 46 (20 %) patients and 2 out of 
37 (5 %) were defined as hypertensive after acute NE. 
2.5 Hormonal disturbances associated with acute viral 
infections and acute renal failure 
2.5.1 Hormonal abnormalities after acute viral infections 
There are a few reports of radiologically confirmed pituitary hemorrhage 
complicating acute hantavirus infection (Suh et al. 1995, Hautala et al. 2002), and 
autopsy studies have revealed three other cases (Valtonen et al. 1995). In patients 
with HTNV infection, repeated brain high-resolution computed tomography scans 
have shown a progressive decrease in the height of the pituitary gland during a 
follow-up of 3 months (Lim et al. 1986). Also some reports of an empty sella 1 to 15 
years after hantavirus infection have been published (Saltevo and Forslund 1992, 
Pekic et al. 2005).  
There are a number of case reports but no systematic studies concerning pituitary 
hormonal dysfunction after PUUV infection (Saltevo and Forslund 1992, Settergren 
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et al. 1992, Hautala et al. 2002, Sane and Färkkilä 2002, Pekic et al. 2005) or other 
hantavirus infections (Lim et al. 1986, Suh et al. 1995, Park and Pyo 1996, Kim et 
al. 2001). In the NE case reports, patients suffered from secondary hypothyroidism, 
hypogonadism and hypocortisolism, i.e. panhypopituitarism. Panhypopituitarism 
was diagnosed in one patient during the acute phase of NE (Hautala et al. 2002), and 
in one patient 15 years after the acute disease (Saltevo and Forslund 1992). In the 
other NE cases, the diagnosis of panhypopituitarism was made 2-9 months after 
acute NE (Settergren et al. 1992, Hautala et al. 2002, Sane and Färkkilä 2002). 
Recently, Stojanovic and co-workers (2008) published a retrospective study of 60 
patients with previous HFRS from Serbia. A median of two years (mean 3.7) after 
acute HFRS they found growth hormone deficiency in 13 %, thyroid axis deficiency 
in 8 %, adrenal axis deficiency in 10 % and gonadal axis deficiency in 12 % of the 
patients. 
There are also some case reports in the literature of other viral infections causing 
meningitis and encephalitis in adults contributing to hypothalamic-pituitary 
dysfunction (Hägg et al. 1978, Kupari et al. 1980, Vesely et al. 2000, Schaefer et al. 
2008, Tsiakalos et al. 2010). The viruses recognized have been herpes simplex 
(HSV), Coxsackie B5 (CVB) and other enteroviruses, influenza-A, varicella, and 
tick-borne encephalitis virus. Evaluation of hypothalamic-pituitary function after 
viral CNS infections has revealed both panhypopituitarism, including diabetes 
insipidus and various partial pituitary defects (Schaefer et al. 2008), but the 
incidence of virus-induced hypopituitarism is unknown.  
Several viral infections have also been linked to thyroid diseases (Desailloud and 
Hober 2009). Retroviruses have been associated with subacute thyroiditis and 
Graves’ disease, the mumps virus with subacute and Hashimoto’s thyroiditis, and 
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the human T lymphotrophic virus-1, enteroviruses, rubella virus, HSV, Epstein-Barr 
virus (EBV) and parvovirus (PV B19) with Hashimoto’s thyroiditis. Furthermore, a 
recent case report describes a patient with HTNV infection and Graves’ disease (Jin 
et al. 2009). However, it remains obscure whether the viruses are responsible for the 
thyroid diseases or are merely innocent bystanders (Desailloud and Hober 2009).  
2.5.2 Hormonal changes in acute renal failure 
Severe acute diseases are known to be associated with a suppression of the 
hypothalamic-pituitary-gonadal axis (Spratt et al. 1993), or high serum levels of 
cortisol (Jurney et al. 1987). However, data on possible hormonal dysfunction 
during acute renal failure are limited.  
Kokot and co-workers (1982) found significantly reduced plasma testosterone 
(Testo) levels and elevated luteinizing hormone (LH) levels, as well as normal 
follicle-stimulating hormone (FSH) levels in male patients during the oliguric phase 
of acute renal failure. Furthermore, significantly elevated levels of serum prolactin 
(PRL) have been reported during acute renal failure. In a report on 20 male patients 
with acute renal failure caused by hypotension or rhabdomyolysis, the serum levels 
of FSH and Testo were low during the oliguric and diuretic phase, but normalized 
after recovery of renal function (Levitan et al. 1984). The serum level of PRL rose 
during the oliguric phase, but fell to normal during the diuretic phase, and the serum 
levels of LH did not change during the course of acute renal failure. The responses 
of FSH and LH to gonadotropin-releasing hormone and of PRL to TSH-releasing 
hormone were abnormal during acute renal failure, but normalized after recovery of 
renal function. Uremia per se or its metabolic consequences, for example secondary 
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hyperparathyroidism, may have been responsible for these hormonal alterations 
(Levitan et al. 1984).   
In chronic renal failure, the hypothalamic-pituitary-thyroid axis and the 
peripheral metabolism of thyroid hormones are affected (Iglesias and Diez 2009). 
Serum levels of thyrotropin (TSH) are usually normal or elevated, and thyroxine 
(T4) and T3 concentrations are normal or low. However, the data on acute kidney 
injury are limited. In a small study by Kaptein and co-workers (1981), patients 
suffering from acute renal failure presented with decreased serum levels of T4 and 
T3, and elevated levels of reverse T3. In a more recent study by Peeters and co-
workers (2003), low serum levels of TSH, and T4 and T3 were found in critically ill 
patients. In the subgroup of patients requiring dialysis treatment, the liver enzyme 
activity contributing to the production of T3 from T4 (type I iodothyronine 
deiodinase) was significantly lower than in patients not requiring dialysis treatment. 
Tubulointerstitial nephritis with uveitis or drug-induced AIN has also been reported 
in association with thyroid dysfunction (Iglesias and Diez 2009).  
2.6 Glomerulonephritis after viral infections 
Viral infections have been recognized to be associated with various glomerular 
diseases. Diagnosis is usually based on clinical and laboratory data as well as 
molecular analyses of renal biopsy specimens. Worldwide the most important viral 
infections relating to glomerulonephritides are hepatitis B (HBV) and C (HCV) 
infections. HBV infection has been mainly associated with membranous GN 
(MGN), membranoproliferative GN (MPGN) and IgAN (di Belgiojoso et al. 2002). 
As regards HCV infection, the cryoglobulinemia-mediated MPGN is the most 
common, but also MPGN without cryoglobulinemia, as well as MGN and IgAN 
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have been diagnosed (di Belgiojoso et al. 2002). Furthermore, human 
immunodeficiency virus (HIV) infection is especially closely related to the 
collapsing form of focal segmental glomerulosclerosis known as HIV-associated 
nephropathy (di Belgiojoso et al. 2002). 
In 1990, Grcevska and co-workers published a report on a patient with HTNV 
infection and diffuse proliferative glomerulonephritis with complete recovery of 
renal function. In a Finnish renal biopsy material of 86 acute NE patients, there was 
one case with IgAN (Mustonen et al. 1994b). In both of these cases the association 
of hantavirus infection with glomerulonephritis may be incidental. Recently, a case 
report of crescentic glomerulonephritis in a patient with HTNV infection and a 3 
months’ period of dialysis treatment was published (Kim et al. 2010). However, the 
association of glomerulonephritis with hantavirus infection in this case has been 
questioned by the reason of the atypical clinical course and lack of serological 
confirmation of recent HFRS (Clement et al. 2011).  
Previously, Mustonen and co-workers (2001) reported 5 patients with MPGN 
emerging during the convalescent phase of acute NE. All 5 patients suffered from 
peripheral swellings shortly after NE. At the time of renal biopsy, the amount of 
daily urinary protein excretion varied from 8 to 16 grams, and urinary sediment also 
revealed hematuria. Renal insufficiency was noted in 4 out of 5 patients with serum 
creatinine varying from 122 µmol/l to 524 µmol/l, and 4 patients were hypertensive. 
Three patients were treated with oral methylprednisolone. Four patients went into 
remission, but one started chronic dialysis treatment 3 months after the MPGN 
diagnosis. Renal biopsies were performed on 5 patients from 3 to 8 weeks after 
serologically verified acute NE. The light-microscopy finding was typical MPGN 
type 1 in all 5 cases, and in the specimens from 4 patients, there were infiltrating 
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polymorphonuclear leukocytes giving the exudative feature. In 4 cases IF specimens 
were available and showed granular and diffuse deposits of complement C1q or C3 
mainly in the capillary walls, and IgA, IgG and IgM were also found in the 
glomeruli.  
Other viruses are also possibly associated with glomerular diseases (di 
Belgiojoso et al. 2002). Hepatitis A virus has been reported with diffuse 
proliferative GN, PV B19 with collapsing glomerulopathy, endocapillary and 
mesangioproliferative GN, and cytomegalovirus (CMV), CVB as well as EBV have 
been suspected to be involved in the pathogenesis of IgAN. Recent case reports also 
suggest an association of CMV with MGN (Georgaki-Angelaki et al. 2009) and of 
EBV with MPGN (Karamadoukis et al. 2008). 
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3. AIMS OF THE STUDY 
The aims of this study were: 
 
1. To establish the long-term outcome of nephropathia epidemica (I and III) 
 
2. To study whether the clinical severity of nephropathia epidemica, as well as 
certain host genetic factors, predict the long-term outcome (II) 
 
3. To determine the prevalence of hormonal defects in patients with acute 
nephropathia epidemica and during long-term follow-up (IV) 
 
4. To describe seven patients presenting with nephrotic syndrome shortly after 
acute nephropathia epidemica (V) 
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4. SUBJECTS AND METHODS 
4.1 Subjects 
4.1.1 Patients 
Studies I, II and IV originally involved 70 prospectively recruited consecutive 
patients with acute hospital-treated NE during the years 1997-1999 (Figure 2). They 
were examined during the acute phase of the condition, and invited to attend a 
follow-up visit 3 and 12 months after acute disease. Fifty patients attended the 3-
month and 56 the 12-month visit. A third follow-up visit was scheduled 4-7 years 
after acute disease in 2004, and 43 patients participated. 
Thirteen out of these 43 patients had had chronic diseases prior to acute NE: 
hypertension in four, hypothyroidism in three, and diabetic nephropathy, 
glomerulonephritis, celiac disease, coronary heart disease, bronchial asthma and 
ankylosing spondylarthritis in one each. Henoch-Schöenlein purpura had been 
diagnosed in one patient over 30 years previously and renal tuberculosis in one 
patient likewise 30 years previously, but neither one showed any signs of chronic 
renal disease during the examinations. 
Since the aim of study I was to establish whether NE induces alterations in renal 
function and blood pressure, patients with a history of hypertension, diabetic 
nephropathy, and glomerulonephritis prior to NE were excluded from that study. 
Study I thus comprised altogether 37 patients (29 males and 8 females) aged 29-70 
(mean 49). The same cohort was included in study II. Neither the clinical severity of 
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acute NE nor the age of 37 patients participating in studies I and II differed from the 
33 dropouts of the original cohort (data not shown). 
Study IV involved 54 out of those 56 patients who participated in the 12-month 
visit, and whose serum samples were available for retrospective hormonal analyses. 
The cohort comprised 37 males and 17 females, aged from 15 to 70 (median 42) 
years (Figure 2). The severity of clinical picture of acute NE of 54 patients did not 
differ from the 16 dropouts of the original cohort (data not shown). However, these 
54 patients were slightly older than the dropouts during the acute NE (43±13 vs. 
35±11 years, P=0.038). 
Forty-six patients attended the 3-month visit. When the third prearranged follow-
up visit was scheduled in 2004, 38 out of these 54 patients attended. All serum 
hormonal levels were analysed retrospectively in 2007. On the basis of the results, 
six patients were invited to make an additional visit in 2008 (9 to 10 years after NE). 
The following chronic diseases were recorded in 14 patients: hypertension in four 
and hypothyroidism in two, as well as ankylosing spondylarthrosis, bronchial 
asthma, aortic valve disease, celiac disease, sequelae of renal tuberculosis, operated 
cancer of the vocal cords, operated meningeoma and osteoporosis in one each.  
The cohort for study III consisted originally of 46 patients hospitalized because 
of acute NE during the years 1990–1995 in Tampere University Hospital (Figure 2). 
Participants were recruited retrospectively. Thirty-six patients, 20 males and 16 
females, were examined 3 to 7 (mean 5) years after acute NE during the period 1996 
to 1997, and for a second time in 2003, 8 to 13 (mean 10) years after acute disease. 
In 2003, they were aged from 32 to 68 (mean 50) years. Five out of the 36 patients 
had suffered from some chronic disease before NE: ankylosing spondylarthritis (two 
patients), as well as coronary heart disease, bronchial asthma and chronic 
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schizophrenia in one each. The patient with asthma also had hypothyroidism. Data 
on the 5-year prognosis of this cohort of 46 patients have been published earlier 
(Mäkelä et al. 2000). 
Study V involved 7 patients (4 females and 3 males, aged from 27 to 59 years) 
with biopsy-proven glomerulonephritis shortly after acute NE (Figure 2). They 
suffered from acute NE during the years 2003-2008, except for one patient in 1992. 
One female patient had type I diabetes without complications, and two female 
patients had used L-thyroxine substitution for hypothyroidism before acute NE. 
None had used antihypertensive therapy before NE. The patients were from four 
different health care districts in Finland: four from Mikkeli Central Hospital and one 
each from Päijät-Häme Central Hospital, Länsi-Uusimaa Hospital and Tampere 
University Hospital. The physicians had diagnosed, treated and followed the 
patients in their own hospitals. 
In studies I-IV all patients continued their regular medication during the studies. 
Three patients in studies I and II, and two in study IV received L-thyroxine 
substitution therapy, but none received corticosteroid therapy.  
4.1.2 Controls 
Thirty-eight healthy controls with negative PUUV-serology had been recruited in a 
previous study of the 5-year prognosis of NE during the years 1996 to 1998 (Mäkelä 
et al. 2000). There were 22 males and 16 females aged from 27 to 64 (mean 44) 
years. The results of these examinations were used in study I. Controls were 
volunteers collected by open advertisement in the notice board of Tampere 
University Hospital. They were matched according to age and body mass index 
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(BMI) with the patients of the previous study of the 5-year prognosis of NE (Mäkelä 
et al. 2000). 
In 2003, a follow-up visit was scheduled. Twenty-nine controls, 14 males and 15 
females aged from 30 to 69 (mean 51) years, took part. They comprised the control 
group for study III. One of the controls in studies I and III suffered from 
hypothyroidism and continued her L-thyroxine substitution therapy during the 
examinations. 
Figure 2. Description of the patient groups of the studies I-V. 
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4.2 Methods 
4.2.1 Study protocols 
During the acute phase of NE (studies I, II and IV), detailed medical histories of the 
patients were obtained and physical examination performed. All blood specimens 
were drawn between 7.30 and 9.30 in the morning. The blood samples for analysis 
of plasma CRP, IL-6 and TNF-α, serum creatinine and blood cell count, as well as 
24-hour urinary protein and overnight α1-microglobulin, were collected on three 
consecutive mornings after hospital admission. The first blood sample for hormonal 
analyses in study IV was obtained on the first morning of hospital care, the second 
was taken on the third morning. The highest and the lowest value for the various 
variables measured during hospitalization were designated as maximum and 
minimum values, respectively. All serum samples for hormone analyses in study IV 
were stored at -70 ºC until analyzed. 
All the follow-up visits in studies I-IV were made on an outpatient basis in 
Tampere University Hospital. All blood samples for these visits were obtained in the 
morning after a minimum 12-hour fast, as were the spot samples of the morning 
urine. 
4.2.2 Analytical methods 
Plasma CRP levels were analyzed by Hitachi 705E analyzer from 1997 to 1998 and 
thereafter by a Roche Diagnostics CRP method using a Cobas Integra analyzer (F 
Hoffmann-LaRoche Ltd, Basel, Switzerland). The blood cell count was carried out 
by H2 or H3 hematological analyzer (Bayer Corporation, Tarrytown, NY, USA). 
From 1990 to 1999 serum creatinine, cholesterol and blood glucose were 
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determined by Vitros (Johnson&Johnson, Rochester, NY, USA), and from 2003 by 
Cobas Integra analyzer. Serum creatinine concentrations showed 10 % lower values 
during the years 2003 and 2004 than from 1990 to 1999 due to this change in 
determination method. The results on serum creatinine concentrations during the 
years 1990 to 1999 were multiplied by the coefficient 0.9 (studies I-III). Fasting 
blood glucose was determined from whole blood until the year 2003, whereafter the 
analysis was performed in plasma, thus producing 12 % higher values. The results 
for fasting plasma glucose before the year 2003 were multiplied by the coefficient 
1.12 (study I). In study I, the limits for impaired fasting glucose (IFG) were 6.1-6.9 
mmol/l, according to the guideline of the European Diabetes Epidemiology Group 
(Forouhi et al. 2006).  
In study IV all serum hormonal levels were analyzed retrospectively in 2007. 
Serum free thyroxine (fT4) and TSH were measured by a chemiluminescent 
microparticle immunoassay (Abbott Architect i2000 system, Abbott laboratories, IL, 
USA), cortisol, PRL, LH, and FSH by fluoroimmunoassay (1235 AutoDELFIA, 
Wallac Ltd., Turku, Finland), and estradiol (E2) as well as Testo by 
radioimmunoassay (1277 Gammamaster, Wallac Ltd). Serum levels of growth 
hormone (GH) were determined by time-resolved fluoroimmunoassay 
(AutoDELFIA hGH, Wallac Ltd.) and antibodies against thyroid peroxidase 
(TPOAb) by immunoluminometric assay (Abbott Architect Anti-TPO, Wiesbaden, 
Germany). 
 The reference ranges in study IV were 9.0-19.0 pmol/l for fT4, 0.4-4.0 mU/l for 
TSH, 180-680 nmol/l for cortisol, < 450 mU/l for PRL in male patients, < 600 mU/l 
in premenopausal women, and < 280 mU/l in postmenopausal women. The male 
reference ranges were 10.4-34.6 nmol/l for Testo, and 0.7-6.7 U/l for LH. As the 
 69 
phase of the menstrual cycle was not known, E2 below 0.1 nmol/l was regarded as a 
hypogonadal value for a premenopausal woman. The GH reference range was 0-
11.5 mU/l and for TPOAb <6 U/ml.  
Peri- and postmenopausal women in study IV were not analyzed for defects of 
the gonadal axis, as they were hypogonadal by definition. Their FSH and E2 levels 
were, however, included in the analysis of hormonal alterations between the acute 
phase of NE and 3 months later. Chronic, overt hypogonadism was defined as Testo 
(in men) and E2 (in premenopausal women) repeatedly below the reference range 
one year or more after acute NE. Chronic, subclinical/compensated testicular failure 
was diagnosed in male patients with chronically elevated LH but Testo within the 
reference range. Chronic, overt hypothyroidism was defined as fT4 repeatedly 
below 9.0 pmol/l and/or TSH repeatedly above 4.0 mU/l in patients with chronic 
thyroiditis, goiter, and/or symptoms suggestive of hypothyroidism (Baskin et al. 
2002). 
The 24-hour urinary protein excretion were measured by the pyrogallolal red 
molybdate method (Olli C, Kone Instruments, Helsinki, Finland) in the 1990s and 
by Cobas Integra 700/800 analyzer in 2003-2004 (studies I-III). The limit for 
increased 24-hour protein excretion was ≥ 0.22 g (study II). The overnight urinary 
excretion of α1-microglobulin was measured by nephelometry (Behring 
Nephelometer II analyzer, Behringwerke AG, Marburg, Germany) (studies I-III). A 
value for overnight urinary excretion of α1-microglobulin ≥7 μg/min was 
considered abnormal, based on the reference values for healthy subjects from the 
laboratory of Tampere University Hospital (studies I-III).  
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4.2.3 Puumala virus serology 
The serology of PUUV infection was detected by analyzing IgM- and IgG-class 
antibodies by enzyme immunoassays (Vapalahti et al. 1996b) (studies I-V). This 
analysis is based on the specific reaction of sera with PUUV NP. In study V, the 
PUUV infection in 3 out of 7 patients was diagnosed by rapid 
immunochromatographic IgM-antibody test (Hujakka et al. 2001). 
4.2.4 Cytokines 
Plasma IL-6 and TNF-α concentrations in studies II and IV were determined using 
commercially available enzyme-linked immunosorbent assays (ELISA; PeliKine 
Compact
TM
 human IL-6 and TNF-α kits; Red Cross Blood Transfusion Service, 
Amsterdam, the Netherlands). The detection limits for the assays were 0.4 pg/mL 
for IL-6 and 1.4 pg/mL for TNF-α. In the calculations, a concentration less than the 
detection limit was regarded as the detection limit of the assay in question. The 
highest plasma cytokine concentration determined during the first 3 days of 
hospitalization was designated the maximum cytokine concentration and used in 
calculations. 
4.2.5 Cytokine gene polymorphism and human leukocyte antigens 
The analyses of TNF-α and IL-6 gene polymorphism in study II were performed as 
described elsewhere (Wilson et al. 1992, Hulkkonen et al. 2001); the analyses of 
HLA-B8, -DR3 and -B27 in studies II and IV were determined as described by 
Westman and co-workers (1993). 
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4.2.6 Blood pressure 
Twenty-four-hour ABP was measured in studies I-III during one 24-hour period by 
oscillometric and/or auscultatory method using a non-invasive, fully automatic 
recorder (Novacor Diasys Integra; Novacor SA, Rueil-Malmaison France). 
Measurements were recorded at 15-minute intervals during the daytime, and at 30-
minute intervals during the night. The cut-off point for ABP used to define 
hypertension was a 24-hour mean ABP of more than 133/82 mmHg with reference 
to a large population study (Staessen et al. 1994).  
In studies II and III, the patients were defined as hypertensive if they were on 
hypertensive therapy, had a mean ABP ≥133/82 mm/Hg, or office BP ≥140/90 
mm/Hg (Guidelines Sub-Committee, 1999). Office BP was used to define 
hypertension only if ABP monitoring was not determined. 
4.2.7 Glomerular filtration rate and effective renal plasma flow 
In studies I-III, GFR was determined by a single-injection method as the plasma 
clearance of
 51
Cr-EDTA after a light meal, and expressed in values normalized for 
body surface area. Based on studies in healthy subjects, increased GFR was defined 
as a GFR ≥ 130 ml/min/1.73 m2 (studies I and II) (Vervoort et al. 2005). ERPF was 
estimated by the clearance of 
131
I-hippurate (studies I-III).  
4.2.8 Renal biopsy 
In study V, the renal biopsy specimens were processed for light-microscopic and IF 
studies. Paraffin sections were stained by hematoxylin-eosin, periodic acid/Schiff, 
Masson’s trichrome and Jones’ periodic Schiff-methenamine methods. IF studies 
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were made on cryostat sections using FITC-conjugated antisera against human IgG, 
IgA, IgM, C1q, C3, fibrinogen as well as kappa and lambda. 
4.2.9 Radiological examinations 
In study IV, thyroid ultrasound imaging (Vivid I, GEMS Ultrasound, Tirat Carmel, 
Israel) was performed by the same investigator (P.J.) on the 6 patients attending the 
additional visit in 2008. The hypothalamic-pituitary region was studied by MRI 
(MAGNETOM Trio 3-Tesla scanner, Siemens, Erlangen, Germany) in patients 
showing distinct hormonal deficits of central origin. 
4.2.10 Mathematical formulas 
Body mass index was calculated by dividing weight (in kilograms) by the square of 
height (in square meters) (studies I and III). FF in studies I and III was calculated as 
the quotient of GFR and ERPF. 
4.2.11 Statistical methods 
To describe data from studies I-IV, means and standard deviations (SDs) are given 
for normally distributed variables, and medians and ranges for skew-distributed 
continuous variables. In studies I-III, groups were compared using independent 
sample t-tests for normally distributed continuous variables, and Mann-Whitney U 
tests for skewed variables (studies I-IV). Categorical data were analyzed by χ2 test 
or Fisher’s exact test (studies I, III-IV). In study II, patients were divided into 2 
groups as having or not having elevated excretion of α1-microglobulin, increased 
GFR or hypertension, respectively. The Wilcoxon signed-rank test was used in 
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study IV to evaluate changes in hormone levels between the acute phase and 3 
months afterwards, and between 3 months and 1 year or 5 years, respectively. 
Correlations were analyzed using Pearson's correlation coefficient (study I) and by 
Spearman’s rank correlation coefficient (study IV). Skew-distributed urinary 
excretion of protein was log-transformed before analysis in study I. Binary logistic 
regression analysis was used in study I to describe the possible influence on results 
of differences in age and gender distribution between the patient and control groups. 
Odds ratios and their 95 % confidence intervals were given (study I). All tests were 
two-sided, and a p-value less than 0.05 was considered statistically significant. All 
analyses were performed with the SPSS for Windows (SPSS Inc., Chicago, IL, 
USA). 
4.3 Ethical considerations 
Written informed consent was obtained from all patients and controls participating 
to studies I-IV. For study V, the physician taking care of the patient asked patients’ 
permission to evaluate their hospital records. Studies I-IV were approved by the 
Ethics Committee of Tampere University Hospital. 
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5. RESULTS 
5.1 Outcome of patients six years after acute nephropathia 
epidemica and the influence of the clinical severity of 
acute disease on the long-term prognosis (Studies I and 
II) 
Patients had higher mean systolic BP, GFR and daily urinary excretion of protein 
than controls six years after acute NE (Table 4). Further, mean night-time systolic 
and diastolic BP values were likewise higher in patients than in controls [109±11 
(mean±SD) vs. 100±9 mmHg, P=0.001 and 70±7 vs. 66±7 mmHg, P=0.035, 
respectively]. Five patients had received antihypertensive medication after acute 
NE, and they continued their medication during the study, while none of the controls 
used antihypertensive drugs. Altogether 10 out of 37 (27 %) patients were found to 
be hypertensive after acute NE. GFR ≥130 ml/min/1.73m2 was detected in 10 out of 
37 (27 %) patients compared with 4 out of 38 (11 %) controls (P=0.067). ERPF and 
FF did not differ between the patient and control groups (646±116 vs. 627±105 
ml/min/1.73m
2
, P=0.470 and 19±3 vs. 18±3 %, P=0.166, respectively). Increased 
urinary excretion of α1-microglobulin was detected in 9 out of 35 (26 %) patients 
compared with 1 out of 38 (3 %) controls (P=0.005). 
Patients were approximately five years older than controls, and their serum low-
density lipoprotein cholesterol and fasting blood glucose levels were higher than in 
controls (Table 4). BMI or serum creatinine values did not differ between the 
groups. Type 2 diabetes had been diagnosed in one male patient after acute NE, and 
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one female patient was found to have high fasting blood glucose during the study. 
IFG was found in 7 out of 37 (19 %) patients, but in none of the controls (P=0.005).  
After adjusting for age and sex, the differences between the groups in BP, GFR 
and urinary protein excretion remained (P < 0.05 in each). GFR correlated inversely 
with age in the patient group, but not in the control group (r=─0.512 (correlation 
coefficient), P=0.001 and r=0.008, P=0.963, respectively). GFR was essentially the 
same in patients with diabetes or IFG compared with those with normal blood 
glucose values (118±15 vs. 119±20 ml/min/1.73 m
2
, P=0.194). Proteinuria and GFR 
were also positively correlated in the patient group (r=0.495, P=0.003), but 
proteinuria did not correlate with age or BP in either group (data not shown).  
 
Table 4. Clinical and laboratory findings in patients six years after acute NE 
compared with healthy controls. 
Finding Patients (n=37) Controls (n=38) P value 
Males/females (percentages of males) 29/8 (78 %) 22/16 (58 %) NS 
Age (years) 49 ± 11 44 ± 10 0.042 
Body mass index (kg/m2) 26 (20-47) 25 (21-34) NS 
24-hour mean systolic BP (mmHg)a 123 ± 11 117 ± 9 0.012 
Serum creatinine (µmol/l) 70 ± 12 73 ± 11 NS 
GFR (ml/min/1.73m2) 119 ± 19 109 ± 14 0.016 
Proteinuria (g/day)b 0.17 ± 0.05 0.14 ± 0.04  0.006  
Fasting blood glucose (mmol/l) 5.7 ± 0.6 5.1 ± 0.5 <0.001 
Serum LDL cholesterol (mmol/l) 3.5 (2.4-5.3) 3.2 (2.2-4.7) 0.039 
Means±SD are given for normally distributed variables and medians (range) for skew-distributed variables. 
Abbreviations: BP=blood pressure, GFR=glomerular filtration rate. 
aABP  monitoring was completed in 27 patients and 37 controls. 
bUrine for measurement of proteinuria was collected from 34 patients. 
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Tables 5 and 6 show the relation of variables reflecting the clinical severity of 
acute NE to the presence of urinary excretion of α1-microglobulin (Table 5), as well 
as to the presence of increased GFR and hypertension (Table 6) six years after acute 
disease. The results imply that abnormal findings found at six-year examinations 
cannot be predicted by the clinical course of acute NE. However, the maximum 
plasma IL-6 level during the acute phase of NE was higher in patients with 
increased urinary excretion of α1-microglobulin at six years than in patients with no 
excretion of α1-microglobulin (Table 5). Neither the plasma levels of IL-6 nor TNF-
α during the acute phase had any relation to the daily urinary excretion of protein, 
GFR or hypertension six years later (data not shown). Furthermore, the HLA-B8,                                        
-DR3, -B27 alleles, or TNF-α(-308) allele A or IL-6(-174) allele G were not related 
to renal function, urinary excretion of protein or hypertension six years after acute 
NE (data not shown). 
Table 5. Acute-phase laboratory findings in patients with increased or normal 
urinary excretion of α1-microglobulin six years after NE. 
Finding during the acute 
phase of NE 
Urinary excretion of α-microglobulin 6 years after acute NE 
 Increased (n=9)* Normal (n=26) P value 
B-Thrommin (10
9/l) 52 ± 26 68 ± 32 0.190 
S-CRPmax (mg/l) 84 (50-213) 64 (20-175) 0.128 
S-Creamax (µmol/l) 242 (81-653) 241 (70-878) 0.725 
dU-Proteinmax (g/day) 1.78 (0.71-17.78) 1.68 (0.30-10.00) 0.697 
cU-α1-miglomax (µg/min) 37 (11-46) 27 (7-209) 0.725 
P-IL-6max (pg/ml) 25.0 (14.8-59.1) 14.0 (3.3-43.7) 0.038 
P-TNF-αmax (pg/ml) 7.0 (1.8-16.3) (n=6) 5.7 (1.6-37.4) (n=19) 0.975 
Means±SD are given for normally distributed variables and medians (range) for skew-distributed variables. Abbreviations: B-
Thrommin=lowest blood platelet count, S-CRPmax=highest serum C-reactive protein concentration, S-Creamax=highest serum 
creatinine, dU-Proteinmax=highest daily urinary protein excretion, cU-α1-miglomax=highest overnight urinary α1-microglobulin, 
P-IL-6max=highest plasma interleukin-6, P-TNF-αmax=highest plasma tumor necrosis factor.  *≥ 7 µg/min 
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Table 6. Acute-phase laboratory findings in patients with increased or normal 
GFR, and in those with hypertension or normotension six years after acute 
NE. 
Finding during the 
acute phase of NE 
GFR 6 years after acute NE Hypertension 6 years after acute NE 
 Increased 
(n=10) 
Normal    
(n=27) 
P value Present 
(n=10) 
Absent  
(n=27) 
P value 
B-Thrommin (10
9/l) 60 ± 32 64 ± 32 0.770 75 ± 28 59 ± 33 0.192 
S-CRPmax (mg/l) 80 (20-175) 72 (22-213) 0.656 100 (22-213) 69 (20-157) 0.098 
S-Creamax (µmol/l) 285 (78-626) 192 (70-878) 0.906 321 (70-878) 187 (77-749) 0.335 
dU-Proteinmax 
(g/day) 
1.74 (0.14-
10.00) 
1.66 (0.30-
17.78) 
0.801 1.75 (0.30-
4.85) 
1.66 (0.14-
17.78) 
0.555 
cU-α1-miglomax 
(µg/min) 
24 (7-209) 29 (11-137) 0.511 29 (11-209) 26 (7-137) 0.371 
Means±SD are given for normally distributed variables and medians (range) for skew-distributed variables. 
Abbreviations: B-Thrommin=lowest blood platelet count, S-CRPmax=highest serum C-reactive protein 
concentration, C-Creamax=highest serum creatinine, dU-Proteinmax=highest daily urinary protein excretion, cU-
α1-miglomax=highest overnight urinary α1-microglobulin. 
5.2 Ten-year prognosis of acute NE (Study III) 
Compared to controls patients had higher mean ambulatory systolic and diastolic 
BP (Figure 3) as well as daytime and night-time systolic BP (data not shown) five 
years after acute NE. At ten years there was no difference between the groups either 
in mean ambulatory systolic and diastolic BP (Figure 4) or in daytime and night-
time BP (data not shown). However, according to the definition applied for the 
prevalence of hypertension there was a trend toward more hypertensive subjects in 
the patient group than in the control group at 10 years (39 % vs. 17 %, P=0.098). 
Table 7 shows the results on daily urinary protein excretion and nightly excretion 
of α1-microglobulin 5 and 10 years after acute NE in patients compared with 
healthy controls. There was more proteinuria in patients than controls at 5 years, but 
 78 
not at 10 years. There were also higher percentages of patients than controls at 5 
years evincing elevated urinary excretion of α1-microglobulin, but the difference did 
not reach statistical significance. GFR was higher in patients than in controls at 5 
years (121±19 vs. 109±16 ml/min/1.73 m
2
, P=0.012), while at 10 years patients’ 
GFR had decreased to the same level as in controls (113±20 vs. 108±17 ml/min/1.73 
m
2
, P=0.370). There were no statistically significant differences between the groups 
in ERPF or FF 5 and 10 years after NE (ERPF at 5 years: 627±105 vs. 615±112 
ml/min/1.73 m
2
, P=0.652, FF at 5 years: 20±3 vs. 18±3 %, P=0.071 and ERPF at 10 
years: 606±115 vs. 592±109 ml/min/1.73 m
2
, P=0.623, FF at 10 years: 19±4 vs. 
19±3 %, P=0.670). 
Patients had 1.8 units higher BMI at 10 years than at 5 years, whereas BMI 
among controls had not changed [27 (19-48) (median (range)) vs. 29 (22-44) kg/m
2
 
and 26 (21-34) vs. 26 (21-33) kg/m
2
, respectively], and the differences in BMI 
between patients and controls at 10 years were significant (P=0.003). Fasting blood 
glucose did not differ between the groups at 5 years (4.5±0.5 vs. 4.5±0.4 mmol/l, 
P=0.838), but was higher in patients at 10 years (5.1±0.6 vs. 4.6±0.4 mmol/l, 
P=0.002). 
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Figure 3. The mean ambulatory systolic and diastolic BP in patients 5 years after 
acute NE compared with healthy controls. Box plots of mean ambulatory 
systolic and diastolic BP show the median (─), the 25% and 75% 
percentiles (boxes), and the lowest and highest values (whiskers) which 
are not outliers. The outliers in mean systolic BP in controls and mean 
diastolic BP in patients are indicated by open circles. Outliers are the 
values which are between one and a half and three box lengths from either 
end of the box. The P values for both systolic and diastolic BP are < 0.05. 
Abbreviations: BP=blood pressure.  
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Figure 4. The mean ambulatory systolic and diastolic BP in patients 10 years after 
acute NE compared with healthy controls. Box plots of mean ambulatory 
systolic and diastolic BP show the median (─), the 25% and 75% 
percentiles (boxes), and the lowest and highest values (whiskers) which 
are not outliers. The outliers in mean systolic BP in controls and patients 
are indicated by open circles. Outliers are the values which are between 
one and a half and three box lengths from either end of the box. The P 
values for both systolic and diastolic BP are non-significant. 
Abbreviations: BP=blood pressure. 
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Table 7. Daily urinary protein excretion and the prevalence of nightly urinary α1-
microglobulin excretion in patients five and ten years after acute NE 
compared with healthy controls. 
 Patients        
(n=34-36) 
Controls      
(n=29) 
 Patients       
(n=36) 
Controls      
(n=29) 
 
Study year 1998 (5 years) 1998 P value 2003 (10 years) 2003 P value 
UPE 
(g/day) 
0.19 (0.12-0.38) 0.14 (0.09-0.24) <0.001 0.14 (0.07-0.24) 0.13 (0.06-0.31) 0.610 
α1-miglo 
(yes/n)a 
7/34 (21 %) 1/29 (3 %) 0.060 4/36 (11 %) 2/29 (7 %) 0.684 
Medians (range) are given for skew-distributed variables. 
Abbreviations: UPE=urinary protein excretion, α1-miglo=α1-microglobulin. 
a
Yes=urinary excretion of α1-micro ≥7 µg/min. 
 
 
5.3 Hormonal changes associated with NE (Study IV) 
5.3.1 Hormonal changes during acute NE and 3 months later 
Altogether 30 out of 54 (56 %) patients evinced abnormalities of the gonadal and/or 
thyroid axis during acute NE. The itemized prevalences of these abnormalities are 
shown in Table 8. Altogether 22 out of 54 (41 %) had multiple hormonal 
abnormalities. One of the five patients with elevated TSH and low-normal fT4 
levels, had been diagnosed with primary hypothyroidism previously and was using 
L-thyroxine substitution during the study.  
Central hormonal defects were detected in 19 and primary defects in 13 patients. 
Those with central hormonal defects had higher plasma creatinine concentrations 
and blood leukocyte counts compared with those with normal hormonal levels 
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(creatinine: 368 (79-749) vs. 208 (76-878) µmol/l, P=0.029 and blood leukocyte 
count: 13.4 (4.4-22.8) vs. 9.2 (6.7-23.4) x10
9
/l, P=0.033). The clinical picture of 
acute NE in patients with primary hormonal deficiencies did not differ from those 
with normal hormonal levels (data not shown). Neither were the cytokine levels nor 
HLA-B8, -DR3 and -B27 alleles related to the primary hormonal defects (data not 
shown). 
 
Table 8. Prevalence of gonadal and thyroid hormone deficiencies during acute NE. 
Group of patients 
 
Males (n=37) Premenopausal 
women (n=6) 
All patients (n=54) 
Serum hormone level 
abnormalities 
Low Testo Elevated LH 
with normal 
Testo  
Low E2 and FSH  Low fT4 
and low-
normal TSH 
Elevated TSH 
and low-
normal fT4 
Number of patients (%) 18/37 (49 %) 5/37 (14 %) 3/6 (50 %) 2/54 (4 %) 5/54 (9 %) 
Abbreviations: Testo=testosterone, LH=luteinizing hormone, E2=estradiol, fT4=free thyroxine, 
TSH=thyrotropin. 
 
In males, serum Testo levels were lower during acute NE compared with the 
levels 3 months later (Figure 5A) (9.9 (1.1-27.0) vs. 17.3 (7.8-25.4) nmol/l), 
whereas there was no difference in serum LH levels (Figure 5B) (4.0 (0.9-18.0) vs. 
3.6 (2.0-7.9) U/l). In females, serum FSH levels were lower during acute NE 
compared with those measured 3 months later (4.7 (0.6-40.4) vs. 23.7 (3.0-73.2) U/l, 
P=0.001), but no differences were noted in E2 levels (0.07 (0.02-0.42) vs. 0.11 
(0.04-0.49) nmol/l, P=0.263). Serum levels of cortisol (Figure 6) and PRL (Figure 
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7) were higher in both females and males during the acute phase than 3 months later 
(cortisol: 506 (358-928) vs. 305 (163-606) nmol/l in females and 551 (267-1157) vs. 
376 (182-553) nmol/l in males, prolactin: 269 (102-1364) vs. 212 (84-550) mU/l in 
females and 247 (32-829) vs. 124 (46-270) mU/l in males). Likewise, TSH was 
higher during acute NE compared with the serum levels 3 months later in the whole 
study group (1.90 (0.10-9.00) vs. 1.70 (0.02-7.60) mU/l, P=0.011), whereas the 
serum fT4 levels did not differ (data not shown).  
In males, the minimum serum Testo levels correlated inversely with age and 
blood leukocyte count (r=─0.341, P=0.039, and r=─0493, P=0.002, respectively), 
and with maximum levels of serum creatinine, IL-6, CRP and PRL (r=─0.437, 
P=0.007; r=─0.411, P=0.011; r=─0.352, P=0.032; r=─0.363, P=0.027, 
respectively), but not with BMI (r=─0.009, P=0.957). In the whole study group, the 
serum cortisol and PRL levels during the acute NE correlated positively with 
maximum plasma creatinine (r=0.352, P=0.009 and r=0.511, P<0.001, respectively) 
as well as IL-6 levels (r=0.319, P=0.019 and r=0.338, P=0.012), and with blood 
leukocyte count (r=0.370, P=0.006 and r=0.421, P=0.002). Serum cortisol levels 
also correlated positively with serum PRL levels during the acute phase of NE 
(r=0.402, P=0.003). Serum fT4 and TSH levels measured during acute NE did not 
correlate with age, BMI, plasma creatinine, CRP or cytokine levels (data not 
shown).  
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Figure 5. Serum Testo levels (A) and serum LH levels (B) in males during acute NE and after three 
months. The serum Testo levels were lower during acute NE than 3 months after, 
whereas serum LH levels did not differ between the acute phase and 3 months after. 
(P<0.001 for Testo and P=0.399 for LH; reference range for Testo 10.4-34.6 nmol/l and 
for LH 0.7-6.7 U/l). 
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Figure 6. Serum cortisol levels in female (A) and male patients (B) during acute NE and after three 
months. The levels were higher during acute NE than 3 months after in both sexes. 
(P=0.004 for females and P<0.001 for males; reference range 180-680 nmol/l).   
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Figure 7. Serum prolactin levels in female (A) and male patients (B) during acute NE and after 
three months. The levels were higher during acute NE than 3 months after in both sexes. 
(P=0.017 for females and P<0.001 for males; reference values <600 mU/l in 
premenopausal women, <280 mU/L in postmenopausal women, and <450 mU/l in 
males).  
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5.3.2 Hormonal changes 1 to 10 years after acute NE 
The serum levels of cortisol, PRL, fT4, TSH, Testo, LH, E2 and FSH measured 3 
months after acute the NE did not differ from the levels measured at 1 or 5 years 
(data not shown). During the median follow-up of 5 years, 9 out of 54 (17 %) 
patients presented with chronic, overt hormonal deficits. Four out of these 9 patients 
presented with central hypogonadism (all males), 4 with primary hypothyroidism (3 
males and 1 female), and one female with central hypogonadism and primary 
hypothyroidism. Due to the hormonal results, six out of these 9 patients were invited 
to an additional visit in 2008. A 43-year-old male patient with low testosterone and 
declining fT4 levels within the low reference range during acute NE, as well as at 3 
and 12 months, died for an unknown reason soon after his 1-year follow-up visit. 
The abnormal hormonal levels suggesting central hypogonadism and possible 
hypothyroidism were analyzed post mortem. The overt hormonal deficiencies in the 
other patients were also noted only during the additional visit in 2008. Only one 
female patient was on L-thyroxine substitution which was started 9 years after acute 
NE. Neither age or gender distributions, nor the clinical severity of acute NE 
differed between patients with chronic hormonal defects and those with normal 
hormonal levels. The host genetic factors studied were not related to the prevalence 
of chronic hormone deficiencies (data not shown). 
5.3.3 Radiological examinations 
Thyroid ultrasound was performed on 5 patients with primary hypothyroidism 
during the additional visit in 2008, and showed diffuse or patchy hypoechogenicity 
compatible with thyroiditis in all cases. Only two of these five patients had 
measurable levels of TPOAb. A pituitary MRI scan was also undertaken in 2008 on 
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two male patients with symptoms and hormonal changes suggesting defects of 
central origin, one with apparent GH deficiency and one with secondary 
hypogonadism and probable secondary hypothyroidism. The MRI scans revealed a 
normal hypothalamic-pituitary region in both of them.  
5.4 Glomerulonephritis diagnosed shortly after acute NE 
(Study V) 
Study V describes seven patients with glomerulonephritis diagnosed shortly after 
acute NE. The acute phase of NE was clinically typical and serologically verified in 
all patients. The lowest blood platelet count varied from 32 to 159 x10
9
/l, and the 
highest serum creatinine level ranged from 50 to 777 µmol/l and highest plasma 
CRP from 8 to 149 mg/l.  
These patients evinced symptoms and signs of nephrotic syndrome and were 
readmitted to the hospital 1 to 12 weeks after acute NE. Table 9 shows the 
histological and laboratory data and treatment during the follow-up, and also the 
time to remission. Renal biopsies, revealing MPGN type 1 in 5 patients, and MGN 
and MesGn in one each, were performed 4 to 56 weeks after NE. The lowest serum 
albumin at the time of renal biopsy varied from 13 to 32 g/l, and patients with 
MPGN or mesangial GN (MesGN) also had microscopic hematuria. In addition, 5 
of the patients were hypertensive. 
The renal biopsies of the patients with MPGN were performed 4 to 5 weeks after 
acute NE (Table 9). They showed typical signs of MPGN type 1 with lobular 
appearance of the glomerular tuft, and mesangial expansion as well as 
hypercellularity. Also double contouring of the glomerular basement membrane was 
detected. However, infiltrating polymorphonuclear leukocytes in glomeruli (patient 
 89 
1), slight mononuclear cell infiltration in the interstitium (patient 2) and interstitial 
edema (patients 4 and 5) were also found in the renal biopsy specimens. IF results 
were available for patients 2-5, showing capillary IgG in patients 2, 3 and 5, IgM 
(patients 2-4) and C3 (patients 2-5) as well as C1q (patient 3), and also mesangial 
IgG and IgM (patient 2) and mesangial C3 (patients 2 and 5). Table 9 presents the 
follow-up characteristics of MPGN patients, showing the median time to remission 
to be 0.6 years. Two out of the 5 MPGN patients were treated with corticosteroids 
by reason of worsening renal function. Furthermore, two patients received 
anticoagulation therapy, one for severe nephrotic syndrome and the other for 
pulmonary embolization.  
The renal biopsy specimen from patient 6 showed MGN with spikes and 
vacuoles on the capillary basement membrane without hypercellularity, and 
capillary IgG and C1q. In a biopsy of the patient with MesGn there was an increased 
mesangial matrix with mesangial IgG, IgM, IgA and C1q in IF study. The renal 
biopsy of the patient with MGN was performed over one year after the first 
symptoms and signs of nephrotic syndrome, as he was on anticoagulation therapy 
for thromboembolic complications. He received corticosteroids and 
cyclophosphamide for persistent severe nephrotic syndrome (Table 9). Table 9 
shows the follow-up details of the MGN and MesGn patients, respectively. 
As shown in Table 9, all patients achieved remission, the median time being 0.6 
(range 0.5-5.5) years. The median follow-up time was 1.7 (0.7-15.6) years. 
  
Table 9. Histological and laboratory findings, and time to remission in seven patients with glomerulonephritis shortly after acute NE. 
Patient Renal biopsy 
finding 
Time from acute NE to 
renal biopsy (weeks) 
Treatment S-Crea at the time 
of renal biopsy 
(µmol/l) 
S-Crea at the 
end of follow-up 
(µmol/l) 
Proteinuria at the 
time of renal 
biopsy (g/d) 
Proteinuria at the 
end of follow-up 
(g/d) 
Time to remission 
(years) 
1 MPGN 4 Di 200 79 14.9 < 0.30 1.3 
2 MPGN 5 ACEi 91 80 7.3 0.24 0.5 
3 MPGN 5 Di 62 49 9.8 0.17 0.6 
4 MPGN 4 Di,Wa,Co 233 75 27.2 0.09 0.6 
5 MPGN 5 Di,Wa,Co 186 114 4.3 0.15 0.5 
6 MGN 56 ACEi,Di,Co,CP,Wa 90 80 21.2 0.30 5.5 
7 MesGN 20 ARB 108 86 11.0 0.30 2.1 
Abbreviations: MPGN=membranoproliferative glomerulonephritis, MGN=membranous glomerulonephritis, MesGN=mesangial glomerulonephritis, Di=diuretics, ACEi=angiotensin-converting 
enzyme inhibitor, Wa=warfarin, Co=corticosteroids, CP=cyclophosphamide, ARB=angiotensin receptor blocker, S-Crea=serum creatinine. 
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6. DISCUSSION 
6.1 Long-term outcome of NE 
The long-term prognosis of PUU-hantavirus-induced acute tubulointerstitial 
nephritis is favorable. Five to 6 years after acute NE patients here had higher GFR 
and urinary protein excretion, as well as higher 24-hour systolic BP compared to 
healthy controls, but the differences between the groups disappeared during the 
follow-up of 10 years. The possibility of an increased risk of elevated BP after acute 
NE nonetheless remains. 
Limitations of studies I-III are relatively small sample sizes and the selection of 
only hospitalized NE patients, excluding milder forms of disease. Furthermore, 
study III was retrospective, and there were dropouts of 10 patients and 9 controls 
between the follow-ups from 5 to 10 years after acute NE. However, the results at 5 
years were essentially the same whether these lost study subjects were included or 
not. 
6.1.1 Renal function and proteinuria 6 and 10 years after acute NE 
Study I showed that 6 years after acute NE patients had higher GFR than controls, 
and glomerular hyperfiltration was detected in 27 % of the patients. Furthermore, 
patients had more proteinuria and more often urinary excretion of α1-microglobulin 
than controls. Most previous publications on the long-term prognosis of renal 
function and proteinuria after NE or other hantavirus infections have been reports on 
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small groups of patients (Rubini et al. 1960, Lähdevirta 1971, Lähdevirta et al. 
1978, Elisaf et al. 1993, Ala-Houhala et al. 2002) or seroepidemiological studies 
(Glass et al. 1990, Glass et al. 1993). Findings have suggested renal tubular 
dysfunction, proteinuria and decreased or increased creatinine clearance one to 
several years after acute hantavirus infection. In a recent retrospective study from 
Bosnia and Herzegovina, there were 14 patients with PUUV infection and 31 with 
DOBV infection, examined 10 years after acute disease (Tulumovic et al. 2010). 
The authors found that creatinine clearance in the DOBV-infected patients was 
lower than that in PUUV-infected patients, but was in both groups within normal 
limits. 
The study by Mäkelä and co-workers (2000) and study I are the first reports 
involving increased GFR 5 to 6 years after AIN compared with healthy controls. In 
a study from Croatia, one third of HFRS patients likewise presented with increased 
creatinine clearance values from 3 to 6 years after acute disease (Ledina et al. 2003). 
Glomerular hyperfiltration is a common observation in early diabetes mellitus, and 
is closely related to the progression of diabetic nephropathy (Wirta and Pasternack 
1995). Furthermore, there is evidence of increased GFR in early essential 
hypertension (Schmieder et al. 1997), and glomerular hyperfiltration predicting the 
development of microalbuminuria in hypertension (Palatini et al. 2006). Increased 
glomerular filtration rates have also been detected in early polycystic kidney disease 
(Wong et al. 2004). Probably the mechanisms causing hyperfiltration in these 
heterogeneous clinical situations are at least partly different.  
In study I, the finding that patients were older than controls cannot explain the 
difference in GFR between the groups, since GFR usually declines with age. 
Patients also had higher fasting blood glucose levels and more often IFG than 
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controls, which may have contributed to the results. However, there was no 
correlation between GFR and blood glucose, and GFR in patients with IFG or 
diabetes was essentially on the same level as GFR in those with normal blood 
glucose levels. Furthermore, in a previous study of the 5-year prognosis of NE with 
a similar difference in GFR between patient and control groups, there was no 
difference in fasting blood glucose levels (Mäkelä et al. 2000). Higher BP in 
patients compared with controls could also explain the difference in GFR, but there 
was no correlation between these parameters in study I. In addition, the increase in 
GFR was not accompanied by an increase in renal plasma flow, and the FF was thus 
higher in patients than controls. Mäkelä and co-workers (2000) suggest that this 
might contribute to increased intraglomerular pressure and GFR via an altered 
balance between the tone of afferent and efferent glomerular arterioles. However, 
the mechanism underlying the increased glomerular filtration rate 5 to 6 years after 
acute NE is not known, and according to study II neither the clinical severity of the 
acute phase of NE nor host genetic factors bore any relation to it. 
Study III showed the long-term prognosis of NE to be favorable. The differences 
in renal function between the patient and controls groups 5 years after NE 
disappeared during the follow-up of 8 to 13 years. The GFR in patients decreased to 
the same level as controls. The BMI of the patients increased during the follow-up 
and at 10 years was significantly higher than that of the controls. There are some 
data indicating higher GFR in patients with overweight compared with lean subjects 
irrespective of the presence of hypertension (Ribstein et al. 1995). Although the 
patients in study III had gained weight, their GFR showed a decreasing trend. 
Longer follow-up would probably have shown whether the GFR in the patients is an 
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early sign of renal injury which could lead to a further decline in GFR compared 
with controls. 
The urinary excretion of protein 6 years after NE was only mildly elevated in 
patients in study I, but nevertheless higher than in controls. The pathophysiological 
background to this finding is obscure, although renal biopsies from patients from 4 
to 5 years after acute NE have shown increased numbers of hyalinized glomeruli, a 
slight thickening of basement membrane and periglomerular fibrosis as well as 
patchy interstitial fibrosis, tubular atrophy and tubular casts (Lähdevirta et al. 1978). 
In addition, Elisaf and co-workers (1993) carried out a renal biopsy on one patient 
one year after acute HFRS, and the specimen showed some degree of interstitial 
fibrosis and tubular atrophy together with sclerosed glomeruli. Further, higher BP 
and GFR in patients than in controls may explain the difference in proteinuria 
between the groups. Indeed, GFR correlated positively with urinary protein 
excretion in the patient group, whereas BP did not, which is in accord with previous 
findings (Mäkelä et al. 2000). According to study II, neither the clinical severity of 
acute NE nor host genetic factors explained the presence of proteinuria 6 years after 
acute NE. In study III, the difference between the patient and control groups in 
urinary excretion of protein no longer prevailed, confirming the favorable long-term 
renal outcome of NE. 
Increased urinary excretion of α1-microglobulin was more usual in patients than 
in controls 6 years after NE in study I, as was also found in the earlier study by 
Mäkelä and co-workers (2000). Alpha-1-microglobulin is a low-molecular-weight 
glycoprotein produced by the liver and found in most organs, also in the kidney 
(Berggård et al. 1998). It is freely filtered by glomeruli, re-absorbed in proximal 
tubules and mostly degraded in the kidney, but a small part of it is also excreted in 
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the urine. In one recent study it was concluded that the excretion rate of α1-
microglobulin is higher in the daytime than during the night, and it is also higher in 
males than in females (Andersson et al. 2008). In studies I-III here, the urinary 
excretion of α1-microglobulin was measured only at nighttime. In studies I and II, 8 
out of 9 patients showing increased excretion of α1-microglobulin were males. The 
biological function of α1-microglobulin is unknown, but it is considered to have 
immunosuppressive and radical reductant properties (Åkerstrom et al. 2007).  
In renal diseases, increased urinary excretion of α1-microglobulin has been found 
to be a sign of disturbed tubular function and tubulointerstitial damage (Bazzi et al. 
2000, Bakoush et al. 2001). Furthermore, some data suggest a role for α1-
microglobulin in predicting an unfavorable outcome of acute tubular necrosis 
(Herget-Rosenthal et al. 2004, Parikh et al. 2010) and of glomerulopathies (Bazzi et 
al. 2001, Branten et al. 2005). There is also evidence from a study of drug-induced 
AIN that α1-microglobulin may predict the severity of tubular atrophy, interstitial 
edema and inflammatory infiltration in renal biopsy specimens (Wu et al. 2010). In 
studies I and II, the increased urinary excretion of α1-microglobulin in NE patients 6 
years after acute phase can be considered to be a sign of tubular dysfunction.  
In study II, neither the clinical severity of acute NE nor the amount of α1-
microglobulin excretion during acute NE predicted the occurrence of α1-
microglobulin excretion 6 years after. However, the highest plasma IL-6 levels 
during acute NE were higher in patients with increased urinary excretion of α1-
micorglobulin 6 years later than in patients with no raised excretion of α1-
microglobulin. The possible link between plasma IL-6 levels and increased 
excretion of α1-microglobulin is obscure. From a rat model there is controversial 
evidence of IL-6 stimulating the synthesis of α1-microglobulin in the liver 
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(Pierzchalski et al. 1992). Furthermore, in a recent study of newly diagnosed 
hypertensive patients, α1-microglobulin was found to be associated with circulating 
acute-phase proteins such as CRP, amyloid A and fibrinogen (Vyssoulis et al. 2007). 
The authors suggested that there can be increased synthesis of α1-microglobulin in 
the liver stimulated by proinflammatory cytokines, or increased urinary excretion of 
α1-microglobulin may also be a sign of disturbed proximal tubular function. 
There are only a limited number of studies of the long-term outcome of AIN, and 
they mostly concern the drug-induced disease. Baker and Pusey (2004) published a 
review of 3 series of studies of AIN with different etiologies, of which about 15 % 
were infection-related. In the series in question, 12.5 % of the patients had remained 
on renal replacement therapy and 23.4 % had achieved partial recovery. Increasing 
age of the patients was associated with poorer prognosis, but not the peak serum 
creatinine concentration. In a retrospective study of 56 biopsied patients with AIN, 
median serum creatinine one year after acute disease was 140 µmol/l, whereafter 
most patients maintained a stable GFR (Clarkson et al. 2004). There are also 
conflicting findings regarding the correlation between renal biopsy findings of 
cellular infiltration, tubulitis, interstitial fibrosis in AIN and renal outcome (Baker 
and Pusey 2004, Praga and Gonzalez 2010). These observations may be due to the 
patchy nature of the disease and random sampling on renal biopsy (Baker and Pusey 
2004). 
In summary, the prospective study I confirmed the previous findings in a 
retrospective study that NE patients have a higher glomerular filtration rate and 
more daily urinary excretion of protein as well as overnight excretion of α1-
microglobulin 6 years after the acute phase compared with healthy controls. Study II 
showed that these findings are not determined by the clinical severity of acute NE. 
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Finally, 10 years after acute NE the differences in GFR and proteinuria were no 
longer prevalent, confirming the favorable renal prognosis of NE (study III).  
6.1.2 Blood pressure 6 and 10 years after acute NE 
In study I, the mean and night-time systolic and night-time diastolic BP in ABP 
were higher in patients than in healthy controls 6 years after acute NE. This is in line 
with previous findings on BP in patients compared with controls 5 years after the 
acute phase (Mäkelä et al. 2000). Furthermore, in study I antihypertensive 
medication had been initiated in 5 out of 37 (14 %) patients after acute NE 
compared with none among the controls. Previous publications regarding the 
possible contribution of hantavirus infection to hypertension have been case reports 
with shorter follow-up times (Rubini et al. 1960, Lähdevirta 1971, Lähdevirta et al. 
1978) or seroepidemiological studies (Glass et al. 1990, Glass et al. 1993, Niklasson 
et al. 1994). In one recent study of 10-year outcomes of PUUV- and DOBV-infected 
patients, there were altogether 42 % hypertensive patients and no difference 
between the groups in the prevalence of hypertension (Tulumovic et al. 2010). This 
finding, together with the results of study II, suggests that even mild-type hantavirus 
infection may predispose to hypertension. However, in the study from Bosnia and 
Herzegovina the possibility of elevated BP before PUUV or DOBV infection was 
not ruled out (Tulumovic et al. 2010). There are no data on BP after AIN with 
different etiologies. 
The patients here were approximately 5 years older than the controls in study I. 
This may have contributed to the difference in BP between the groups, although 
there was no significant correlation between age and BP, and the difference between 
the groups also remained after adjusting for age. The results also remained the same 
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if subjects using antihypertensive medication were excluded from the study. Study 
II showed that neither the clinical severity of acute NE nor host genetic factors 
predict the emergence of elevated BP in patients 6 years after acute phase. 
Study III showed that there was no difference in ABP between patients and 
controls 10 years after acute NE. Combined analysis defining hypertensive subjects 
as those using antihypertensive medication, having elevated BP in ABP or elevated 
office BP showed that 5 years after NE there were more hypertensive subjects 
among the patients compared to the control group. At 10 years 39 % of patients and 
17 % of controls were hypertensive, but this difference was not statistically 
significant. On the other hand, at 10 years BMI in the patient group was higher 
compared with that of controls, this probably also contributing to the BP results. 
Furthermore, there were dropouts of 10 patients and 9 controls during the follow-up 
from 5 to 10 years, which may also have had an effect on the results, although the 
outcome of BP at 5 years was essentially the same with the larger group of patients 
and controls in the previous study (Mäkelä et al. 2000). 
The possible etiopathogenetic link between hantavirus infection and hypertension 
is not known. It has been suggested that in the pathogenesis of hypertension renal 
involvement has an important role (Johnson et al. 2008). Hypertension may be 
initiated by the agents causing systemic and renal vasoconstriction, leading to 
intrarenal microvascular disease especially in the outer medulla (Johnson et al. 
2002, Johnson et al. 2008). In theory, hantavirus infection might act as an initiating 
factor for renal vasoconstriction. Autopsy studies or renal biopsies from patients 
with hantavirus infection have shown that the renal medulla is the most seriously 
affected part of the kidney, with congestion and hemorrhages around the vessels 
together with interstitial inflammatory cell infiltrates (Lähdevirta 1971, Gajdusek 
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1982, Collan et al. 1991, Mustonen et al. 1994b). Moreover, the tendency of 
hantavirus to infect vascular endothelial cells could contribute to vascular damage 
(Yanagihara and Silverman 1990, Pensiero et al. 1992, Glass et al. 1993). 
In summary, study I showed that patients have higher 24-hour systolic BP 
compared to the control group 6 years after acute NE, and that the severity of acute 
NE bears no relation to it, as shown in study II. However, 10 years after acute NE 
the difference in BP between the patient and control groups no longer persists, 
confirming the favorable outcome of the patients (study III). There was nevertheless 
a tendency to a greater prevalence of hypertension in the patient than control group, 
suggesting a possible role of hantavirus infection predisposing to hypertension. 
6.2 Hormonal deficiencies and NE 
The prevalence of hormonal abnormalities during the acute phase of NE has not 
hitherto been systematically evaluated. In study IV, 56 % of the patients with acute 
NE were found to have hypogonadism and/or hypothyroidism of either central or 
peripheral etiology. 
Most hormonal deficiencies of the gonadal axis during the acute phase of NE 
were of central origin, and disappeared within 3 months. Approximately half of the 
male patients presented with low serum Testo levels and half of the premenopausal 
women with low serum E2 and FSH levels in the acute phase. The serum Testo 
levels in males and FSH levels in females increased significantly, while the serum 
LH levels of males did not change within 3 months, implying a central origin of 
temporary hypogonadism in most cases. However, there were also 8 male patients 
presenting with primary hypogonadism during acute NE, although clinical orchitis 
was not detected, and later 3 of them had chronically elevated serum LH levels with 
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serum Testo levels within normal limits. Altogether, the prevalence of primary 
hypogonadism in study IV with males of a median age of 39 years was higher than 
reported in males of this age group in general (Härkönen et al. 2003, Tajar et al. 
2010).  
Viral orchitis has been connected with several viruses, but is most commonly 
caused by the mumps virus, which may predispose to testicular failure, including 
decreased Testo production (Dejucq and Jegou 2001). Acute renal failure may also 
contribute to both central and peripheral hypogonadism, as has been suggested in 
previous studies (Kokot et al 1982, Levitan et al. 1984). The low serum Testo levels 
in male patients during the acute NE were related to the degree of inflammation and 
severity of acute renal failure. In one earlier study of male patients in an intensive 
care unit, the serum Testo and FSH levels were also lower in patients with severe 
illness compared with those with mild or moderate illness (Spratt et al. 1993). Many 
forms of stressors, for example infection, may suppress the activity of circulating 
gonadotropins and gonadal steroid hormones (Low 2007), which is in accord with 
the results of study IV. Furthermore, the high serum PRL levels detected during the 
acute phase of NE may have contributed to the high prevalence of central 
hypogonadism, as hyperprolactinemia is known to disrupt the central regulation of 
the gonadal axis (Bachelot and Binart 2007). 
The present study (IV) also showed that serum cortisol, PRL and TSH levels 
were higher during the acute phase of NE compared with the results 3 months later.  
Furthermore, high serum cortisol and PRL levels during the acute phase were 
related to the severity of the disease. The fact that the kidneys are involved in the 
elimination of cortisol, PRL and TSH (Bauer et al. 1980, Whitworth et al. 1989, 
Kaptein 1996) may also have contributed to the increased serum levels, as the 
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clearance of these hormones may be diminished during acute renal failure. 
However, stress caused by acute illness is known to activate the hypothalamic-
pituitary-adrenal axis, and cytokines such as IL-1β have also been suggested to have 
the same effect (Low 2007).  
Altogether 17 % of the present cohort of NE patients developed chronic 
hormonal deficiencies during a median follow-up of five years. Four males and one 
female among these 9 patients presented with central hypogonadism. In a study by 
Stojanovic and co-workers (2009) involving 60 patients with previous HFRS, 18 % 
had at least one pituitary hormone deficit. Four out of five patients with multiple 
pituitary hormone deficiencies were further evaluated by brain MRI, which revealed 
empty sella in all of them. In the present series (IV) the brain MRI scan yielded no 
pathological findings in the patients studied for central hormonal defects. Previous 
case reports and autopsy studies have reported pituitary hemorrhage complicating 
acute hantavirus infection (Suh et al. 1995, Valtonen et al. 1995, Hautala et al. 
2002), which may lead to central hormonal deficiencies. The mechanisms of 
pituitary hemorrhage are obscure, but hypotension or low platelet count may 
contribute to it. Also vascular injury and dysfunction of platelets induced by uremia 
may predispose to a risk of bleeding (Cosgriff 1991). In study IV here neither 
platelet count nor hypotension during the acute phase of NE correlated with 
hormonal changes during the acute phase or later.  
It is possible that mechanisms other than ischemia or hemorrhage of the pituitary 
gland contribute to the development of the hormonal dysfunctions, since there are 
reports of pituitary hormone deficits after NE (Settergren et al. 1992) or other 
hantavirus infections (Lim et al. 1986) without any signs of radiological pituitary 
abnormalities. PUUV antigen has been found in the pituitary gland of an NE patient 
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at autopsy (Hautala et al. 2002), but so far there is no evidence of a direct cytopathic 
effect of hantaviruses on pituitary cells. Probably the immune-mediated damage to 
the endothelial cells and increased vascular permeability in acute hantavirus 
infection also contribute to pituitary hormone abnormalities. 
Peripheral hormonal disturbances were surprisingly common in the present 
material (IV), although neither clinical symptoms nor signs of thyroiditis or orchitis 
have so far been described in acute NE. The prevalence of hypothyroidism was 24 
% in female patients and 8 % in males, figures clearly higher than the prevalences 
found in the general population (Bjoro et al. 2000, Hollowell et al. 2002). Thyroid 
ultrasound examination of the patients with primary hypothyroidism after acute NE 
showed a hypoechogenic structure of the thyroid gland, indicating chronic 
thyroiditis (Hegedüs 2001). Three out of 5 patients had no antibodies against thyroid 
peroxidase, which suggests a non-autoimmune etiology of their thyroiditis. The 
mechanisms underlying peripheral thyroidal or testicular hormonal alterations 
during or after acute NE are unclear. The role of immune-mediated endothelial cell 
damage induced by overproduction of cytokines during acute NE and contributing 
to the increased vascular permeability can be suspected. However, the peripheral 
hormonal disturbances did not correlate with the plasma levels of cytokines in study 
IV. According to one recent review, viral infections may contribute to Hashimoto’s 
thyroiditis via bystander activation of autoreactive T cells or via signaling molecules 
associated with antiviral responses (Mori and Yoshida 2010).  
The chronic hormonal defects detected in study IV did not correlate with the 
clinical severity of acute NE or with host genetic factors. In a retrospective study by 
Stojanovic and co-workers (2009), 6 months to 17 years after HFRS, GH, T4 and 
Testo deficiencies were all related to the severity of acute disease. In that study the 
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clinical picture of acute HFRS was more severe, as 58 % of the patients required 
dialysis treatment compared with 6 % in the present study. However, the Serbian 
paper did not report any peripheral hormonal defects (Stojanovic et al. 2009), and it 
is possible that the mechanisms behind central and peripheral hormonal 
abnormalities are different. 
By reason of the retrospective nature of the study, there are no complete data on 
possible symptoms and signs of hormonal alterations during the acute phase or 
follow-up. This may have led to underestimation of the prevalence of hormonal 
sequelae, in that milder changes cannot be diagnosed by means of basal hormone 
levels alone. Interestingly, fatigue lasting several weeks after acute NE is usual 
(Lähdevirta 1971), and it has been suggested that in an infectious CNS disease this 
might be explained by central hormonal deficiencies (Schaefer et al. 2008).  
In summary, hormonal abnormalities during acute NE were common (study IV), 
and they correlated with the severity of the acute disease, i.e., the levels of renal 
failure and inflammatory markers. A considerable proportion (17 %) of the patients 
also developed chronic hormonal deficiencies, which could not be predicted by the 
severity of acute NE, or by the host genetic factors studied.  
6.3 Glomerulonephritis and NE 
Study V reported on 7 patients with symptoms and signs of nephrotic syndrome 
emerging shortly after serologically verified acute NE. In 5 of these patients, MPGN 
was diagnosed by renal biopsy, and in 2 patients MGN and MesGN, respectively. 
All patients achieved remission in approximately 0.6 years. 
Establishment of an etiopathogenetic connection between viral infection and 
glomerular disease requires the clinical symptoms of viral infection, serological 
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diagnosis, identification of specific viral antigenemia, and the detection of viral 
antigens and host antibodies in renal biopsy specimens (di Belgiojoso et al. 2002). 
Additional criteria are an improvement of renal disease with clearance of the 
suspected antigen or a recurrence of it after reinfection (di Belgiojoso et al. 2002). 
The glomerular injury in viral infections may be mediated by circulating 
immunocomplexes, which can be derived from viral antigens or host antiviral 
antibodies, or from endogenous antigens modified by viral injury and host auto-
antibodies (Glassock 1991). Viral antigens binding to the glomerular structures may 
also cause injury by in situ immune-mediated mechanisms (Golbus and Wilson 
1979, Couser 1985). In addition, expression of viral proteins or abnormal host 
proteins can induce cell dysfunction, necrosis (di Belgiojoso et al. 2002) or 
apoptosis (Conaldi et al. 1998), or increased matrix synthesis and decreased matrix 
degradation (di Belgiojoso et al. 2002), or release of chemokines (Segerer et al. 
2000), cytokines, adhesion molecules and growth factors (di Belgiojoso et al. 2002). 
Furthermore, circulating cryoglobulins may be induced by the host response to viral 
infection (D'Amico 1998), and a direct cytopathic effect of virus on glomerular cells 
is also possible (Glassock et al. 1990). It is probable that different viruses induce 
renal injury by different mechanisms, but an unambiguous causal relation between 
viral infection and renal disease is usually difficult to establish (di Belgiojoso et al. 
2002).  
During recent years, more data have been obtained on the possible role of toll-
like receptors (TLRs) in the pathogenesis of immune complex-mediated 
glomerulonephritis. TLRs are transmembrane proteins which can recognize 
pathogen-associated molecular patterns and also be activated by endogenous 
ligands. Based on mouse models it has been suggested that TLRs could mediate 
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glomerular injury by modulating the expression of chemokines and contributing to 
the deposition of immunocomplexes (Banas et al. 2008). TLRs have been linked to 
HCV–associated MPGN (Wörnle et al. 2006), and interestingly, in a recent in vitro 
study HTNV was shown to induce the expression of TLR4 and enhance the 
production of cytokines (Jiang et al. 2008). 
The etiopathogenetic link between PUUV infection and glomerulonephritis is 
obscure. In the present context (V) and in a study by Mustonen and co-workers 
(2001), PUUV was not sought in renal biopsy specimens. A previous 
immunohistochemical study of renal biopsies from acute NE patients reported no 
evidence of PUUV in the biopsy specimens (Temonen et al. 1996). HTNV antigen 
has been reported to be found in the epithelial cells of the distal nephrons in one 
case of fatal disease (Poljak and Avsic Zupanc 1994). Groen and co-workers (1996) 
found PUUV antigen in 6 out of 10 renal biopsies from seropositive patients, 
localized in the cytoplasm of the tubular epithelial cells. Furthermore, in a study 
from Korea, 22 out of 23 renal biopsy specimens from HTNV patients showed viral 
glycoproteins in the cytoplasm of the tubular epithelial cells (Kim et al. 1993). In 
HCPS, hantavirus has been found in the endothelial cells of interstitial capillaries in 
the renal medulla (Zaki et al. 1995). There is no evidence of persistent or recurrent 
hantavirus infections. Viral RNA can be found within the first 9 days of 
symptomatic PUUV infection, but convalescent samples are PCR-negative (Hörling 
et al. 1995, Plyusnin et al. 1997b, Plyusnin et al. 1999).  
The type of exudative MPGN has previously been linked to infectious diseases 
(D'Amico and Ferrario 1992). In the present series (V), a renal biopsy from one 
patient with MPGN showed infiltrating polymorphonuclear leukocytes in the 
glomeruli, giving the appearance of the exudative form of MPGN. Furthermore, in 
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the aforementioned study by Mustonen and co-workers (2001), 4 out of the 5 
MPGN patients had exudative features detected in renal biopsies. 
Usually the clinical feature of adult idiopathic MPGN varies from nephrotic-
range proteinuria to nephrotic syndrome, hematuria, hypertension and some degree 
of renal function impairment (Nakopoulou 2001). MPGN is considered to carry an 
unfavorable prognosis, since 5 years after diagnosis 50 % of patients either need 
renal replacement therapy or die (Schmitt et al. 1990). Two patients in study V 
received corticosteroids, one with a clinical picture of rapidly progressive 
glomerulonephritis and the other also with worsening renal function. However, the 
impact of corticosteroids on the clinical course of MPGN in these patients remains 
uncertain. Hemodynamic changes may have explained the worsening renal function, 
as both diuretic therapy and nephrotic syndrome can predispose to relative 
hypovolemia and renal ischemia (Orth and Ritz 1998). The efficacy of various 
therapeutic regimens, including corticosteroids, in adult MPGN is difficult to assess 
in the absence of larger and controlled trials (Levin 1999). Spontaneous remission of 
MPGN is also rare, reported in only 2-20 % of cases (Williams 1998). However, 
Mustonen and co-workers (2001) report the incidence of remission of MPGN to be 
exceptionally high, implying a better prognosis of MPGN after acute NE than usual. 
Nevertheless, one patient in that study developed end-stage renal failure. In a recent 
case report of EBV infection –related MPGN, remission of the nephrotic syndrome 
was achieved within 6 months (Karamadoukis 2008). The clinical course of MPGN 
associated with HCV infection varies, and treatment with antiviral agents or anti-
inflammatory or cytotoxic drugs has been tried with variable responses (Meyers et 
al. 2003). 
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Study V also reports on patients with MesGN and MGN shortly after acute NE. 
The patient with MesGN had heavy proteinuria during the time of renal biopsy but 
went into spontaneous remission within 2 years. The patient with MGN had severe 
and relapsing nephrotic syndrome with thromboembolic complications, and was 
treated with corticosteroids and cyclophosphamide. The treatment of MGN with 
corticosteroids or cytotoxic drugs is controversial by reason of the probability of 
persistent spontaneous remission of about 30 % in untreated patients with nephrotic 
syndrome (Ponticelli 2007). Choice of treatment thus requires a thorough evaluation 
of probable benefits and risks. MGN associated with HCV or HBV infection may be 
treated with antiviral drugs (Ponticelli 2007). In a recent case of an infant with CMV 
infection and MGN, ganciclovir therapy followed by valganciclovir was 
administered and remission achieved (Georgaki-Angelaki et al. 2009).    
In summary, study V yielded additional data on the relationship of PUUV 
infection and subsequent glomerulonephritis. The prognosis of MPGN emerging 
shortly after acute NE seems to be favorable compared with its usual clinical course 
with nephrotic syndrome, although larger follow-up studies are called for to confirm 
this finding. Further, patients with MGN and MesGN shortly after acute NE were 
described. 
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7. SUMMARY AND 
CONCLUSIONS 
The main findings in the present series were as follows: 
1. NE patients had higher GFR, more proteinuria and higher BP than 
seronegative, healthy controls 5 to 6 years after the acute phase. However, after 10 
years’ follow-up, the differences between the patient and control group in renal 
function, proteinuria and BP disappeared, confirming the favorable long-term 
outcome of NE. 
2. The clinical severity of acute NE had no association with renal function, the 
prevalence of proteinuria or the level of BP 6 years later. 
3. Gonadal and thyroid hormone deficits were common during acute NE, and 
central deficiencies were associated with the severity of renal failure and 
inflammation. Surprisingly many patients developed chronic central and peripheral 
hormonal deficiencies, which were not related to the severity of acute NE. This 
suggests that even relatively mild NE may predispose patients to chronic hormonal 
alterations. 
4. Glomerulonephritis may complicate the convalescent phase of acute NE. Renal 
biopsy specimens showed MPGN in five patients, and MGN and MesGN in one 
each. The median time to remission was 0.6 years, indicating a favorable outcome in 
most cases.  
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than the controls.  Conclusions: These results confirm our 
previous findings of a higher prevalence of tubular protein-
uria and increased urinary protein excretion, GFR and sys-
tolic blood pressure 6 years after acute NE. 
 Copyright © 2009 S. Karger AG, Basel 
 Introduction 
 Nephropathia epidemica (NE) is a mild type of hem-
orrhagic fever with renal syndrome. It is caused by Puum-
ala virus, a member of the hantavirus genus in the Bun-
yaviridae family that is carried by bank voles  (Myodes 
glareolus)  [1, 2] . NE is characterized by sudden onset of 
fever, headache, backache and abdominal pain  [3–5] . 
Proteinuria, hematuria and oliguria followed by polyuria 
are common clinical findings, while acute tubulointersti-
tial nephritis is the typical histopathologic lesion on renal 
biopsy  [3, 6] . The clinical picture of the disease varies in 
severity,  and  complete  recovery  is  the  usual outcome 
 [3–5] .
 Previously, we performed a retrospective analysis of 
46 patients 5 years after acute NE and found higher uri-
nary protein excretion and increased glomerular filtra-
 Key Words 
 Acute interstitial nephritis   Glomerular filtration   
Hemorrhagic fever of renal syndrome   Nephropathia 
epidemica   Puumala hantavirus 
 Abstract 
 Background/Aims: We previously found increased urinary 
protein excretion, glomerular filtration rate (GFR) and blood 
pressure in a retrospective analysis of patients with previous 
nephropathia epidemica (NE). Here, we evaluated the long-
term outcome after NE in a prospectively recruited patient 
group.  Methods: Proteinuria, GFR and ambulatory 24-hour 
blood pressure were assessed 4–7 years (mean 6) after acute 
NE in 37 patients, and these values were compared to those 
from 38 seronegative controls.  Results: Six years after NE, 
the prevalence of elevated urinary   1 -microglobulin excre-
tion was higher in the patients than controls (9/35 vs. 1/38; 
p = 0.005). The patients also had higher urinary protein ex-
cretion (0.17  8 0.05 vs. 0.14  8 0.04 g/day; p = 0.006), GFR (119 
 8 19 vs. 109  8 14 ml/min/1.73 m 2 ; p = 0.016) and mean sys-
tolic (123  8 11 vs. 117  8 9 mm Hg; p = 0.012), nighttime sys-
tolic (109  8 11 vs. 100  8 9 mm Hg; p = 0.001) and nighttime 
diastolic blood pressure (70  8 7 vs. 66  8 7 mm Hg; p = 0.035) 
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tion rate (GFR), filtration fraction (FF) and systolic blood 
pressure in the patients than in healthy control subjects 
 [7] . Recently, we were able to re-examine 36 patients from 
the same group 5 years later, i.e. 10 years after acute NE. 
At that stage the differences between the patients and 
controls with regard to proteinuria, GFR, FF and blood 
pressure were no longer present, which supports the view 
that the long-term prognosis of NE is favorable  [8] .
 In the present study, we evaluated the reliability of the 
results of our previous retrospective investigation  [7] and 
examined urinary protein excretion, renal function and 
ambulatory blood pressure (ABP) in a new prospectively 
recruited group of patients 4–7 years (mean 6) after acute 
NE. The results were compared with those of the same 
seronegative controls as in our previous study  [7] , in or-
der to avoid the influence of possible variations between 
different control populations.
 Methods 
 Study Population and Protocol 
 The patient group consisted of 43 consecutive patients hospi-
talized due to serologically verified NE at Tampere University 
Hospital  [9] , Finland, during the years 1997–1999. They were pro-
spectively collected for this longitudinal study. Six of these 43 pa-
tients were excluded from the present study; 4 of them had hyper-
tension before acute NE, 1 patient had diabetic nephropathy and 
1 had mesangial glomerulonephritis. Thirty-seven patients (29 
males and 8 females) aged 29–70 years (mean 49) were examined 
as outpatients 4–7 years (median 6) after acute NE in 2004. One 
patient had suffered from Henoch-Schöenlein purpura in child-
hood and 1 patient had been treated for renal tuberculosis in the 
1960s. Neither of them showed any findings of chronic renal dis-
ease following these conditions. Prior to the episode of acute NE, 
the other chronic diseases in 7 of the patients were hypothyroid-
ism (in 3 patients) and celiac disease, coronary heart disease, 
bronchial asthma and ankylosing spondylarthritis (each in 1 pa-
tient). The patient group was compared with the same group of 38 
healthy, Puumala virus-seronegative controls (22 males and 16 
females), aged from 27 to 64 years (mean 44), that was used in our 
previous study  [7] . One of the controls had hypothyroidism. All 4 
subjects with hypothyroidism were euthyreotic with thyroxin 
substitution.
 All subjects gave informed consent before participation, and 
the study was approved by the Ethics Committee of Tampere Uni-
versity Hospital.
 Laboratory Specimens and Electrocardiogram 
 Blood specimens were obtained in the morning after a mini-
mum 12-hour fast. In the studies that took place from 1997 to 
1999, serum creatinine, urea, triglycerides, blood glucose and to-
tal, high-density and low-density lipoprotein cholesterol were de-
termined by Vitros (Johnson & Johnson, Rochester, N.Y., USA), 
and the blood cell count was evaluated by Technicon H3 (Bayer 
Diagnostics, Elkhart, Ind., USA). In 2004, the same laboratory 
parameters were analyzed by Cobas Integra 700/800 and Bayer 
Advia 120, respectively. Serum creatinine concentrations showed 
10% lower values in 2004 than during the years 1997–1999 due to 
the above change in the determination method. Fasting blood 
glucose was determined from whole blood until the year 2003, 
after which the analysis was performed in plasma, thus producing 
12% higher values. In this study, the results of serum creatinine 
concentrations from the years 1997–1999 were multiplied by the 
coefficient 0.9, and the results of fasting plasma glucose before the 
year 2003 were multiplied by the coefficient 1.12. The limits for 
impaired fasting glucose (IFG) were 6.1–6.9 mmol/l, according to 
the guideline of the European Diabetes Epidemiology Group 
 [10] .
 Nighttime, daytime and 24-hour urinary protein excretion 
was measured by the pyrogallol red molybdate method (Olli C, 
Kone Instruments, Helsinki, Finland) in the 1990s and by Cobas 
Integra 700/800 in 2004. The overnight urinary excretion of   1 -
microglobulin, albumin and immunoglobulin G (IgG) was mea-
sured by nephelometry (Behring Nephelometer II Analyzer, Beh-
ringwerke AG, Marburg, Germany). Values for overnight urinary 
excretion of   1 -microglobulin  6 7   g/min, albumin  6 11   g/min 
and IgG  6 5   g/min were considered abnormal, based on the ref-
erence values for healthy subjects from our laboratory. The spot 
samples  of  morning  urine  were  collected  after  a minimum of 
12 h of fasting and analyzed for osmolality, erythrocytes, leuko-
cytes, albumin, nitrite, glucose, pH and ketones. Urine osmolal-
ity was measured by the Advanced Cryomatic TM Osmometer (Ad-
vanced Instruments Inc., Needham Heights, Mass., USA). Urine 
for the measurement of proteinuria was not collected for 3 pa-
tients.
 Electrocardiograms (ECGs) were evaluated according to the 
Minnesota codes. Left ventricular mass was evaluated by the sum 
of the height of the S wave in lead V1 and the R wave in lead V5 of 
a 12-lead resting ECG. Body mass index was calculated by divid-
ing weight (in kilograms) by the square of height (in square me-
ters).
 Determination of Renal Function 
 GFR was determined by a single-injection method as the plas-
ma clearance of  51 Cr-EDTA after a light meal and expressed in 
values normalized for body surface area. Effective renal plasma 
flow (ERPF) was estimated by the clearance of  131 I-hippurate. The 
FF was calculated as the quotient of GFR and ERPF. Based on 
studies in healthy subjects, increased GFR was defined as a GFR 
 6 130 ml/min/1.73 m 2  [11] .
 Blood Pressure Monitoring 
 The 24-hour ABP was measured with a fully automatic re-
corder. The cutoff point for hypertension was a 24-hour mean 
ABP  6 133/82 mm Hg, according to the results of a large popula-
tion study  [12] . One control subject and 10 patients either refused 
ABP measurement or had missing measurements due to technical 
failure.
 Statistical Analysis 
 To describe the data, means and standard deviations (SDs) are 
given for normally distributed variables and medians and ranges 
for skew-distributed continuous variables. Groups were com-
pared using independent-sample t tests for normally distributed 
variables and Mann-Whitney U tests for skewed variables. Cate-
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gorical data were analyzed by   2 test or by Fisher’s exact test. Cor-
relations were analyzed by Pearson’s correlation coefficient. 
Skew-distributed urinary excretion of protein was log trans-
formed before analysis. Binary logistic regression analysis was 
carried out to determine whether the differences in proteinuria, 
GFR and mean systolic, nighttime systolic or nighttime diastolic 
blood pressure between the groups could be ascribed to the dif-
ferences in age and gender distribution between the groups. Odds 
ratios (ORs) and their 95% confidence intervals (CIs) were given. 
All tests were two-sided, and analyses were performed with SPSS 
for Windows, version 13 (SPSS Inc., Chicago, Ill., USA).
 Results 
 Clinical and Laboratory Data 
 The characteristics of the study population and basic 
laboratory values are shown in  table 1 . The patients were 
on average 5 years older than the controls, and their fast-
ing blood glucose and serum low-density lipoprotein 
cholesterol levels were slightly higher than in controls. 
Medication for type 2 diabetes had been initiated for 1 
male patient after acute NE, but he showed no evidence 
of albuminuria during this study. One female patient had 
fasting blood glucose of 7.1 mmol/l and her hemoglobin 
A1 concentration was 6.4%, pointing to type 2 diabetes. 
Recurrent microscopic hematuria, in the absence of pro-
teinuria, was also detected after NE. Her clinical, labora-
tory and radiological examinations showed normal blood 
pressure, renal function and renal ultrasound. Moreover, 
there were no specific findings on cystoscopy, while uri-
nary cytology showed class II cells with atypical degen-
erative changes. Seven out of 37 patients (19%) had IFG, 
while none of the 38 controls had abnormal fasting blood 
glucose (p = 0.005, Fisher’s exact test). Altogether, 9 of the 
37 patients (24%) had IFG or type 2 diabetes.
 One patient had right bundle branch block on the 
ECG, but no pathological Q waves or ST-T wave altera-
tions were recorded. The sum of the S wave in lead V1 and 
R wave in lead V5 did not differ between the patients and 
controls (24 and 23 mm, respectively; p = 0.482, indepen-
dent-samples t test).
 Proteinuria and Renal Function 
 Table 2 and  figure 1 show proteinuria ( fig. 1 a) and re-
nal function ( fig. 1 b) in patients 6 years after acute NE 
compared with seronegative controls. The urinary pro-
tein excretion was higher in patients than in controls, and 
after adjusting for age and sex, the difference still re-
mained statistically highly significant. A positive correla-
tion between proteinuria and GFR was detected in the 
patients (r = 0.495, p = 0.003, Pearson’s correlation) but 
not in the controls (r = 0.255, p = 0.123), while proteinuria 
did not correlate with age or systolic or diastolic blood 
pressure in either group (data not shown). In addition, the 
prevalence of elevated urinary excretion of   1 -microglob-
ulin was higher among the patients than the controls 
(9/35 vs. 1/38; p = 0.005, Fisher’s exact test), but there was 
no difference between the groups in the overnight excre-
tion of albumin or IgG (data not shown).
Patients
(n = 37)
Controls
(n = 38)
p 
value
Males/femalesa 29/8 (78) 22/16 (58) NS
Age, years 49811 44810 0.042
Body mass index 26 (20–47) 25 (21–34) NS
Blood hemoglobin, g/l 14489 141811 NS
Serum creatinineb, mol/l 70812 73811 NS
Serum cholesterol, mmol/l 5.5 (4.4–8.8) 5.2 (4.0–7.8) 0.039
Serum LDL cholesterol, mmol/l 3.5 (2.4–5.3) 3.2 (2.2–4.7) NS
Serum triglycerides, mmol/l 1.12 (0.46–5.11) 1.38 (0.49–3.57) NS
Fasting blood glucoseb, mmol/l 5.780.6 5.180.5 <0.001
Urine osmolality, mOsm/kg 7768175 7498221 NS
Means 8 SD are given for normally distributed variables and medians (range) for 
skew-distributed variables. LDL = Low-density lipoprotein; NS = not significant.
a Figures in parentheses represent the percentage of males.
b Determination methods for serum creatinine and fasting blood glucose changed 
during the study (see Methods).
Table 1. Clinical and basic laboratory 
findings in patients 6 years after acute 
NE and in controls
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 The mean GFR was higher in patients than in controls, 
but there was no difference in ERPF or FF between the 
groups ( table 2 ,  fig. 1 b). After adjusting for age and sex, 
the difference in GFR remained statistically significant 
(OR 1.047, 95% CI 1.01–1.09; p = 0.010). Increased GFR 
( 6 130 ml/min/1.73 m 2 ) was found in 10 of the 37 patients 
(27%) compared to 4 of the 38 controls (11%) (p = 0.067, 
  2 test). GFR correlated inversely with age in the patient 
group (r = –0.512, p = 0.001, Pearson’s correlation) but not 
in controls (r = 0.008, p = 0.963). Furthermore, GFR 
showed no correlation with blood pressure or fasting 
blood glucose in either group (data not shown). The mean 
GFR was 118  8 15 ml/min/1.73 m 2 in patients with dia-
betes or IFG and 119  8 20 ml/min/1.73 m 2 in patients 
with normal fasting blood glucose (p = 0.194, indepen-
dent-samples t test). Furthermore, increased GFR was 
found in 3 of the 9 patients with diabetes or IFG compared 
to 7 of the 28 patients with normal fasting blood glucose 
(p = 0.679, Fisher’s exact test). The clinical severity of acute 
NE, as indicated by the highest serum creatinine concen-
tration measured during the hospital stay, had no relation 
to proteinuria or GFR 6 years later (data not shown).
 Blood Pressure 
 ABP monitoring was successfully completed in 27 pa-
tients and 37 controls. The patients had higher mean 
( fig. 1 c) and nighttime systolic blood pressure and night-
time diastolic blood pressure than the controls ( table 2 ).
 After adjusting for age and sex, the difference between 
the groups with regard to mean and nighttime systolic 
blood pressure remained (OR 1.07, 95% CI 1.00–1.14, p = 
0.038, and OR 1.08, 95% CI 1.01–1.14, p = 0.019, respec-
tively). In the whole group of study subjects, neither the 
mean, daytime nor nighttime systolic and diastolic blood 
pressure correlated with age (data not shown). The high-
est serum creatinine measured during acute NE had no 
relation to the results of ABP measurement 6 years later 
(data not shown).
Table 2. Proteinuria, renal function and ABP in patients 6 years 
after acute NE and in controls
Patients
(n = 27–37)
Controls
(n = 37–38)
p value
Proteinuria, g/day 0.1780.05 0.1480.04 0.006
GFR, ml/min/1.73 m2 119819 109814 0.016
ERPF, ml/min/1.73 m2 6468116 6278105 NS
FF, % 1983 1883 NS
Mean 24-hour BP, mm Hg
SBP 123811 11789 0.012
DBP 7886 7687 NS
Mean daytime BP, mm Hg
SBP 125812 12189 NS
DBP 8087 7987 NS
Mean nighttime BP, mm Hg
SBP 109811 10089 0.001
DBP 7087 6687 0.035
BP = Blood pressure; SBP = systolic blood pressure; DBP = di-
astolic blood pressure; NS = not significant.
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 Fig. 1. Urinary protein excretion ( a ), GFR ( b ) and mean ambulatory systolic blood pressure (SBP) ( c ) in controls 
(n = 38) and prospectively recruited patients (n = 36) 6 years after acute NE. Variables are depicted as means 
( $ ), standard errors of the mean (boxes) and SD (whiskers).  * p  ! 0.05;  * * p  ! 0.01. 
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 Antihypertensive medication had been initiated in 5 
of the patients 1–6 years after acute NE, and all continued 
their medication during the examinations. The classes of 
the medications were   -adrenoceptor blockers, calcium 
channel blockers, angiotensin-converting enzyme inhib-
itors and angiotensin II receptor antagonists. None of the 
controls were on antihypertensive medication during the 
study. It is noteworthy that differences in mean systolic 
and nighttime systolic blood pressure between the groups 
remained significant even if the subjects using antihy-
pertensive medication were excluded from the statistical 
analysis.
 Discussion 
 The long-term prognosis of Puumala hantavirus-in-
duced acute tubulointerstitial nephritis is considered to 
be favorable. However, this longitudinal study with a pro-
spectively recruited patient group confirmed our previ-
ous findings that 4–7 years after acute NE, patients have 
higher urinary protein excretion, GFR and ambulatory 
systolic blood pressure than healthy controls  [7] .
 As also previously described, this study showed in-
creased urinary protein excretion and higher prevalence 
of abnormal   1 -microglobulin excretion in patients than 
in controls several years after NE  [7, 13] . In a recent ret-
rospective analysis of 30 Croatian patients, performed 
3–6 years after acute hemorrhagic fever with renal syn-
drome, 6 of the 23 patients (26%) had increased excretion 
of   2 -microglobulin, while proteinuria exceeding 150 
mg/day was detected in 11 of the 23 patients (48%)  [14] . 
The pathophysiological mechanism of mild proteinuria 
several years after acute hemorrhagic fever with renal 
syndrome is obscure. However, in 1978, Lähdevirta et al. 
 [15] from Finland published a study of renal biopsies from 
9 patients 4–5 years after the episode of acute NE. The 
samples showed slight residual interstitial fibrosis and 
occasionally atrophic tubuli, tubular casts, increased 
numbers of hyalinised glomeruli and minor changes in 
other glomeruli. Two specimens also showed fibrotic 
scars in the cortex.
 In this study, the patients who presented with higher 
GFR than the controls 6 years after acute NE were older 
than the controls, who were age-matched with the previ-
ous patient cohort  [7] . Usually GFR declines with age  [16] , 
and also in the present study, GFR correlated inversely 
with age in the patient group. This indicates that age can-
not explain the difference in GFR between the groups. 
The mechanism underlying increased glomerular filtra-
tion after acute interstitial nephritis is not known at pres-
ent. In early diabetic nephropathy, glomerular hyperfil-
tration is a typical feature, and similar findings have been 
reported in essential hypertension and polycystic kidney 
disease  [17–20] . Furthermore, in a recent report on stage 
I hypertensive patients, glomerular hyperfiltration was 
shown to predict the development of microalbuminuria 
 [21] . In the present investigation, increased GFR in pa-
tients might have been related to the higher frequency of 
IFG in patients than in controls. However, the GFR of pa-
tients with diabetes or IFG compared with the patients 
with normal fasting blood glucose was essentially the 
same. Neither did we find any correlation between the 
GFR and fasting blood glucose levels in this study. High-
er GFR could also have been a consequence of the higher 
systolic blood pressure in the patient group, although the 
fact that GFR showed no correlation with blood pressure 
is in conflict with this view.
 Our patients had higher ambulatory systolic blood 
pressure than the controls 4–7 years after acute NE, as in 
our previous study  [7] . Furthermore, antihypertensive 
medication had been started in 5 patients during the fol-
low-up, and all of them continued their medication dur-
ing the study. If the subjects treated with antihyperten-
sive compounds were excluded from the analyses, the 
outcome of the analysis of ABP results remained the 
same, i.e. the patients still showed increased systolic 
blood pressure. Furthermore, we did not find any signif-
icant correlation between age and blood pressure, and the 
difference in blood pressure between the groups remained 
after adjusting for age and sex.
 We recently re-examined 36 patients from our previ-
ous retrospective analysis of a patient cohort 10 years af-
ter acute NE  [8] . The results showed no difference in pro-
teinuria, GFR or FF between the patients and the con-
trols. As in all long-term clinical follow-up studies, there 
were some dropouts. As the dropouts did not differ es-
sentially from the study population, it seems safe to con-
clude that the 10-year prognosis of NE is favorable  [22] . 
Nevertheless, the possibility remains that NE may predis-
pose some patients to the development of hypertension.
 In conclusion, in a new prospectively recruited popu-
lation of patients with prior NE, we were able to confirm 
our previous findings of higher prevalence of tubular 
proteinuria, increased GFR and higher systolic blood 
pressure 6 years after acute Puumala hantavirus-induced 
nephritis compared with a healthy control group. The 
underlying mechanisms of the tubular proteinuria and 
the increased glomerular filtration remain unclear.
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or 24-hour urinary protein excretion observed 6 years later. 
The degree of inflammation during the acute phase was 
higher in patients who had increased urinary excretion of   1 -
microglobulin 6 years later compared with those with no   1 -
microglobulin excretion.  Conclusion: Neither the severity of 
acute NE nor the host genetic factors determined the pre-
dicted renal function, blood pressure or 24-hour urinary pro-
tein excretion 6 years later.  Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Puumala hantavirus causes a mild type of hemorrhag-
ic fever with renal syndrome, a condition also known as 
nephropathia epidemica (NE). An average of 1,000–3,000 
serological diagnoses have been made annually in Fin-
land during recent years, but the seroprevalence is 5%, 
implying that most infections remain undiagnosed  [1] . 
Typical symptoms are acute onset of fever, headache, 
backache and abdominal pain  [2, 3] . Renal involvement 
results in proteinuria, microscopic haematuria and acute 
renal failure with oliguria followed by polyuria  [3] . The 
 Key Words 
 Acute interstitial nephritis   Nephropathia epidemica   
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 Abstract 
 Background/Aims: We have found greater urinary protein 
excretion and higher glomerular filtration rate (GFR) and 
blood pressure in patients 6 years after acute nephropathia 
epidemica (NE) compared with seronegative controls. The 
present aim was to establish whether the long-term out-
come is determined by the severity of acute illness.  Meth-
ods: Serial plasma interleukin-6 (IL-6), tumour necrosis fac-
tor-  (TNF-  ), creatinine, C-reactive protein, blood cell count 
as well as 24-hour urinary protein and overnight   1 -micro-
globulin and albumin excretions were measured in 37 pa-
tients with acute NE. Human leucocyte antigen (HLA)-B, 
HLA-DRB1, TNF-  (–308) and IL-6(–174) alleles were also ana-
lyzed. After 6 years, GFR, blood pressure and urinary protein 
excretion were examined.  Results: There were no associa-
tions between the clinical severity of acute NE or the genet-
ic factors determined and the increased GFR, hypertension 
 Received: November 24, 2009 
 Accepted: January 10, 2010 
 Published online: May 21, 2010 
 Marja Miettinen, MD 
 Department of Internal Medicine, Central Hospital of Jyväskylä 
 Keskussairaalantie 19 
 FI–40620 Jyväskylä (Finland) 
 Tel. +358 14 269 1811, Fax +358 14 269 2711, E-Mail marja.miettinen   @   ksshp.fi 
 © 2010 S. Karger AG, Basel
1660–2110/10/1162–0089$26.00/0 
 Accessible online at:
www.karger.com/nec 
 Miettinen et al. Nephron Clin Pract 2010;116:c89–c94c90
characteristic renal histopathological lesion is acute tu-
bulointerstitial nephritis  [4] . The clinical severity varies 
considerably, but complete recovery is the rule  [2, 3, 5] .
 The long-term prognosis of NE seems to be favourable 
 [2, 5, 6] . However, we have previously found in 2 indepen-
dent groups of patients that 5–6 years after acute NE pa-
tients had higher systolic blood pressure and a glomeru-
lar filtration rate (GFR), and greater urinary protein ex-
cretion compared with healthy seronegative controls  [7, 
8] . As far as we know, no studies have addressed the effect 
of clinical severity of the acute disease on the possible 
long-term consequences several years after NE.
 Several cytokines are secreted in response to a hanta-
virus infection  [9] . Significantly elevated plasma levels of 
tumour necrosis factor-  (TNF-  ), interleukin-6 (IL-6), 
IL-2 and interferon-  (IFN-  ) have been detected during 
the acute phase of NE  [10, 11] . Our study of cytokine lev-
els during acute NE showed that especially urinary excre-
tion of IL-6 was markedly increased  [11] . The IL-6(–174) 
G/C polymorphism has been shown to be associated with 
plasma IL-6 levels, higher levels being found in homozy-
gotes for allele G and G/C heterozygotes in healthy sub-
jects  [12] . Furthermore, there is evidence of genetic pre-
disposition to the severity of NE, as patients with human 
leucocyte antigen (HLA)-B8, -DR3, and -DQ2 alleles 
have proved to be at a higher risk of severe disease  [13, 14] , 
while patients with the HLA-B27 allele have presented 
with mild disease  [15] .
 The aim of the present study was to establish whether 
the severity of the disease or inflammation during the 
acute phase of NE, or host genetic factors, could predict 
the clinical outcome 6 years later.
 Methods 
 Study Design and Participants 
 Originally, this study involved 70 prospectively collected con-
secutive patients who were admitted to Tampere University Hos-
pital, Finland, due to serologically verified NE  [16] during the 
years 1997–1999. In 2004, 4–7 (median 6) years after acute NE, 43 
out of these 70 patients attended a scheduled follow-up examina-
tion. The clinical characteristics of these patients have recently 
been described in detail  [8] . Six of the 43 patients were now ex-
cluded; 4 patients had had hypertension before acute NE, 1 had 
diabetic nephropathy and 1 mesangial glomerulonephritis. The 
study population thus comprised 37 patients (29 males and 8 fe-
males) aged from 29 to 70 years (mean 49). All subjects gave in-
formed consent before participation, and the study was approved 
by the Ethics Committee of Tampere University Hospital.
 Blood samples for analysis of plasma IL-6, TNF-  , C-reactive 
protein (CRP), serum creatinine, and blood cell count, as well as 
24-hour urinary protein and overnight   1 -microglobulin, albu-
min, IL-6 and TNF-  excretions were collected on 3 consecutive 
mornings after hospital admission. The highest and the lowest 
values of the various variables measured during hospitalization 
were designated as maximum and minimum.
 Since the degree of inflammation can be evaluated by several 
parameters, we determined an inflammation score to describe it. 
The maximum values of acute-phase plasma CRP, IL-6 and blood 
leucocytes were categorized into 2 groups by dividing each vari-
able from its median value (lower than median/higher than me-
dian). The inflammation score was then calculated by counting 
up the number of variables whose values were over the median, 
and grouped them as follows: combined median values  ^  1 (group 
1) and  6 2 (group 2).
 Laboratory Specimens 
 Plasma CRP levels were analyzed by a Hitachi 705E analyzer 
from 1997 to 1998 and thereafter by the Roche Diagnostics CRP 
method using a Cobas Integra analyzer. Blood cell counts were 
conducted on haematological cell counters by Bayer. From 1997 
to 1999 serum creatinine was determined by Vitros (Johnson & 
Johnson, Rochester, N.Y., USA), and in 2004 by a Cobas Integra 
analyzer. Serum creatinine concentrations showed 10% lower val-
ues in 2004 than during the years from 1990 to 1999, this by rea-
son of the above change of determination method. For this study, 
results for serum creatinine concentrations during the years 
1990–1999 were multiplied by the coefficient 0.9.
 Plasma and urinary TNF-  and IL-6 concentrations were de-
termined as previously described  [11] . The detection limits for the 
assays were 0.4 pg/ml for IL-6 and 1.4 pg/ml for TNF-  . In calcu-
lations, a concentration less than the detection limit was regarded 
as the detection limit for the assay in question. The highest plasma 
or urinary cytokine concentration measured during the first 3 
days of hospitalization was designated the maximum cytokine 
concentration and used in calculations. The analyses of alleles 
HLA-B8, -B27 and -DR3, and the analysis of TNF-  and IL-6 gene 
polymorphism were performed as described elsewhere  [17–19] .
 The 24-hour urinary protein excretion was measured by the 
pyrogallol red molybdate method (Olli C.; Kone Instruments, 
Helsinki, Finland) in the 1990s and by the Cobas Integra analyz-
er in 2004. The overnight urinary excretion of   1 -microglobulin 
and albumin were measured by nephelometry (Behring Nephe-
lometer II analyzer, Behringwerke AG, Marburg, Germany). 
Overnight urinary excretion of   1 -microglobulin  6 7   g/min and 
albumin  6 11   g/min were considered abnormal based on healthy 
reference material in our laboratory. The limit for increased 24-
hour protein excretion was  6 0.22 g.
 Determination of Renal Function 
 GFR was determined by the single-injection method as a plas-
ma clearance of  51 Cr-EDTA after a light meal, and expressed in 
values normalized for body surface area. Based on studies in 
healthy subjects, increased glomerular filtration was defined as a 
GFR  6 130 ml/min/1.73 m 2  [20] .
 Blood Pressure Monitoring 
 Six years after NE, the 24-hour ambulatory blood pressure 
(ABP) was measured with a fully automatic recorder (Novacor 
Diasys Integra; Novacor SA, Rueil-Malmaison, France). The cut-
off point for hypertension was a 24-hour mean ABP  6 133/82 mm 
Hg as established in a large population study  [21] . Office blood 
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pressure was also measured, the cutoff point for hypertension be-
ing according to the World Health Organization/International 
Society of Hypertension guidelines  6 140/90 mm Hg  [22] . We de-
fined patients as hypertensive if they were on antihypertensive 
therapy, had a mean ABP  6 133/82 mm Hg, or office blood pres-
sure  6 140/90 mm Hg. Office blood pressure was used to define 
hypertension only if ABP monitoring had not been conducted. 
Ten out of the 37 patients (27%) either refused ABP measurement 
or it failed for technical reasons.
 Statistical Methods 
 To describe the data, means and standard deviations (SD) are 
given for normally distributed variables, and medians and ranges 
for skew-distributed continuous variables. Patients were divided 
into 2 groups as having or not having elevated excretion of   1 -
microglobulin, increased GFR or hypertension, respectively. The 
groups were compared using the independent samples t test for 
normally distributed variables and the Mann-Whitney U test for 
skewed variables. Categorical data were analyzed by   2 test or 
Fisher’s exact test. All tests were 2-sided and analyses were per-
formed with the SPSS for Windows version 14.0 (SPSS Inc., Chi-
cago, Ill., USA).
 Results 
 Clinical and Laboratory Findings 6 Years after
Acute NE 
 Six years after NE, the mean serum creatinine level in 
the patients was 70  8 12   mol/l and 5/37 (14%) patients 
were on anti-hypertensive medication. Nine out of 35 
(26%) patients had elevated urinary excretion of   1 -mi-
croglobulin. This was not related to the systolic or dia-
stolic blood pressure (data not shown). Increased 24-hour 
urinary protein excretion was detected in 4/33 (12%) pa-
tients and albuminuria in 2/35 (6%). Ten out of 37 patients 
(27%) had GFR  6 130 ml/min/1.73 m 2 and 10/37 (27%) 
had hypertension according to our criteria.
 The Association of the Clinical Findings during the 
Acute Phase of NE with the Outcome after 6 Years 
 The relationships between the clinical and laboratory 
variables describing the clinical severity of acute NE and 
the prevalence of urinary excretion of   1 -microglobulin, 
increased GFR and hypertension 6 years later are shown 
in  table 1 . There were no differences in any acute-phase 
variable studied between those patients who suffered 
from sequelae 6 years later compared to those who did 
not. Further, acute-phase findings did not differ between 
patients showing increased overnight urinary excretion 
of albumin or 24-hour protein excretion after 6 years 
(data not shown).
 Three out of 37 (8%) patients needed dialysis treatment 
during the acute phase. One of these patients showed el-
evated urinary excretion of   1 -microglobulin and hyper-
tension 6 years after NE. GFR ranged from 100 to 121 ml/
min/1.73 m 2 6 years after NE in those patients who had 
required dialysis treatment during the acute illness.
Table 1.  Clinical and laboratory variables during the acute phase of NE in those patients who had increased overnight urinary excre-
tion of 1-microglobulin, increased GFR or hypertension 6 years later compared with those who did not
Acute phase of NE 6 years after acute NE
urinary 1-microglobulin (n = 35) GFR (n = 37) b lood pressure (n = 37)
increased
(n = 9)
normal
(n = 26)
p increased
(n = 10)
normal
(n = 27)
p hypert ensives
(n = 10)
normotensives
(n = 27)
p
B-Hcrmin, % 37.384.0 35.784.1 0.291 36.382.4 36.284.5 0.939 36.582.9 36.184.4 0.796
B-Thrommin, 109/l 52826 68832 0.190 60832 64832 0.770 75828 59833 0.192
B-Leukmax, 109/l 8.6 (7.2–20.4) 11.2 (5.7–22.6) 0.838 11.9 (7.1–22.6) 10.3 (5.7–20.4) 0.302 12.3 (7.1–16.6) 10.2 (5.7–22.6) 0.257
S-CRPmax, mg/l 84 (50–213) 64 (20–175) 0.128 80 (20–175) 72 (22–213) 0.656 100 (22–213) 69 (20–157) 0.098
S-Creamax, mol/l 242 (81–653) 241 (70–878) 0.725 285 (78–626) 192 (70–878) 0.906 321 (70–878) 187 (77–749) 0.335
dU-Proteinmax, g/day 1.78 (0.71–17.78) 1.68 (0.30–10.00) 0.697 1.74 (0.14–10.00) 1.66 (0.30–17.78) 0.801 1.75 (0.30–4.85) 1.66 (0.14–17.78) 0.555
cU-Albmax, g/min 987 (211–6,246) 724 (14–5,793) 0.753 895 (4–5,642) 708 (14–6,246) 0.578 997 (14–2,980) 709 (4–6,246) 0.880
cU-1mmax, g/min 37 (11–46) 27 (7–209) 0.725 24 (7–209) 29 (11–137) 0.511 29 (11–209) 26 (7–137) 0.371
Hospital stay, days 883 782 0.468 882 782 0.634 882 782 0.305
Mea ns are given for normally distributed variables and median (range) 
for skew-distributed variables. Groups were compared by independent 
samples t test (normally distributed variables) or Mann-Whitney U test 
(skew-distributed variables). B-Hcrmin = Lowest blood hematocrit; B-
Thrommin = lowest blood platelet count; B-Leukmax = highest blood leuko-
cyte count; S-CRPmax = highest serum C-reactive protein concentration; 
S-Creamax = highest serum creatinine; dU-Proteinmax = highest daily uri-
nary protein excretion; cU-Albmax = highest overnight urinary albumin 
excretion; cU-1mmax = highest overnight urinary 1-microglobulin.
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 Host Genetic Factors and Clinical Findings
6 Years Later 
 Eight out of 32 (25%) patients had both HLA-B8 and 
-DR3 alleles and 3 out of 31 (10%) had the HLA-B27 allele. 
Thirteen out of 37 (37%) patients were TNF(–308) allele 
A carriers and 76% (28/37) were IL-6(–174) allele G carri-
ers. The HLA-B8-DR3 haplotype or HLA-B27 allele, the 
carriage of TNF(–308) allele A or IL-6(–174) allele G was 
not related to renal function, urinary protein excretion or 
hypertension 6 years after acute NE (data not shown).
 Plasma Levels and Urinary Excretion of Cytokines 
during the Acute Phase of NE Compared with the 
Clinical Findings 6 Years Later 
 Figure 1 a shows that acute-phase plasma IL-6 levels 
were higher in patients who had urinary excretion of   1 -
microglobulin 6 years later compared with patients show-
ing no excretion of   1 -microglobulin. Acute-phase plas-
ma TNF-  levels did not differ between the groups 
( fig. 1 b). Neither acute-phase plasma IL-6 nor TNF-  lev-
el had any relation to hypertension, GFR, albuminuria or 
24-hour urinary protein excretion 6 years after acute dis-
ease (data not shown). Overnight urinary excretion of 
IL-6 and TNF-  during the acute phase of NE had no as-
sociation with renal function or urinary protein excre-
tion later (data not shown).
 According to our inflammatory score (see Methods), 8 
out of 9 patients with elevated urinary excretion of   1 -mi-
croglobulin belonged to group 2 compared with 1 patient 
belonging to group 1 (p = 0.048). The degree of inflamma-
tion had no relation to GFR, hypertension or 24-hour uri-
nary protein excretion 6 years later (data not shown).
 Discussion 
 This is to our knowledge the first report evaluating the 
influence of clinical severity of acute hantavirus infection 
on the long-term outcome. In this prospectively gathered 
group of consecutive patients, we established that the de-
gree of renal insufficiency or any other clinical finding 
during acute NE had no significant association with renal 
function, urinary protein excretion or blood pressure 6 
years later.
 Our assumption was that the severity of acute NE 
might have an influence on the long-term outcome, since 
in a previous study we found out that 5 out of 9 patients 
with hypertension 5 years after acute NE had suffered 
from severe renal insufficiency during the acute phase 
 [7] . In the present study, this hypothesis was not con-
firmed, and we actually found that long-term conse-
quences might occur even after a relatively mild course of 
NE. This notwithstanding, there was a trend toward 
more severe acute renal failure in those patients who were 
hypertensive 6 years later, the difference between the 
groups being however not statistically significant. Here 
the small sample size may have influenced results.
 We have previously found that patients have higher 
GFR and blood pressure and greater urinary protein ex-
cretion 5–6 years after acute interstitial nephritis (AIN) 
caused by the Puumala hantavirus compared with sero-
negative healthy controls  [7, 8] . The literature offers only 
limited data on prognostic factors in the long-term out-
come of AIN. Most published data concern patients with 
drug-related AIN. In a review of 3 series of AIN, 71% of 
cases were drug-related and showed poorer prognosis 
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 Fig. 1. Highest plasma IL-6 ( a ) and TNF-  
( b ) concentration during acute NE in pa-
tients who had increased excretion of   1 -
microglobulin 6 years later compared with 
those who did not. Variables are depicted 
as medians (–), quartiles (boxes), and min-
imum and maximum values (whiskers) 
and outliers.  *  p  ! 0.05. 
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with increasing age, but not with peak creatinine concen-
tration  [26] . In the present study, the degree of renal in-
sufficiency or age did not affect the long-term outcome.
 The clinical course of acute NE is highly variable  [2,
3, 5] . The HLA-B8-DR3 haplotype and the carriage of 
TNF(–308) allele A have been shown to be associated 
with severe acute NE, although the relationship of TNF-
(–308) allele A is probably due to the strong linkage dis-
equilibrium with HLA-B8-DR3  [23, 24] . Furthermore, in 
a recent Belgian study, high serum creatinine and lower 
blood platelet count were found to be associated with 
TNF-  (–238) G/A polymorphism and the lowest ex vivo 
TNF-  production in patients with acute NE  [25] . Among 
the present limited number of patients, the HLA-B8-DR3 
haplotype, the carriage of TNF(–308) allele A or IL-6-
(–174) allele G showed no association with the long-term 
outcome.
 Plasma IL-6 concentrations and the degree of inflam-
mation during the acute phase of NE were higher in pa-
tients evincing increased urinary excretion of   1 -micro-
globulin 6 years later compared with those with no uri-
nary excretion of   1 -microglobulin.   1 -Microglobulin is 
a low-molecular weight protein produced by the liver, 
freely filtered by glomeruli and reabsorbed by proximal 
tubuli. It is considered to have immunosuppressive prop-
erties in inhibiting the adhesion of neutrophils and 
monocytes to the vascular endothelium  [27] . Increased 
urinary excretion of   1 -microglobulin can also be a sign 
of disturbed tubular function  [28] . Furthermore, in acute 
tubular necrosis it may constitute an early predictor of an 
unfavourable clinical outcome  [29] , and in membranous 
nephropathy of the subsequent development of renal in-
sufficiency  [30] . In the present study,   1 -microglobulin 
excretion during acute NE did not predict urinary pro-
tein excretion, renal function or hypertension 6 years lat-
er. It has not so far been documented whether the elevat-
ed plasma IL-6 concentrations during the acute phase of 
NE contribute to the tubular function and excretion of 
  1 -microglobulin several years later. There is controver-
sial evidence from a rat model that the synthesis of   1 -
microglobulin may be stimulated by IL-6  [31] . Recently, 
Vyssoulis et al.  [32]  have found that urinary   1 -micro-
globulin is independently associated with circulating 
acute-phase proteins in patients with newly diagnosed 
hypertension.
 In conclusion, neither the clinical severity of acute NE 
nor certain host genetic factors had an effect on the 24-
hour urinary protein excretion, GFR or blood pressure 6 
years later. We were thus unable to identify any specific 
group of patients who should be strictly followed up after 
acute NE. Plasma IL-6 concentration and the degree of 
inflammation during the acute phase of NE were associ-
ated with increased urinary   1 -microglobulin excretion 
after 6 years. The clinical significance of this finding re-
mains to be elucidated.
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Abstract Previous reports have described panhypopituitarism
associated with severe cases of hemorrhagic fever with renal
syndrome (HFRS), but the prevalence of hormonal deficien-
cies after nephropathia epidemica (NE), a milder form of
HFRS, has not been studied. This study was conducted in
order to determine the prevalence of hormonal defects in
patients with acute NE and during long-term follow-up. Fifty-
four patients with serologically confirmed acute NE were
examined by serum hormonal measurements during the acute
NE, after 3 months, and after 1 to 10 (median 5) years. Thirty
out of 54 (56%) patients had abnormalities of the gonadal and/
or thyroid axis during the acute NE. After a median follow-up
of 5 years, 9 (17%) patients were diagnosed with a chronic,
overt hormonal deficit: hypopituitarism was found in five
patients and primary hypothyroidism in five patients. In
addition, chronic subclinical testicular failure was found in
five men. High creatinine levels and inflammatory markers
during NE were associated with the acute central hormone
deficiencies, but not with the chronic deficiencies. Hormonal
defects are common during acute NE and, surprisingly, many
patients develop chronic hormonal deficiencies after NE. The
occurrence of long-term hormonal defects cannot be predicted
by the severity of acute NE.
Introduction
Nephropathia epidemica (NE) is a form of hemorrhagic
fever with renal syndrome (HFRS), caused by Puumala
hantavirus (PUUV) [1]. PUUV along with its host, the bank
vole (Myodes glareolus), is found all over Europe,
excluding the Mediterranean region. In Finland, 1,000–
3,000 serologically verified cases occur annually and the
average PUUV seroprevalence in the population is 5%.
Other hantaviruses causing HFRS include Hantaan (HTNV),
Dobrava (DOBV), Saaremaa, and Seoul viruses, while
several others found in the Americas cause hantavirus cardio-
pulmonary syndrome [1]. NE is clinically characterized by
fever, headache, nausea, backache, and abdominal pain, as
well as transient renal insufficiency [2–4]. Hemorrhages are
rare. Complete recovery from NE is the usual outcome, but
a convalescent phase with fatigue may last for months [2–4].
Genetic susceptibility seems to determine the severity of
NE, as individuals with the HLA B8 DRB1*0301 haplotype
have been shown to suffer from a severe form of the disease
[5], while the HLA B27 allele correlates with a mild clinical
course [6].
There are case reports of hypophyseal hemorrhage and
panhypopituitarism in patients with acute NE [7–11].
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Postmortem studies of patients with HTNV-induced HFRS,
as well as in the few fatal cases of NE, have revealed
hemorrhage and necrosis of the pituitary gland in 50–100%
of the autopsies [11–13]. The PUUV antigen has been
detected in hypophyseal neuroendocrine and endothelial
cells of a patient with fatal NE [8]. In a recent retrospective
Serbian study of 60 adults with a previous HFRS, a high
prevalence of hypopituitarism was identified after recovery
from HFRS [14]. Immunological factors including tumor
necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) have
been suggested to be involved in the pathogenesis of NE
[15]. Cytokines produced in inflammatory foci may also
cause changes in the endocrine system, including activation
of the hypothalamic-pituitary-adrenal (HPA) axis [16, 17].
In the present study, we examined the prevalence of
hormonal abnormalities in hospital-treated patients with
NE, during both the acute illness and long-term follow-up.
We also studied whether the hormonal abnormalities
associated with NE were related to the clinical severity of
the acute illness, the intensity of the cytokine response
(plasma IL-6 and TNF-α levels), or the immunogenotype of
the patient (HLA-B8, -DR3, and -B27 alleles).
Materials and methods
Subjects
The original patient group consisted of 70 prospectively col-
lected consecutive patients, hospitalized due to serologically
verified acute PUUVinfection at Tampere University Hospital,
Finland, during the years 1997 to 1999. The specific sero-
logical diagnosis was based on an immunoglobulin M-capture
enzyme immunoassay and PUUV Sotkamo strain full-length
N protein expressed by using the baculovirus system in Sf9
insect cells [18]. In comparison with various other protocols,
the assay showed optimal sensitivity and specificity [19].
Fifty-four of the patients attended the 12-month follow-up
visit, and they comprised the present study population. The
median patient age was 42 years (range 15–70 years), and 37
(69%) of them were male. Fourteen patients had previous
diseases: hypertension in four patients, hypothyroidism in
two, as well as ankylosing spondyloarthritis, bronchial asthma,
aortic valve disease, coeliac disease, sequel of renal tuber-
culosis, operated cancer of the vocal cords, operated menin-
gioma, and osteoporosis in one each. All of the patients
continued their regular medications during the study, including
two patients with L-thyroxine substitution for hypothyroidism.
None of the patients received corticosteroid therapy, or any
other drug that could possibly affect plasma hormone concen-
trations, except for the two patients on L-thyroxine substitution
therapy. One female patient was breast-feeding during acute
NE and her estradiol (E2), follicle-stimulating hormone (FSH),
and prolactin (PRL) values were excluded from the analyses.
The Ethics Committee of Tampere University Hospital
approved the study and every patient gave a written informed
consent to participate.
Study protocol
All of the patients were examined during their hospital stay.
Detailed medical histories were obtained, and a careful
physical examination was performed. All blood specimens
were obtained between 0730–0930 h in the morning. Blood
samples for plasma creatinine, C-reactive protein (CRP),
IL-6, TNF-α, and blood cell counts, as well as 24-h urinary
protein excretion were collected on three consecutive
mornings after hospital admission. The first blood sample
for hormonal analyses was obtained on the first morning of
hospital care, and the second sample was taken on the third
morning. The highest or the lowest value of each variable
measured during hospitalization was designated as the
maximum or the minimum value, respectively. All of the
serum samples for hormone analyses were stored at −70°C
until their use.
The patients were scheduled to an outpatient examina-
tion 3 and 12 months after the acute disease. Forty-nine
patients attended the 3-month visit (74 to 146 days, median
102 days after admission), and 54 the 12-month visit. The
last prearranged follow-up visit was organized in 2004
(4 to 7 years, median 5 years after NE), and 38 patients
participated. All serum hormonal levels were analyzed in
2007. Due to the hormonal results, we invited six patients to
an additional visit in 2008 (9 to 10 years, median 10 years
after NE), and they underwent physical, laboratory, and
imaging studies, as appropriate (see the next section).
Methods
Plasma creatinine and CRP concentration, blood cell counts,
and 24-h urinary protein excretion were determined by
standard laboratory methods. Plasma IL-6 and TNF-α con-
centrations were determined using enzyme-linked immuno-
sorbent assays (ELISA; PeliKine Compact™ human IL-6
and TNF-α kits, Red Cross Blood Transfusion Service,
Amsterdam, The Netherlands). The analyses of the alleles
HLA-B8, -DR3, and -B27 were performed as described
elsewhere [20].
Serum free thyroxine (fT4) and thyrotropin (TSH) were
measured by a chemiluminescent microparticle immuno-
assay (Abbott Architect i2000 system, Abbott Laboratories,
IL, USA), cortisol, PRL, luteinizing hormone (LH), and
FSH by fluoroimmunoassay (1235 AutoDELFIA, Wallac
Ltd., Turku, Finland), and E2 as well as testosterone (Testo)
by radioimmunoassay (1277 GammaMaster, Wallac Ltd.).
The six patients invited to an additional visit in 2008 were
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also studied for serum levels of growth hormone (GH) by
time-resolved fluoroimmunoassay (AutoDELFIA hGH,
Wallac Ltd.), insulin-like growth factor 1 (IGF-1) by immu-
noluminometric assay (DiaSorin Liaison IGF1, Saluggia,
Italy), antibodies against thyroid peroxidase (TPOAb) by
immunoluminometric assay (Abbott Architect Anti-TPO,
Wiesbaden, Germany), as well as for adrenocortical function
by the standard 250-μg ACTH stimulation test.
The reference ranges were 9.0–19.0 pmol/l for fT4, 0.4–
4.0 mU/l for TSH, 180–680 nmol/l for cortisol, <450 mU/l
for PRL in male patients, <600 mU/l in premenopausal
women, and <280 mU/l in postmenopausal women. The
male reference ranges were 10.4–34.6 nmol/l for Testo and
0.7–6.7 U/l for LH. As the phase of menstrual cycle was
not known, E2 below 0.1 nmol/l was regarded as a
hypogonadal value for a premenopausal woman. GH
reference range was 0–11.5 mU/l, and the age-specific
reference values for IGF-1 were 19–65 nmol/l at 18–
20 years, 15–45 nmol/l at 21–30 years, 14–36 nmol/l at 31–
50 years, 10–29 nmol/l at 51–70 years, and 8–23 nmol/l
over 70 years of age. The TPOAb reference range was
<6 U/ml. Cortisol response exceeding 550 nmol/l was
considered to be normal in the ACTH test.
Peri- and postmenopausal women were not analyzed for
defects of the gonadal axis, as they were hypogonadal by
definition. However, their FSH and E2 levels were included
in the analysis of hormonal alterations between the acute
illness and 3 months afterwards. Chronic, overt hypo-
gonadism was defined as Testo (in men) or E2 (in pre-
menopausal women) repeatedly below the reference range
one year or more after the acute NE. Chronic, subclinical/
compensated testicular failure was diagnosed in a male
patient with chronically elevated LH but Testo within the
reference range. Chronic, overt hypothyroidism was defined
as fT4 repeatedly below 9.0 pmol/l and/or TSH repeatedly
above 4.0 mU/l in a patient with chronic thyroiditis, goiter,
and/or symptoms suggestive of hypothyroidism [21].
Thyroid ultrasound imaging (Vivid I, GEMS Ultrasound,
Tirat Carmel, Israel) was performed by the same investiga-
tor (P.J.) on the six patients attending the additional visit in
2008. The hypothalamic-pituitary region was studied by
magnetic resonance imaging (MRI; MAGNETOM Trio 3-
Tesla scanner, Siemens, Erlangen, Germany) in the patients
showing distinct hormonal deficits of central origin.
Statistics
To describe the data, medians (ranges) were given for con-
tinuous variables and percentages for categorical variables.
Comparisons between the groups were made with the Mann–
Whitney U-test for continuous variables, while Pearson’s
Chi-square test or Fisher’s exact test was used for categorical
data. Wilcoxon’s signed-rank test was used to evaluate
changes in serum hormone levels between the acute phase of
NE and 3 months afterwards, and between 3 months and
1 year or 5 years, respectively. Correlations were calculated
by means of Spearman’s rank correlation coefficient. A
p-value of less than 0.05 in two-sided testing was con-
sidered to be statistically significant. Statistical analyses
were performed using SPSS for Windows version 7.5
(SPSS Inc., Chicago, IL, USA).
Results
Clinical and laboratory findings during acute NE
The clinical picture was typical of acute NE in all patients.
All had fever lasting for a median of 5 days (range 2 to
14 days). Ten (19%) received empirical antibiotics, but in
none of them could a bacterial infection be confirmed.
Acute impairment of renal function (maximum plasma
creatinine concentration measured during hospital stay
>100 μmol/l) was observed in 78% of the patients, and
three needed transient dialysis therapy. Thrombocytopenia
(blood platelet count <150×109/l) was present in all
patients, but none had major bleeding complications.
Hypotension (systolic blood pressure <90 mmHg) was
observed on admission in three patients and was corrected
by fluid infusion.
Serum hormone levels during the acute phase of NE
Table 1 shows that the serum median cortisol and PRL
levels were higher and Testo concentrations lower during
the acute phase of NE compared to the corresponding values
after 3 months. The serum median LH level did not change.
There were, however, remarkable individual differences in
the direction and magnitude of serum Testo and LH alter-
ations (Fig. 1). The serum TSH level was slightly higher and
FSH concentration lower during the acute phase than after
3 months (Table 1). There were no differences between the
median hormone levels (cortisol, PRL, fT4, TSH, Testo,
LH, E2, and FSH) measured at 3 months compared to the
levels measured after 1 or 5 years (data not shown).
The serum cortisol concentration during acute NE
correlated positively with the maximum plasma creatinine
and IL-6 levels (r=0.352, p=0.009, and r=0.319, p=0.019,
respectively), with blood leukocyte count (r=0.370, p=
0.006), and with serum PRL level (r=0.402, p=0.003).
Similarly, the serum PRL level correlated with creatinine
and IL-6 levels (r=0.511, p<0.001, and r=0.338, p=0.012,
respectively), and with blood leukocyte count (r=0.421,
p=0.002).
Eighteen out of 37 (49%) men presented with a low
Testo level during the acute phase of NE. Fifteen of them
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had a coincident serum LH level within the reference range,
and three had an increased LH level. In addition, 5 (14%)
men had an elevated LH concentration together with a
Testo level within the reference range. None of the eight
male patients with acute primary hypogonadism (elevated
LH) complained of testicular pain. The minimum Testo
concentration correlated inversely with age and leukocyto-
sis (r=−0.341, p=0.039, and r=−0.493, p=0.002, respec-
tively), and with maximum creatinine, IL-6, CRP, and PRL
levels (r=−0.437, p=0.007; r=−0.411, p=0.011; r=−0.352,
p=0.032, r=−0.363, p=0.027, respectively), but not with
body mass index (BMI) (r=−0.009, p=0.957). Three out of
six premenopausal women (aged 16, 21, and 37 years)
presented with low E2 and FSH levels during the acute
phase of NE (E2 range 0.04–0.05 nmol/l, and FSH range
0.08–0.8 U/l).
Two patients had a low serum fT4 level together with a
low-normal TSH level during the acute phase. Five out of
Fig. 1 Serum testosterone (A) and luteinizing hormone (LH) (B)
levels measured in 37 men during acute nephropathia epidemica (NE)
and after 3 months. Testosterone levels were below the reference range
in half of the men during acute NE, while LH levels were within the
reference range in the majority, indicating that the hypogonadism was
mostly of central origin. The reference ranges were 10.4–34.6 nmol/l for
testosterone (vertical line showing lower reference limit) and 0.7–6.7 U/
l for LH (vertical line showing higher reference limit)
Table 1 Serum hormone levels during acute nephropathia epidemica (NE) and after 3 months
Acute phasea At 3 months p-value
Median Range Median Range
All patients (n=54)
Cortisol (nmol/l) 520 267–1,157 361 163–606 <0.001c
Prolactin (mU/l)b 266 32–1,364 131 46–550 <0.001c
Thyrotropin (mU/l) 1.9 0.1–9.0 1.7 0.02–7.6 0.011c
Free thyroxine (pmol/l) 12.2 7.5–18.1 12.8 10.1–17.4 0.526
Males (n=37)
Testosterone (nmol/l) 9.9 1.1–27.0 17.3 7.8–25.4 <0.001c
Luteinizing hormone (U/l) 4.0 0.9–18.0 3.6 2.0–7.9 0.399
Females (n=16)b:
Follicle-stimulating hormone (U/l) 4.7 0.6–40.4 23.7 3.0–73.2 0.001c
Estradiol (nmol/l) 0.07 0.02–0.42 0.11 0.04–0.49 0.263
a The highest or the lowest serum concentration of each hormone measured during hospitalization, as appropriate
b One patient was breast-feeding during acute NE and her E2, FSH, and PRL values were excluded from the analyses (see Subjects and Methods sections)
c Statistically significant difference between hormone levels measured in the acute phase and 3 months later (Wilcoxon signed-rank test)
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54 (9%) patients presented with an increased serum TSH
level together with fT4 within the low-normal range; one of
them had a previously diagnosed primary hypothyroidism,
and she used L-thyroxine substitution throughout the study.
Serum fT4 and TSH levels measured during acute NE did
not correlate with age, BMI, plasma creatinine, CRP, or
cytokine levels (data not shown).
Altogether, 30 out of 54 (56%) patients had abnormalities
of the gonadal and/or thyroid axis during the acute phase of
NE. Central hormonal defects were found in 19 patients,
while 13 patients had a primary deficit. As shown in Table 2,
the patients with central hormonal deficiencies had a higher
plasma creatinine concentration and blood leukocyte count
than the patients with normal hormone levels.
There were no differences in the clinical picture or basic
laboratory findings during acute NE between the patients
with primary hormonal deficiencies and those with normal
hormone levels (data not shown), and neither did the
cytokine levels or HLA-B8, -DR3, and -B27 alleles predict
the acute primary hormone deficits.
Hormonal deficiencies one to ten years after NE
During a median follow-up of 5 years, 9 out of 54 (17%)
NE patients presented with chronic, overt hormonal
deficits. Table 3 shows the serial plasma hormone levels
of these patients. The clinical diagnoses of overt hormonal
deficiencies were based both on the hormone measurements
and on the clinical signs and symptoms of the patients.
One of the two patients with hormone levels suggestive
of combined pituitary hormone defects, a 43-year-old male
patient (patient 1, Table 3), presented with low testosterone
levels and declining fT4 levels within the low reference
range during acute NE, as well as after 3 and 12 months
(Testo 7.1–7.8–7.6 nmol/l, LH 2.8–2.1–1.8 U/l, fT4 11.9–
10.6–10.4 pmol/l, and TSH 2.8–3.8–1.9 mU/l, respec-
tively). He died for an unknown reason soon after his
1-year follow-up visit. The hormone levels, indicating
central hypogonadism and possible hypothyroidism, were
analyzed only after his death. The overt hormonal
deficiencies of the other patients had also gone unnoticed
until the patients were invited to the additional visit in
2008. Only one female patient had been started on L-
thyroxine, due to overt hypothyroidism diagnosed 9 years
after the acute NE (patient 8, Table 3).
There were no differences in the age or gender distribution,
clinical picture, or basic laboratory findings during acute NE
between those nine patients who presented with chronic
hormone deficiencies after NE and those with normal
hormone levels (Table 4). None of the three patients who
were hypotensive on admission developed chronic hormonal
deficiencies. The prevalence of HLA-B8, -DR3, and -B27
alleles did not differ between the groups (data not shown).
Imaging studies during the additional visit in 2008
Thyroid ultrasound examination showed diffuse or patchy
hypoechogenicity, pertinent with thyroiditis, in the five
patients with primary hypothyroidism, while TPOAb were
measurable in only two of them. A sellar MRI scan was
performed during the additional visit in 2008 in two men
whose symptoms and hormone levels suggested central
Table 2 Clinical and laboratory findings of the 19 patients diagnosed with central hormonal defects during the acute phase of NE compared to
those of the 23 patients with normal hormone levels
Finding Central hormonal defects (n=19) Normal hormone levels (n=23) p-value
Median Range Median Range
Age (years) 41 17–62 41 24–70 0.909
Gender (M/F) 15/4 13/10 0.125
Body mass index (kg/m2) 25 19–37 26 19–42 0.456
Creatinine max (µmol/l) 368 79–749 208 76–878 0.029a
Leukocytes max (109/l) 13.4 4.4–22.8 9.2 6.7–23.4 0.033a
Platelets min (109/l) 62 13–127 53 18–136 0.869
C-reactive protein max (mg/l) 78 22–213 67 27–136 0.791
Plasma IL-6 max (pg/ml) 19.6 5.9–40.7 13.5 3.3–59.1 0.052
Plasma TNF-α max (pg/ml) 3.4 1.4–26.9 3.8 1.4–37.4 0.693
Proteinuria max (g/day) 1.8 0.2–9.5 2.0 0.3–17.8 0.990
Duration of hospital stay (days) 8 5–13 7 3–11 0.134
M = male; F = female; IL = interleukin; TNF-α = tumor necrosis factor alpha; min = minimum; max = maximum
a Statistically significant difference between patients with acute central hormone deficits and those with normal hormone levels. The Mann–Whitney U-test
was used for continuous variables and Pearson’s Chi-square test was used for gender
Eur J Clin Microbiol Infect Dis (2010) 29:705–713 709
hormonal defects. One had an apparent GH deficiency
(patient 5, Table 3), and the other was a 41-year-old patient
who developed a marked secondary hypogonadism and a
probable secondary hypothyroidism (patient 2, Table 3).
The MRI scans showed no pathology of the hypothalamic-
pituitary region in either of them.
Discussion
To our knowledge, this is the first study on hormonal
alterations occurring during and after NE. Serum cortisol
and PRL levels were higher and serum Testo concentrations
lower during acute NE compared to the corresponding
Table 3 Serial plasma hormone levels of nine NE patients who
presented with chronic, overt hormonal deficits during a median
follow-up of 5 years. The hormone levels presented in the table were
measured during the acute phase of NE (first value in each series) and
on the follow-up visits 1 to 10 years later (second and third value of
each series). Abnormal values are printed in bold
Patient Gender/age during
acute NE (years)
Duration of
follow-up
(years)
Testosterone in
males and E2 in
females (nmol/l)
LH in males
and FSH in
females (U/l)
fT4 (pmol/l) TSH (mU/l) Clinical
diagnosis
1 M/43 1a 7.1–7.6 2.8–1.8 11.9–10.4 2.8–1.9 CHG
2 M/41 9 11.6–8.1–7.4 1.6–2.0–2.6 12.5–10.4–10.4 1.2–1.0–0.9 CHG
3 M/59 5 1.9–11.5–7.6 1.7–3.6–2.3 11.0–11.4–12.1 1.3–1.7–1.5 CHG
4 M/52 1a 7.9–9.8 2.5–2.8 14.5–13.3 2.3–1.5 CHG
5 M/42 9 11.3–15.7–21.9 18.0–5.5–6.8 11.2–13.9–13.4 1.9–4.3–5.0 PHTb
6 M/58 9 12.5–15.3–10.7 6.9–6.7–9.2 14.0–12.8–12.0 3.7–4.3–5.7 PHT
7 M/60 7 1.1–19.2–21.1 2.8–5.0–4.0 9.4–10.9–11.7 1.7–5.8–9.9 PHT
8 F/17 9 0.05–0.07–<0.06 0.6–2.8–0.4 16.2–11.5–12.5 3.5–2.7–6.6c CHG, PHT
9 F/47 9 0.05–<0.02–<0.06 2.6–41.5–39.8 9.5–9.9–9.4 9.0–11.5–16.1 PHT
CHG = central hypogonadism; PHT = primary hypothyroidism; E2 = estradiol; LH = luteinizing hormone; FSH = follicle-stimulating hormone;
fT4 = free thyroxine; TSH = thyrotropin
a Only the hormone levels measured during acute NE and 1 year later are shown for the two patients whose follow-up ended at the 1-year visit
b And a possible growth hormone (GH) deficiency: an undetectable GH level and insulin-like growth factor-1 6.5 nmol/l (reference range 10–29 nmol/l)
c On L-thyroxine treatment
The reference ranges were 10.4–34.6 nmol/l for testosterone and 0.7–6.7 U/l for LH in men. An E2 level below 0.1 nmol/l was considered to be
hypogonadal in premenopausal women, as the phase of menstrual cycle was not known. Peri- and postmenopausal women were not analyzed for
gonadal defects, as they were hypogonadal by definition. The reference range for fT4 was 9.0–19.0 pmol/l and for TSH, it was 0.4–4.0 mU/l
Table 4 Clinical and laboratory findings during the acute phase of NE in the nine patients who developed chronic hormonal defects after NE
compared to those in the 45 patients whose hormone levels remained normal during the follow-up
Chronic hormonal defects (n=9) No chronic defects (n=45) p-value
Median Range Median Range
Age (years) 47 17–60 39 15–70 0.194
Gender (M/F) 7/2 30/15 0.512
Body mass index (kg/m2) 26 21–37 25 19–42 0.347
Creatinine max (μmol/l) 380 98–725 213 76–878 0.190
Leukocytes max (109/l) 11.2 5.7–20.4 10.3 4.4–23.4 0.926
Platelets min (109/l) 54 17–139 62 3–136 0.898
C-reactive protein max (mg/l) 72 25–213 67 20–136 0.423
Plasma IL-6 max (pg/ml) 19.9 5.0–43.0 14.2 3.3–59.1 0.102
Plasma TNF-α max (pg/ml) 2.8 1.4–8.7 3.7 1.4–37.4 0.267
Proteinuria max (g/day) 0.9 0.3–3.9 2.0 0.1–17.8 0.114
Duration of hospital stay (days) 6 5–13 7 3–12 0.883
The Mann–Whitney U-test was used for continuous variables and Pearson’s Chi-square test was used for gender
M = male; F = female; IL = interleukin; TNF-α = tumor necrosis factor alpha; min = minimum; max = maximum
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values after 3 months. These acute hormonal alterations
were related to the severity of acute renal insufficiency and
inflammation. After one to ten years, surprisingly, many
patients suffered from chronic hormonal deficits of either
central or peripheral origin. The chronic defects could not
be predicted by renal insufficiency, degree of inflammation,
or other markers of the clinical severity of acute NE, or by
the host genetic factors studied.
Approximately half of the men and premenopausal
women presented with low serum gonadal hormone levels
during the acute phase of NE. Serum Testo levels, in
general, increased during a 3-month follow-up, while
concomitant LH levels remained stable, indicating that the
acute hypogonadism was transient and of central origin in
most cases. The degree of hypothalamic-pituitary-gonadal
axis suppression, as well as the increase in plasma cortisol
production, are known to be related to the severity of acute
illness [22, 23]. Also, in our patients with acute NE, low
Testo levels and high cortisol and PRL levels were related
to the degree of inflammation and the severity of acute
renal failure. As the kidneys are involved in the elimination
of PRL and corticosteroids [24, 25], the acute impairment
of renal function during NE may have resulted in
diminished clearance of PRL and cortisol, contributing to
their increased serum levels.
We also found eight male patients with acute primary
hypogonadism during PUUV infection. Three out of these
eight acute testicular failures developed into chronic,
compensated failures, i.e., Testo levels remained within the
normal range, while LH levels were chronically elevated. In
addition, two cases of chronic, compensated hypogonadism
developed during the follow-up, without testicular dysfunc-
tion during the acute NE. There are no previous reports of
clinical orchitis or primary hypogonadism in hantaviral
diseases. However, the possibility remains that PUUV
infection may have contributed to the pathogenesis of acute
and chronic primary hypogonadism, which were over-
represented [26, 27] in this relatively young group of
patients (median age in males 39 years, the youngest patient
with chronic hypogonadism 30 years).
Primary hypothyroidism was remarkably frequent in our
patients with NE. Two patients had been diagnosed with
hypothyroidism prior to NE, and five more diagnoses of
primary hypothyroidism were made during the follow-up.
The overall prevalence of primary hypothyroidism thus
mounted up to 24% in the female patients and 8% in the
males, which are about three-fold prevalences compared to
those recently reported for similar age groups in the general
population [28–30]. All of the patients diagnosed with
primary hypothyroidism in the present study showed a hypo-
echogenic structure of the thyroid on ultrasound examination,
suggesting chronic thyroiditis [31, 32]. TPOAb were present
in only two of the five “new” cases of hypothyroidism, which
may indicate that in the other three cases, the thyroiditis was
not of autoimmune origin, but was possibly induced by the
PUUVinfection. The primary thyroid, or gonadal, defects did
not relate to age, gender, or the degree of renal insufficiency
or inflammation during acute NE. A high level of vigilance
for possible signs of thyroid or gonadal dysfunction seems
warranted in patients with a history of previous NE.
Seventeen percent of the present study patients were
diagnosed with a chronic, overt hormonal deficit. In a
recent retrospective Serbian study, the prevalence of any
endocrine deficiency 2 years after HFRS was 18% [14]. It
is noteworthy that the patients in the Serbian study had a
more severe HFRS than our patients. In the present study,
only three patients needed dialysis treatment, while 57% of
the Serbian patients were dialyzed. PUUV and DOBV
coexist in the Balkan area, and induce HFRS with
significant differences in severity [33, 34]. DOBV-infected
patients have more frequently suffered from acute renal
failure requiring dialysis treatment, shock, severe thrombo-
cytopenia, and hemorrhagic complications than patients with
PUUV [33, 34]. In the present study, chronic hormonal
defects could not be predicted by the severity of acute NE.
Hence, it is worth noticing that chronic hormonal deficits
might occur even after a relatively mild hantaviral infection.
Previous case reports of severe HFRS have described
hypophyseal hemorrhage and panhypopituitarism associated
with PUUV and HTNV infections [7–11, 35–38]. The
development of hypophyseal hemorrhage and subsequent
panhypopituitarism has varied from acute to subacute. The
mechanisms of pituitary hemorrhage are unknown, although
hypovolemic shock and thrombocytopenia may contribute to
the pathogenesis. In the present patients, thrombocytopenia
or hypotension during acute NE did not correlate with either
acute-phase or long-term hormonal abnormalities. Neither
were there any MRI findings pertinent with previous
hypophyseal or hypothalamic hemorrhage in the patients
with central hormonal defects. It is likely that the secondary
hormone deficiencies found in the present series of NE
patients developed by mechanisms other than an acute
hemorrhagic disruption of the pituitary.
Headache, vertigo, visual disturbances, and other signs
of central nervous system involvement occur frequently in
NE [2, 3, 39, 40], and cases of PUUV-induced meningo-
encephalitis have been reported [2, 3, 41, 42]. The presence
of PUUV RNA in cerebrospinal fluid in a patient with acute
NE has been confirmed [43]. It has recently been shown
that infections of the central nervous system may cause
transient or permanent hypothalamic and/or pituitary dys-
function [44]. Viral meningoencephalitis or hypophysitis
may also have contributed to the central hormone defects
frequently found in our patients.
An important feature in hantaviral infections is a
universally increased capillary permeability, causing tissue
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edema and hypotension [1]. Immunological factors, including
the overproduction of pro-inflammatory cytokines during
acute infection, are probably involved in the pathogenesis
and might result in immune-mediated damage to the
endothelial cells [15]. The endothelial damage and increased
vascular permeability may have been involved in the
pathogenesis of central and peripheral hormonal defects of
the NE patients. A tight interaction between the immune and
endocrine systems, mainly through the HPA axis [16, 17], is
also likely to play a central role in the hormonal alterations,
at least during acute NE.
Our study has some limitations. First, due to the
retrospective nature of the hormonal analyses, we did not
have complete data on the possible signs and symptoms
related to hormonal alterations during and after NE. This
may have resulted in underestimation of the hormonal
sequelae of NE, as milder forms of pituitary failure cannot
be diagnosed by means of basal hormone levels alone.
Stimulatory tests of the GH-IGF-1 axis or the HPA axis could
have revealed more subtle hormonal defects, over and above
the prevalence of overt hormonal failures reported here. In
addition, it would have been valuable to include patients with
other viral infections as controls. These limitations, however,
should be weighed against the strengths of investigating a
prospectively gathered group of consecutive patients both
during the acute phase of NE and repeatedly during the long-
term follow-up. The findings of the present study give rise to
prospective, controlled studies to verify the prevalence of
hormonal defects after hantaviral diseases, and to clarify the
pathogenesis of these hormonal alterations.
In summary, hormonal alterations were common during
acute NE, and the acute hormone deficits of central origin
correlated with the clinical severity of NE. Chronic
hormonal defects, however, could not be predicted by the
severity of acute NE, and chronic deficits emerged even
after a relatively mild course of NE. Patients with a history
of NE should be readily investigated for hormonal
deficiencies, in view of the high prevalence of chronic
central and peripheral hormone defects in these patients.
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